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Abstract 
  
Hepatitis C virus (HCV) is an increasingly common cause of liver disease 
worldwide. HCV may be present in saliva suggesting possible transmission via 
oral fluids. However the precise influence of peripheral blood carriage of HCV 
upon the frequency and load of HCV in oral fluids remains unknown.  
The objectives of the study were to determine the frequency of oral carriage of 
HCV and determine the influence of plasma and peripheral blood 
mononuclear cells (PBMCs) HCV levels upon HCV levels in oral fluids. 
The study group comprised 85 patients with treated (18) or untreated (67) 
HCV infection resident in northern Brazil. HCV 5’-NCR and NS5b regions 
were detected by quantitative Real Time PCR and nested block based PCR 
respectively in whole saliva, plasma, CD2+, CD14+, CD19+, and CD45+ 
PBMCs for both methods.  
Approximately 32% of the total group had detectable HCV RNA in whole 
saliva. In contrast HCV was present in 82.5% of plasma and up to 82.1% of 
PBMC. There was no significant difference in the genotypes between oral and 
blood compartments and no evidence of genetic diversity within the oral 
compartment. There was no correlation between the salivary prevalence of 
HCV with load of plasma. HCV RNA viral load in saliva was almost always 
below the level of quantification. 
Given the low viral load presented in patient with a high plasma titration in the 
30% saliva positive patients, HCV transmission via the saliva is highly unlikely, 
but cannot be discarded. There is no evidence for HCV compartmentalization 
as sequences from different compartments were closely related, although 
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mutations were identified more frequently within genotype 1b in all 
compartments. This finding suggest a new trend towards hepatitis C evolution, 
as genotypes 1a and 1b do not usually differentiate in terms of treatment 
outcome, being both traditionally related to poor antiviral response. 
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1.1. Background 
 
Viral hepatitis research started in the 1950s and 1960s with the “infectious” 
and “serum” hepatitis, later proven to be caused by the hepatitis A virus (HAV) 
and hepatitis B virus (HBV), respectively (reviewed by Houghton, 2009). 
 
The hepatotropic viruses (A, B, C, D and E) are a diverse group of micro-
organisms that share the ability to cause hepatic inflammation and different 
degrees of necrosis. Each of these viruses can cause acute hepatitis, although 
only hepatitis B, D (which requires hepatitis B virus for its replication) and C 
give rise to chronic hepatitis (Aguilera et al., 2006). The putative viruses 
hepatitis F and G (HGV, GBV-C) have also been described. The earlier could 
be part of the Togaviridae family, but no specific virus was identified as 
hepatitis F, while the later is a positive sense RNA virus distantly related to 
HCV (HGV and GBV-C being virtually identical). There is little evidence that 
hepatitis G can cause significant liver disease, despite persistent viraemia. 
While hepatitis A and E are transmitted via faecal-oral route, the others are 
blood-borne viruses (Kelly et al., 2002).  
 
For many years, the hepatitis laboratory of Chiron Biotechnology Company 
had attempted to identify the NANBH (see section 1.2) genome by cloning 
nucleic acids either from infected human or chimpanzee materials. This was 
followed by the identification of viral clones by showing their specific 
hybridization to radioactive cDNA probes derived from infected liver or blood 
samples.   
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After exhaustive attempts, one clone out of six clones screened (the others 
were shown to be derived from host genes encoding proteins apparently 
eliciting an autoimmune response) was shown to have been truly derived from 
the putative HCV genome, containing around 150 base-pairs (Houghton, 
2009). The others were show to have been derived from host genes encoding 
proteins, apparently eliciting an autoimmune response. 
 
1.2. Hepatitis C Virus 
 
When serological tests to detect HAV and HBV were developed in the mid-
1970s, it rated that many cases of parenterally transmitted hepatitis were not 
due to either virus, hence heralding the term Non-A, Non-B hepatitis (NANBH), 
later named hepatitis C virus (Houghton, 2009).  Hepatitis C virus belongs to a 
separate genus of the Flaviviridae family of viruses (Simmonds, 2004), it was 
first described in detail in 1989, and is the principal cause of the previously 
termed group of NANBH (Choo et al., 1989). 
 
The elucidation of the genetic organization of HCV was possible after the 
complete sequence of the virus was identified (see Figure 1.1). From 
sequence comparison with other RNA viruses, it was apparent that HCV 
encodes a conserved serine-like protease domain, a helicase domain and a 
RNA polymerase domain (Choo et al., 1991). 
 
The main challenges for the identification of HCV resided in three main 
aspects: HCV is genetically heterogeneous, has low titres in blood and has a 
natural history comprising of a lengthy asymptomatic phase during the early 
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years of chronic infection. It was thus difficult to detect the genome and virus-
encoded proteins by conventional methods and there was a lack of 
pathological landmarks to utilize in the development of chronic hepatitis 
(Feitelson, 2006). 
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1.3. Genome Structure and Organisation 
 
The HCV viral particle is about 50nm in diameter and consists of an envelope 
derived from host cell membrane into which are inserted virally encoded 
glycoproteins E1 and E2. The membrane surrounds a nucleocapsid and a 
positive sense, single stranded RNA genome of about 9,600 nucleotides 
(Choo et al., 1989). 
    
The genome comprises highly conserved untranslated regions (UTRs) at both 
the 5’ and 3’ termini which flank a single Open Reading Frame (ORF) that 
encodes a polyprotein of about 3010-3033 amino acids (Chambers et al., 
1990). The genetic organization of the virus is such that the amino-terminal 
end of this polyprotein encodes the structural proteins of HCV while the 
remainder encodes a family of non structural (NS) proteins that are involved in 
virus maturation and replication (Feitelson, 2006). This polyprotein is 
processed co-translationally and post-translationally by cellular and viral 
proteases to produce a series of specific viral gene products that consist of 
the structural (core, E1 and E2) and non-structural proteins (NS2, NS3, NS4A, 
NS4B, NS5A and NS5B). The structural proteins are at the N-terminal end of 
the polyprotein. The different components of the virus, which have different 
ratios of preservation between the various genotypes, (Simmonds, 2004) are 
summarised in Table 1.1 (Lauer et al., 2001). 
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Figure 1.1. Open reading frame, proteolysis and protein functions of 
HCV (Houghton, 2009) 
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The C terminus of each structural protein is composed of a hydrophobic amino 
acid sequence, which acts as a signal peptide to target the proteins located 
downstream to the endoplasmic reticulum (ER). Cleavage at the C/E1, E1/E2, 
E2/p7 and p7/NS2 sites is mediated by ER-resident host signal peptidase(s). 
Although cleavage at the C/E1 and E1/E2 sites proceeds to completion rapidly 
after translation, cleavage at E2/p7 and p7/NS2 is delayed resulting in an 
E2p7NS2 species (Dubuisson et al., 1994). Furthermore, cleavage at the 
E2/p7 site has been shown to be incomplete, resulting in two E2-specific 
species, E2 and E2p7 (Lin et al., 1994, Mizushima et al., 1994). The 
significance of these two forms of E2 has not been established, although it is 
conceivable that both play functional roles in the virus life cycle (Isherwood et 
al., 2005).  
    
Although recent reports indicated that p7 forms channels conducting ions 
across membranes and is essential for HCV infection, its exact role in the viral 
life cycle remained elusive. Steinmann et al. (2007) illustrated that HCV relies 
on p7 function for efficient assembly and release of infectious progeny virions 
from liver cells. Conversely, entry of HCV particles into new host cells is 
independent of p7. This new evidence supports the recent proposal to include 
p7 into the family of viroporins that comprises proteins from diverse viruses, 
for instance, HIV-1 and influenza A virus. Members of this group of 
functionally related proteins form membrane pores that promote virus release 
and in some cases also virus entry. Moreover, conserved p7 residues crucial 
for the efficient functioning of this protein have been identified. These amino 
acids possibly stabilize the structure of p7 or directly participate in channelling 
of ions. Interestingly, p7 variants from divergent patient isolates differ with 
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regard to their ability to promote virus production, suggesting that p7 also 
modulates viral fitness, i.e., its ability to cause disease (Steinmann et al., 
2007). 
    
All cells permissive to HCVpp (pseudotype particles that display functional E1 
E2 glycoprotein complexes) co-express low-density lipoprotein receptor 
(LDLr), CD81 and scavenger receptor class B type I (SR-B1), and are of 
hepatic origin.  However, other cell types also express these receptors yet are 
not, or poorly, permissive to HCVpp infection.  This suggests that additional 
liver-specific factors are necessary for HCV cellular entry (Bartosch et al., 
2003, Szabo et al., 2003). 
    
Low density lipoprotein receptor (LDLr) is involved at an early stage in 
infection of normal human hepatocytes by serum-derived HCV virions playing 
a critical role at this early step of infection (Molina et al., 2007). 
 
As noted above, the 5’-UTR and the 3’-UTR are the most conserved regions of 
the HCV genome.  Within E2, there are two hypervariable regions (HVR1 and 
HVR2), each of which have considerable sequence variability. This variability 
is thought to be the result of selective pressure by virus-specific antibodies. E2 
also contains the binding site for CD81 – one putative receptor or co-receptor 
for HCV.  As denoted in Table 1.1, the non-structural proteins principally 
function as proteases (NS2, NS3 and NS4A), helicases (NS3) or RNA-
dependent RNA polymerase (NS5B).  A region within NS5A has been linked 
to the response to interferon alpha, and is thus termed interferon-sensitivity-
determining region (ISDR) (Lauer et al., 2001). Compared to the DNA-
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dependent DNA polymerases found in eukaryotic cells, the HCV RNA-
dependent RNA polymerase is a relatively small, simple enzyme that lacks 
accessory functions such as proof-reading.  As a result, replication of HCV, in 
common with most RNA viruses, is relatively error-prone, and is associated 
with rapid genetic change. Nevertheless, Simmonds and Smith (1997) found 
that throughout the genome, most nucleotide changes were silent i.e. did not 
affect the sequence of the encoded amino acid sequence. The relative 
infrequency of non-silent changes is found in most coding sequences of all 
organisms, and reflects constraints upon the extent to which proteins may 
vary in sequence and yet remain functional (Simmonds et al., 1997).  
    
The life cycle of HCV has only recently been elucidated. Five years ago, a 
Japanese research group achieved robust hepatitis C virus infection in vitro 
for the first time. This was achieved by the transfection of Huh-7 cells with in 
vitro–transcribed JFH-1 (Japanese fulminant hepatitis 1) RNA, leading to the 
production of viral particles that are infectious for naive Huh-7 cells and can be 
serially passaged, thereby allowing study of the entire life cycle of HCV in 
tissue culture. Enveloped virus particles bind to specific surface receptors of 
host cells and are then internalised (Zhong et al.  2005). Putative receptors for 
Hepatitis C virus are CD81 tetraspanin, SR-B1, mannose-binding lectins DC-
SIGN and L-SIGN, LDLr, heparan sulphate proteoglycans and the 
asialoglycoprotein receptor (Cocquerel et al., 2006).  
 
The recent development of functional models to analyze the early steps of the 
hepatitis C virus (HCV) life cycle has highlighted that HCV entry is a slow and 
complex multistep process involving the presence of several entry factors. 
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Initial host cell attachment may involve glycosaminoglycans and the low-
density lipoprotein receptor, after which the particle appears to interact 
sequentially with three entry factors: the scavenger receptor class B type I, the 
tetraspanin CD81 and also the tight-junction protein claudin-1. Several serum 
components may also modulate HCV entry, while the recently discovered 
CD81 partner EWI-2wint can block the interaction of the viral particle with 
CD81, potentially preventing infection in the cell types in which it is expressed. 
After binding to the host cell, the HCV particle is internalized by clathrin-
mediated endocytosis, with fusion likely occurring in early endosomes (Helle 
et al., 2008). 
 
The claudin-1 receptor (CLDN1) must play a role in a late step of the entry 
process, probably after virus binding and interaction with CD81. Thus far, no 
direct interaction between CLDN1 and the HCV particle has been reported, 
but such an interaction may require a conformational change in the envelope 
glycoproteins triggered by an initial interaction between E2 and another entry 
factor, e.g.CD81 or SRBI. The precise role of CLDN1 in HCV entry remains to 
be determined. However, since CLDN1 is strictly localized to the tight 
junctions in polarized hepatocytes, the authors of this study felt tempted to 
speculate that CLDN1 acts after lateral migration of a virus-receptor complex 
to the tight junctions (Helle et al., 2008). 
      
The fusion of the viral and cellular membranes leads to release of the single 
stranded RNA HCV genome into the cytoplasm of the cell.  This RNA (thus) 
forms the template for the translation of viral proteins and the production of 
new viral RNA (Lindenbach et al., 2005, Zeisel et al., 2006). HCV replication 
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occurs in a specific membrane alteration – the membranous web induced by 
the NS4B protein (Egger et al., 2002, Hugle et al., 2001). The virons are 
thought to form by budding into the endoplasmic reticulum of the cell and then 
exit from the cell via its secretory pathway. Some aspects of this life cycle 
remain unknown (Zeisel et al., 2006, Lindenbach et al., 2005). 
    
A Swedish research group indicated that single amino acid substitutions in the 
N terminus of NS4B can have a great impact on replication, both positively 
and negatively (Lindstrom et al., 2006). In another paper from the same group, 
they have shown that translocation of the N terminus may be influenced by the 
presence of NS5A and may be associated with the ability of NS4B to 
rearrange the intracellular membranes. Together, these facts suggest an 
important role for the N-terminus of NS4B in the viral life cycle (Lundin et al., 
2006). 
    
Based on the fact that most HCV proteins are membrane-binding proteins it 
has been postulated that there are at least two replication steps of HCV, i.e., 
RNA replication and virion formation are endoplasmatic reticulum - membrane 
associated. Egger et al. demonstrated that HCV proteins have the propensity 
to induce distinct alterations of endoplasmatic reticulum membranes, which 
may represent, in productively infected cells, the scaffolds necessary for virus 
multiplication (Egger et al., 2002). 
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Table 1.1. Hepatitis C Virus Proteins (from amino- to carboxy-terminus, the polyprotein that encodes C-E1-E2-p7-NS2-NS3-
NS4A-NS4B-NS5A-NS5B) 
 
Protein Function Reference 
C It is a structural protein, important in encapsulation of viral RNA. This protein may also interact with cellular proteins to aid 
transactivation and suppression 
(Feitelson, 2006). 
E1 & E2 E1 and E2 are structured proteins that lie within the membrane of the virus. E1 interacts with E2 to form a stable complex. 
Important in binding to host cells and aiding viral entry 
(Feitelson, 2006). 
E2-P7 The degree of E2-P7 cleavage by host signal peptidases vary but are reported to be incomplete in genotype 1. The C 
terminus of P7 in E2-P7 showed to be cytoplasmatically orientated suggesting that P7 adopts a dual transmembrane 
topology 
(Isherwood et al., 
2005). 
P7 P7 is primarily involved in the late phase of the HCV replication cycle. Promote virus production, modulates fitness and in 
turn virus persistance and pathogenesis 
(Steinmann et al., 
2007). 
NS2 NS2 is a non-structural protein that binds to N3 to form an NS2-3 complex essential for autoproteolysis of the polyprotein (Feitelson, 2006). 
NS3 NS3 is a non-structured protein that binds with NS2 to form NS2-3. NS3 also has serine protease, helicase and NTPase 
activity 
(Feitelson, 2006). 
NS4A NS4A is a non-structural protein that functions as a co-factor for NS3 serine protease activity (Feitelson, 2006). 
NS4B NS4B is a non-structural protein that induces formation of membranous web (Egger et al., 2002, 
Hugle et al., 2001) 
NS5A NS5A is a non-structural protein, may play a role in RNA replication influencing the topology of NS4B (Lundin et al., 2006). 
NS5B NS5B is a non-structured protein which functions as a RNA dependent RNA polymerase (Feitelson, 2006). 
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Cellular immune responses, particularly those mediated by CD8+ cytotoxic T 
cells, are important components of protective immunity against many viral 
infections, including hepatitis C. In HCV infection, the role of CD8+ cells in 
protecting against viral persistence is unknown (Zein, 2000). It has been 
identified that the core and E2 proteins are targets for HCV-specific CD8+ 
cells in chronically infected persons. HCV-specific cytolytic activity is present 
in bulk-expanded liver-infiltrating lymphocytes in the absence of any in vitro 
antigenic stimulation. Such activity could not be detected in bulk-expanded 
PBMC, suggesting a tissue-specific localization of HCV-specific CD8+ cell 
(Koziel et al., 1993).  
    
The escape of HCV from CD8+ cells-induced immunity may be related to the 
virus heterogeneity. For example, in a chronically infected chimpanzee, CD8+ 
cells obtained from the liver were initially able to recognize an epitope in the 
NS3 region. Over a period of several years, a new strain of the virus emerged 
with a mutation in the CD8+ cell epitope that was no longer recognized by the 
CD8+ cells isolated earlier. An extraordinarily high rate of nucleotide change 
that frequently resulted in codon changes has also been found in 
hypervariable region 1 of the E2 protein of the HCV genome (Zein, 2000). The 
presence of these rapidly changing regions may permit a mechanism by which 
HCV evades host immune surveillance and establishes and maintains 
persistent infection (Simmonds, 2004). 
    
HCV does not integrate into the genome of the hepatocytes. Several viral 
proteins, however, have been suggested to be associated with 
hepatocarcinogenesis, especially the core and NS5 (Szabo et al., 2003).    
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1.4. Genotypes 
 
Hepatitis C virus exhibits considerable genetic heterogeneity. The virus can be 
phylogenetically differentiated into 6 main types or genotypes within which are 
a number of variable, but closely related, genetically distinct subtypes or 
subgenotypes (using letters in order of discovery, e.g. 1a, 1b, etc)  (Simmonds 
et al., 1993). Genotypes beyond genotype 6 have been described, these 
principally being isolates from the developing world.  Novel variants of HCV 
from Vietnam, Thailand and Indonesia have been classified as types 7, 8, 9, 
10 and 11, many of which were subdivided into between two to four subtypes 
(Simmonds et al., 1996). However, it is now recognised that many of these 
newer genotypes bear close similarities to sequences of existing genotypes 
and thus can be ascribed to one of the genotypes 1 to 6 (Simmonds et al., 
2005). Indeed recently it has been recommended that the viruses be assigned 
to one of six clades. Clades 1, 2, 4 and 5 refer to genotypes 1, 2, 4 and 5 
respectively, while genotypes 3 and 10 form clade 3, and genotypes 6, 7, 8, 9 
and 11 form clade 6 (Simmonds et al.  2005). 
    
Early dates for the divergence of HCV genotypes may help explain several 
features of their geographical distribution. In certain geographical regions, a 
single HCV type occurs but this is represented by numerous subtypes, a 
pattern suggestive of a long period of endemic infection. In contrast, in other 
parts of the world, more than one virus type is present, but each type is 
represented by only a few different subtypes. This pattern is consistent with 
relatively recent and limited introductions of HCV from endemic areas. 
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Examples include Northern Europe and North America where types 1a, 1b, 2a, 
2b and 3a are common, and Japan where only types 1b, 2a and 2b occur. The 
history of these introductions can be partially reconstructed by comparing the 
frequency of HCV genotypes in different age groups. For example, types 1a 
and 3a are found in younger individuals who often have drug injection as a risk 
factor, and their recent dissemination is supported by the reduced diversity 
within these subtypes (Smith et al., 1997). 
    
Genotypes of HCV differ from each other by 31 to 33% at the nucleotide level, 
while the subtypes within a genotype differ by 20-25%. Despite this sequence 
diversity, all the genotypes show 60-70% homology and share an identical 
complement of co-linear genes of similar or identified size in the large open 
reading frame (Simmonds et al., 2005). 
 
1.4.1. Genotype Distribution 
 
The clade (or genotype) of HCV is of relevance in both the investigation of 
epidemiology of HCV disease and its therapy.  For example, clade 1 is widely 
distributed in Northern Europe and the USA and is generally associated with 
injecting drug use. Clade 2 is found predominantly in the older HCV-infected 
individuals in Mediterranean countries and the Far East. Clade 3 
predominantly occurs in the Indian subcontinent, Europe and the US. Clade 4 
is widely distributed in the Middle East and associated with unsafe therapeutic 
injections. Clade 5 is distinct to South Africa, while clade 6 (which contains the 
former genotypes 6 to 11) has been associated with injecting drug use in 
Hong Kong, Vietnam and Australia (Simmonds et al.  2005). Clade 1 is the 
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most commonly found in Brazil followed by clade 3, as listed in Table 5.1 
(Chapter 5). 
  
Knowledge of the geographic distribution of the different HCV clades is 
epidemiologically important as it allows infection to be tracked back to its 
source (e.g. following a nosocomial accident). In addition it may allow 
prediction of future health care burden as some genotypes may influence 
disease and/or response to therapy. Steatosis, the accumulation of fat in 
hepatocytes may reduce with therapy in patients who have genotype 3a, 
whereas all other genotypes are not associated with this phenomenon. 
Genotype 1b may be associated with an increased risk of cirrhosis and the 
need for liver transplantation, and recurrence of hepatic disease following 
transplantation (Hnatyszyn, 2005). The HCV genotype is considered to be a 
strong independent prediction of response to therapy. Genotype 4 infection 
responds poorly to interferon-based therapy whereas genotype 5 infection 
responds well. Furthermore, infection with genotype 6 is intermediate in 
response (Nguyen et al., 2005). Genotype 1 is more resistant to interferon and 
ribavirin than genotypes 2 and 3 (Simmonds et al., 2005). The dosage regime 
of interferon and ribavirin may be dependent upon the genotype, such that 
patients with genotypes 2 and 3 may require reduced dosages of interferon 
and ribavirin than other genotype infections. The response to therapy may be 
influenced not only by the genotype, but by mutations leading to quasispecies 
generation. Resistance to interferon has been suggested to be due to 
mutations within NS5A (Hnatyszyn, 2005). 
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Demographic and migration analysis histories of the prevalent HCV subtypes 
1a and 1b were inferred from viral gene sequences samples in 5 countries. 
The parsimony migration analysis suggested that the global subtype 1a and 
1b epidemics are geographically structured, with asymmetrical movement of 
HCV strains among the sampled countries. The coalescent analysis indicated 
that subtype 1a infections in the United States, Brazil, and Indonesia began to 
increase exponentially during the 1940s and 1950s, whereas in Vietnam the 
increase began after the 1970s. In contrast, subtype 1b infections in these 4 
countries and in Japan began to increase exponentially between 1880 and 
1920, with a possible recent decrease in infection rates in Indonesia and 
Japan. In the United States, Brazil, and Vietnam, the epidemic growth rates 
for subtype 1a strains were higher than those for subtype 1b strains, whereas 
the growth rates were similar in Indonesia (Nakano et al., 2004).  
 
1.4.2. Methods for Genotyping 
 
Restriction fragment length polymorphism (RFLP) analysis - that by 
electrophoresis demonstrates banding patterns of digested nucleotide 
sequences - is considered to be an accurate and efficient means of 
determining the genotype of HCV isolates (Furione et al., 1999). However, it 
does require enzymes that can recognise specific sites. Allele-specific 
oligonucleotide hybridisation methods require expensive probes to identify 
mutated regions, and may not detect single nucleotide polymorphisms (SNP).  
Matrix-assisted laser description ionisation time-of-flight spectrometry (MALDI-
TOF) can sequence nucleotides allowing accurate discrimination between 
oligonucleotides 10 to 30 bases in size (Ilina et al., 2005). 
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Genotyping assays are usually based upon an analysis of the sequence of an 
amplified section of the genome, typically the 5’ UTR (the site with the highest 
degree of conservation (Cha et al., 1991). Although this region is highly 
conserved, a number of polymorphisms are predictable and therefore allow 
genotypes to be determined.  Nevertheless, some genotype 6 variants have 5’ 
UTR identical to those of genotype 1a or 1b and thus this site cannot always 
be utilised for genotyping (Hnatyszyn, 2005). 
    
Relative to genotyping in the NS5B region – considered the gold standard for 
genotyping determination – mis-typing seems to be rare, whereas mis-
subtyping is frequent (approaching 10% of cases). This however has no 
clinical consequences, as clinical decisions are not currently based on the 
HCV subtypes (Pawlotsky, 2002). After nested PCR, this part of NS5B region 
about 300 base pairs long (see methods) is sequenced via Sanger method, 
which means DNA sequencing with chain-terminating inhibitors (Sanger et al., 
1977). Another sequencing method is based on E1 region (Forns et al., 1999). 
    
Typically, RNA viruses show high mutation frequencies because of an error-
prone viral RNA polymerase that lacks proof-reading 3′-5′ exonuclease activity 
(Freeman et al., 2001). For HCV, the rate of nucleotide misincorporation has 
been calculated as approximately 10–3 base substitutions per genome site per 
year (Ogata et al., 1991). The resulting genetic diversity defines the evolution 
of a quasispecies: a complex population of closely related HCV variants 
circulating simultaneously in each individual patient (Martell et al., 1992). The 
quasispecies encompass a predominant ‘master’ genome, which is believed to 
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have a superior replicative capacity, and a multitude of distinct ‘minor’ 
genomes. Generally, HCV quasispecies vary by less than 5% in nucleotide 
sequence. The generation and evolution of the quasispecies is likely to have 
important implications for escape from immune surveillance, generation of 
drug resistance and vaccine failure. Considering the potential role of the HVR1 
in cell entry and its high rate of nucleotide diversity, it is conceivable that 
different components of the quasispecies within a single patient may display 
different cellular tropism. This may explain the observation that circulating 
quasispecies do not always reflect those of the intrahepatic virus (Freeman et 
al., 2001). 
    
Fourteen years ago, Ronaghi et al. (1996) showed that natural nucleotides can 
be used to obtain efficient incorporation during a sequencing-by-synthesis 
protocol. The detection was based on the pyrophosphate (PPi) released during 
the DNA polymerase reaction, the quantitative conversion of pyrophosphate to 
ATP by sulfurylase, and the subsequent production of visible light by firefly 
luciferase. However, this PPi-based sequencing method is not without 
drawbacks: The template must be washed thoroughly between nucleotide 
additions to remove unincorporated nucleotides. Also, templates not bound to 
a solid support are difficult to sequence, and the addition of new enzymes to 
each cycle of deoxynucleotide (dATP, dTTP, dGTP, and dCTP) is required 
(Ronaghi et al., 1996).  
    
This technique allows rapid detection of single nucleotide polymorphisms and 
the reading of small lengths of nucleotides from PCR amplicon. This is based 
on the quantitative detection of inorganic pyrophosphate released following 
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nucleotide incorporation into a growing DNA chain. DNA sequencing-based 
method for quantitating SNPs from a very heterogenic RNA pool such as HCV 
is a promising scientific effort. Hepatitis C virus is known to not only have 
heterogenic genome sequences among different genotypes and sub types, but 
also to acquire mutations with drug treatment (Qiu et al., 2003).  
   
One hundred and forty nucleotide-long regions of the HCV genome can be 
correctly sequenced in three Pyrosequencing reactions (Elahi et al., 2003). 
For typing of novel subtypes, the length needs to be extended beyond this 
region (Elahi et al., 2003, Stuyver et al., 1996). Pyrosequencing is a 
sequencing method based upon real-time monitoring of DNA synthesis. In this 
method the DNA is sequenced as it is synthesised, and unlike some of the 
other methods, does not require the use of probes to identify already known 
sequences. Pyrosequencing does not require labelled nucleotides or labelled 
primers and is an automated system; hence the system of large numbers of 
samples can be examined in real time (Ahmadian et al., 2006). It is attractive 
for the study of HCV genotyping.  A recent study utilising multiplex 
pyrosequencing allowed accurate identification of the genotypes of HCV 
isolates from US and Iranian patients when compared with conventional 
sequencing. In this study the sequence of a 237 nucleotide long fragment of 
5’-UTR was examined (Elahi et al., 2003). In contrast, it has been suggested 
that pyrosequencing may not be as accurate as DNA sequencing quantitation 
for the detection of single nucleotide polymorphisms (SNPs) of HCV (Qiu et 
al., 2003). Nowadays pyrosequecing is a novel strategy which can be used to 
identify multiple infections and quasispecies diversity. 
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Denaturing gradient gel electrophoresis (DGGE) is another molecular biology 
technique that permits intrahost screening and can be used for detecting HCV 
quasispecies diversity (Harris et al., 2001). 
    
Line probe assay (LiPA) technology is based on the reverse hybridization 
principle: biotinylated PCR fragments are hybridized to a selection of highly 
specific immobilized probes. In a second step, the biotin group in the 
hybridization complex is revealed by incubation with a streptavidin- alkaline 
phosphatase complex and the appropriate chromogen compounds (Stuyver et 
al., 1993). The second-generation version of this test and its ability to 
discriminate among seven HCV types (types 1 to 6 and 10) and their most 
relevant subtypes was described 3 years later (Stuyver et al., 1996). A new 
generation LiPA has been recently developed (Versant HCV Genotype 2.0 
assay). It is based on the simultaneous detection of 5'-UTR and Core regions 
for genotypes 1 and 6 to provide correct HCV genotypes characterized by 
phylogenetic analysis. Using the new LiPA assay, genotypes 6c to 6l and 1a/b 
samples were more accurately genotyped than with the previous test only 
targeting the 5-UTR (sensitivity of 96% versus 71%, respectively) 
(Noppornpanth et al., 2006). In a set of HCV strains mainly encountered in 
Western countries, Versant HCV Genotype 2.0 assay provided results that in 
conclusion classified it as a useful tool for clinical practice when only the 
discrimination between major HCV genotypes is necessary (Bouchardeau et 
al., 2007). 
    
Antonishyn et al. have developed a fluorescence-based genotyping assay 
called primer-specific extension analysis (PSEA) for the most prevalent HCV 
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genotypes and have demonstrated the capacity of PSEA-HCV for detecting 
mixed genotype HCV infections. The authors claim PSEA-HCV can detect as 
many as five genotypes in one specimen (Antonishyn et al., 2005). 
    
1.5. Multitypic HCV infection and quasispecies 
 
Infection with more than one type of HCV (multitypic HCV infection) can occur, 
particularly in individuals at risk of multiple or repeated HCV exposures (e.g. 
via injecting drug use or repeated blood transfusion or blood product 
donations).  There is, however, considerable variation in the frequency of such 
multitypic infection:  in recipients of blood products, 0 to 25% of patients may 
have multitypic infection (Viazov et al., 2000, Toyoda et al., 1999, Preston et 
al., 1995, Isobe et al., 1995). This wide range may reflect the true frequency of 
such infection (e.g. as a consequence of variable numbers of blood product 
administrations) or reflect the varying different assay methods.  
    
A new method to detect multitypic infection (and thus identify minority species 
that would otherwise not be detected by PCR-based methods) entails real-time 
nucleotide sequencing to characterise PCR clones after amplicons of the 
dominant HCV genotype in a sample of body tissue/fluid have been digested 
by genotype-specific endonuclease action. This method eliminates the 
dominant HCV genotype and permits characterisation of the PCR clones 
originating from the residual genomes (i.e. the minority genotypes). The 
identity of the minority genotypes can be achieved rapidly by pyrosequencing. 
This method permits detection of minority genotypes even when representing 
only 1% of the total HCV population. The disadvantage of this method is that it 
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is only qualitative, providing no data on the viral load of the minority genotype.  
In addition there remains no endonucleases to specifically cleave amplicons 
from genotypes 2 and 4, and the region of the HCV sequence used in this 
technique cannot discriminate between genotypes 1 and 6 (Buckton et al., 
2006). 
    
Harris and Teo provided evidence that HCV genetic complexity and diversity in 
blood donors and IDUs did not differ significantly from those in haemophilia 
patients. This observation led them to hypothesize that multiple HCV infection 
is uncommon because persistent infection by one HCV strain prevents the 
establishment of infection by subsequently introduced strains (Harris et al., 
2001). 
    
Nevertheless, in another study, working with samples, again from two patients, 
with mixed genotype infection determined by RFLP/LiPA, it was verified that 
the patients did indeed have mixed genotype infection instead of a new 
sequence/genotype in which the genotype-specific nucleotide variations for 
both genotypes were present. However, these data do show that mixed 
infection identified by RFLP/LiPA through the genotype-specific conserved 
variations indeed  reflect mixed genotype infection, at least in both cases that 
were examined in that study (Qian et al., 2000). 
    
Ducoulombier et al. showed that during chronic HCV infection, B cells and/or 
monocytes cells (PBMCs) frequently harbor specific HCV variants. The data 
also suggest that these variants are subjected to lesser constraints. This 
phenomenon could be involved in the persistence of HCV and might be an 
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important determinant of the natural history and therapeutic outcome of the 
infection (Ducoulombier et al., 2004). 
 
1.6. Quasispecies 
 
Circulating HCV is not a homogeneous population of identical viral particles, 
but rather a pool of genetically distinct, but clearly related variants referred to 
collectively as a quasispecies (Martell et al., 1992). The quasispecies arise 
from the combination of the high error rate of viral RNA polymerase, the rapid 
replication rate of HCV (1012 virions per day in infected adults) and the large 
viral population size (Pawlotsky, 2006a). The quasispecies nature of HCV 
infection confers a survival advantage by permitting rapid selection of mutants 
best suited for the environmental conditions (e.g. immune response and 
concomitant anti-viral therapy). Of greatest clinical relevance is the opportunity 
that quasispecies have in influencing treatment.  Resistance to IFN-α or 
ribavirin have each been found to reflect changes within the quasispecies 
(Pawlotsky, 2006b). 
    
There are constraints upon the composition of quasispecies. Nucleotide 
mutation can occur at any position on the HCV genome, but different regions 
are subject to different selection constraints upon the functional rate of the 
encoded protein and its specificity to the immune response. The NS5A, NS3, 
NS3 helicase and RdRp regions are well conserved, as any change in the 
nucleotide (and hence amino acid) sequence will alter viral function. In 
contrast the 27 amino acid section at the N-terminus of the E2 envelope 
glycoprotein (the hypervariable region - HVR1) is subject to rapid change such 
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that the HVR1 quasispecies changes rapidly, e.g. with IFN-α therapy 
(Pawlotsky, 2006b). 
    
The consequences of HCV quasispecies distribution are unclear. However, it 
is known that quasispecies from the liver, general circulation and peripheral 
blood mononuclear cells can be slightly different (Roque Afonso et al., 1999). 
After studying PBMCs and a wide range of autopsy tissues from HCV-infected 
immunocompetent subjects, Laskus et al. have found that a number of 
samples contained 5’-UTR quasispecies differing from those found in the liver 
or circulating in the serum. The presence of these tissue-unique sequences is 
compatible with independent viral replication at extrahepatic sites, although the 
lineage of the infected cells was unclear. These results also suggest that 
PBMCs, and probably various tissues, can selectively adsorb viral 
subpopulations differing in the E2 region. That can be easily understood as E2 
region is typically highly divergent, resulting in the presence of multiple viral 
quasispecies (Laskus et al., 2000). This compartmentalisation of quasispecies 
probably reflects differences in tissue tropism. 
    
PBMCs have a limited life span and the most plausible explanation for the 
persistence of compartmentalized quasispecies, as demonstrated in 2004, is 
replication and propagation of HCV RNA within these cells (Roque-Afonso et 
al., 2005). HCV also seems to replicate in the PBMC of patients with occult 
HCV infection. As it has been shown that HCV can propagate in lymphoid cell 
cultures and that the virus derived is infectious, it should be determined 
whether these patients (although they do not have detectable circulating virus) 
are potentially infectious (Castillo et al., 2005, Lins et al., 2005) 
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1.7. Compartmentalization 
          
Genetic diversity and tissue compartmentalization of the Hepatitis C virus are 
described in the literature more then 10 years ago in PBMC, liver and serum, 
(Navas et al., 1998) and it continues to be a great mystery and promising field 
to explore towards a better understanding of the pathogenesis of the disease. 
Liver is the main site of viral replication; however, HCV also may be found in 
extrahepatic locations such as peripheral blood mononuclear cells (PBMCs) 
(Maylin et al.  2008). 
    
Until recently, the “gold standard” tool for the diagnosis of occult HCV infection 
was the detection of HCV RNA in the liver since viral RNA in PBMCs, is 
detectable in only 70% of patients with this occult infection. However with 
simultaneous testing for HCV RNA in PBMCs and in ultracentrifuged serum 
samples, an occult HCV infection can be identified in up to 87% of the cases. 
Therefore, in light of these results, this is a substantial improvement in the 
accurate diagnosis of occult HCV infection without the need for a liver biopsy 
(Bartolome et al., 2007). 
      
B cells (CD19 positive) and monocytes (CD14 positive) are the two main cell 
types involved in HCV compartmentalization according to Ducoulombier et al. 
(Ducoulombier et al., 2004). In a study with chronically infected patients, HCV 
RNA was present in the CD19 cells of all 15 patients, but only 5 (35.7%) of 14 
and 5 (41.6%) of 12 showed HCV RNA in CD3 and CD14 cells, respectively 
(Zehender et al., 1997). An increased number of CD14-positive cells are 
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associated with high inflammatory activity and in advanced fibrosis in hepatitis 
C (Leicester et al., 2006). 
      
The distribution pattern of the HCV genome in lymphocyte subpopulations 
study by Torres et al. was as follows: 87% presence by PCR in the B cell line 
(CD19), either accompanied by presence at other sub population locations 
(45%) or alone (42%); considerable presence in CD14 monocytes (45%); and 
scarce and isolated presence in the lymphocytes CD8 (12%) and CD4 (12%) 
(Torres et al., 2000). 
      
PBMCs are frequently infected by hepatitis C virus (HCV) variants that are not 
found in plasma. (Di Liberto et al., 2006) The consequences of this 
compartmentalization on the natural and therapeutic outcome of hepatitis C 
are currently unknown.  
      
One study of immunocompetent subjects with chronic hepatitis C 
demonstrated that HCV quasispecies compartmentalization among plasma 
and BMC subsets, based on analysis of the HVR1 region, is a common 
phenomenon (Ducoulombier et al., 2004).  
 
Panasiuk et al (2003) showed that in minimal hepatitis, G1, there is a 
statistically significant increase of B lymphocytes CD19+ in peripheral blood. 
At the initiation of inflammatory activity, CD19+ count is primarily strongly 
decreased (G2). Patients with advanced inflammatory changes with periportal 
hepatocyte necrosis showed B lymphocytes such as those in the control 
group. There is no statistical relationship between the stage of fibrosis and B 
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cells in peripheral blood (Panasiuk et al., 2003). Another study showed no 
association of cleared or chronic HCV infection with altered levels of CD4+ or 
CD8+ T cells. Subjects with high level, chronic HCV viremia, but not those with 
cleared HCV infection, had reduced CD19+ B-cell levels (Zhang et al., 2005). 
Jirillo et al (1998) showed that soluble CD14 and interferon γ serum levels 
were significantly higher in chronic hepatitis C patients than those detected in 
normal donors. On the other hand, CD4+/CD8+ antibacterial activity was 
depressed (Jirillo et al., 1998).  
      
Detection of the HCV-RNA positive strand by RT-PCR and fluorescent in situ 
hybridisation confirmed the existence of HCV infection in the PBMC of the 18 
patients with occult HCV infection included in a study. Analysis of the HCV-
RNA negative strand showed that HCV was replicating in the PBMC of the 
majority (61%) of patients with occult HCV infection, with concordant results 
between the two different techniques (Castillo et al., 2005). Significant 
compartmentalization of HCV quasispecies was observed in the PBMC of four 
of nine subjects (three with Mixed Cryoglobulinemic Syndrome) and seven of 
nine cryoprecipitates, which are common findings of the disease (Zehender et 
al., 2005). 
      
Roque-Afonso et al (2005) have shown that a significant proportion of HCV-
infected subjects harbour, in their PBMC, highly divergent variants which are 
not detectable in plasma and which are likely acquired through coinfections or 
superinfections. In 9 out of 109 analyzable patients, viral sequences detected 
in PBMC differed enough to be assigned to a genotype different from the 
predominant strain in plasma. This genotypic compartmentalization was 
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confirmed by analysis of different regions. It has persisted for years in three 
patients, including post-liver transplantation in two (Roque-Afonso et al., 
2005). 
      
Two out of 11 hemodialysis study participants who lost HCV RNA in serum at 
the 30-month follow-up visit retained the virus in their PBMC population. The 
authors have suggested that HCV outbreak investigation and control in the 
hemodialysis setting could consider testing of PBMCs for HCV RNA in addition 
to serum HCV RNA and HCV antibody testing (Thongsawat et al., 2008).  
      
Approximately 30% of women were found to harbor HCV negative strand in 
their genital tract, in two different studies of HCV/HIV co-infected patients 
(Minosse et al., 2006, Nowicki et al., 2005) and positive strand (no-replicating) 
in another study with chronically HCV-infected women (Belec et al., 2003a). 
It’s important to highlight that the methods of the study performed by Minosse 
have been criticized due to a possible artefact of resampling the same viral 
templates or possible contamination (Bull et al., 2007). 
      
HCV RNA was detectable in up to 36% of cases in HCV seropositive 
homeless men. Men with HCV RNA in semen had higher RNA viral load in 
plasma than the ones that did not shed the virus in the semen. On the other 
hand, some men with very high HCV load in plasma did not have detectable 
HCV RNA in their semen, suggesting that passive transfer of viral particles 
from blood into semen could not be the only considerable factor to justify the 
RNA presence in the semen (Pekler et al.  2003). The prevalence of HCV RNA 
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detection in semen of HCV-HIV co-infected men was higher than in HCV 
infected individuals alone according to Briat et al (Briat et al., 2005). 
      
Three of 5 HCV/HIV-coinfected women showed evidence of HCV 
compartmentalization in PBMCs. Additionally, signature sequence analysis 
identified PBMC-specific amino acids in all HCV/HIV-coinfected persons 
(Blackard et al., 2007). 
      
A polymorphism in exon 4 (C77G) of CD45 that alters CD45 splicing has been 
associated with autoimmune and infectious diseases in humans and changes 
in CD45 isoform expression can alter immune function in human C77G 
variants and CD45 transgenic mice. The C77G allele may influence the 
outcome of HCV infection. CD45 isoforms also show altered immune function. 
These data provide convincing evidence that CD45 expression patterns can 
have profound effects on immune function and human diseases (Dawes et al.  
2006). 
      
A study in the setting of liver transplantation (LT) has demonstrated frequent 
HCV compartmentalization between plasma and PBMCs in LT and leukotropic 
variants with PBMC-related amino acid residues. These were not considered 
signatures by the authors due to signature variations observed in amino acid 
alignments by time point and patient, with the corresponding residues possibly 
present in plasma in this study or in a previous study (Ducoulombier et al., 
2004) as defined by VESPA computer software (Schramm et al., 2008). 
Nevertheless, the functional relevance of the identified amino acids to cell 
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tropism, HCV-host interactions, and the pathogenesis of HCV infection is still 
not well established.  
      
By infecting several peripheral blood cell types, such as B and T lymphocytes, 
monocytes, macrophages, and dendritic cells, HCV could interfere with 
antiviral cellular and humoral immune responses (Blackard et al.  2006; 
Roque-Afonso et al.  2005). 
      
It has been proposed that HCV infection of immune cells could contribute to 
viral persistence by altering the ability of these cells to mount an immune 
response (Rodrigue-Gervais et al.  2007).  
      
HCV infection of lymphocytes could contribute to the pathogenesis of 
extrahepatic disease. If PBMCs serve as a reservoir for HCV, they might 
contribute to re-infection of the graft after liver transplant. Furthermore, reports 
that HCV RNA persists in association with PBMCs after successful antiviral 
therapy raise the possibility that PBMC-associated HCV could contribute to 
virologic relapse. Thus, it is important to clarify the mechanisms by which HCV 
RNA may associate with PBMCs and to determine whether these cell subsets 
support viral replication (Marukian et al., 2008). 
 
1.8. HCV Epidemiology 
 
Hepatitis C infection is a major health care problem worldwide.  It is estimated 
that the worldwide prevalence of HCV infection is 2%, thus affecting from 123 
million (Shepard et al., 2005) to 170 million individuals worldwide. Of these, 
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only 22 million (13%) are found in the Americas and Europe. The majority of 
remaining infected individuals (87%) are from Western Pacific countries (62.2 
million), Southeast Asia (32.3 million), Africa (31.9 million), and Eastern 
Mediterranean countries (21.3 million) (Nguyen et al., 2005).  
    
In the developed world HCV is the leading cause of liver transplantation and 
the prevalence of HCV infection varies from 0.5% (e.g. UK) to 2.3% (Japan). 
There is a wide range of prevalence estimates among developing countries, 
and generally less data available to validate assumptions about the burden of 
disease than in the developed world. This range in prevalence is reflected in 
reviewing the estimates from developing countries that are among the world’s 
most populous nations. China, whose citizen’s account for one-fifth of the 
world’s population, has a reported seroprevalence of 3.2%. In India, which 
holds an additional one-fifth of the world’s population, one community-based 
survey reported an overall rate of 0.9%. Indonesia’s rate is 2.1%, but is based 
on serosurveys of voluntary blood donors. More thorough data exist on the 
seroprevalence in Pakistan, where most reported rates range between 2.4% 
and 6.5% (Shepard et al., 2005).  
 
The World Health Organization has published a report with studies by 131 
countries/areas as of June 1999. It is not recent, although it is the best general 
world HCV map available to date. Even though prevalence data is shown, it 
does not necessarily represent the true prevalence in each country, due to 
differences in the population groups studied, methods of data collection, 
interpretation between countries and limitation of data availability in several 
countries (Figure 1.2) (Who, 2000).  
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Figure 1.2. Overview of the prevalence of HCV around the globe in 
percentage (Who, 2000) 
 
  
 
    
 54 
Several co-factors are associated with accelerated HCV-related hepatic 
disease (and resultant complications).  In particular, male gender, older age at 
HCV acquisition, obesity, co-infection with HIV or HBV and alcohol 
consumption (Feitelson, 2006, Shepard et al., 2005). 
 
Chronic infection with HCV is the major infectious cause of chronic liver 
disease in Western countries. A difficulty in understanding the epidemiology of 
HCV is the lack of symptoms associated with both initial infection and for 
prolonged periods of chronic infection (Simmonds, 2001a, Simmonds, 2001b). 
 
Neal et al. (2007) have shown that HCV-infected persons have a death rate 
three times higher than that of the general population. Mortality in HCV-
infected patients is substantially higher than that of control populations 
particularly in those younger people where the lifestyles associated with the 
acquisition of HCV carry increased risk. As patients age, however, there is 
clear evidence of excess mortality from liver-related death and this is likely to 
significantly increase as the cohort (9 HCV-infected individuals) ages and liver 
damage progresses (Neal et al., 2007).  
 
Previous cohort studies exploring the relationship between HCV infection and 
mortality have demonstrated an interesting dichotomy. In several studies 
conducted in selected population subgroups, namely, those who acquired HCV 
infection through blood transfusion or contaminated intravenous 
immunoglobulin, or in military recruits, no significant increase in mortality risk 
from HCV infection was demonstrated. In contrast, community-based studies 
have tended to show that individuals with HCV infection have a demonstrably 
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increased mortality rate compared with the general population over time 
(Pungpapong et al., 2008). 
 
1.8.1. Modes of Transmission 
    
Hepatitis C virus is transmitted principally via parenteral routes such as 
injecting drug use, blood products, unsafe therapeutic injections and a number 
of other health care related procedures (Shepard et al., 2005). The institution 
of blood-screening measures in developed countries has decreased the risk of 
transfusion-associated hepatitis to a negligible level (Lauer et al., 2001) but 
injecting drug use remains the predominant mode of transmission of HCV 
(Ferreiro et al., 2005, Shepard et al., 2005). Indeed in long-term injecting drug 
users, the prevalence may be as high as 94%.  In the developing world, 
unsafe therapeutic injections (e.g. non-availability of sterile syringes 
necessitating re-use) have been a major route of spread of the HCV and 
contaminated equipment used in healthcare-related procedures (Hermida et 
al.  2002; Shepard et al.  2005). In Egypt for example, transmission of HCV 
was attributed to contaminated glass syringes used in national 
schistosomiasis treatment campaigns between 1960 and 1987. Blood 
transfusion was a common mode of HCV transmission in the developing world 
(Ferreiro et al.  2005; Shepard et al.  2005), although better screening 
methods of blood donations have reduced this risk (Shepard et al., 2005). 
Transmission via nosocomial sharps injury is rare. Unknown factors for HCV 
acquisition may play a significant role in HCV epidemiology. Those would 
more likely be represented by sexual transmission, which can occur (Ferreiro 
et al., 2005), but is rare, as is transmission via oral fluids (e.g. bites) (see 
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later), perinatal exposure (from an infected mother to her baby during birth) 
(Ferreiro et al.  2005; Shepard et al.  2005) and percutaneous or mucous-
membrane exposure (Lauer et al., 2001).  
    
It is interesting to take into account the study by Mastromoteo et al., when 
there was a prevalence of 5% HCV plasma RNA and 3.6% of HCV saliva RNA 
infected individuals within family members or co-habitants of chronic hepatitis 
C patients raising the possibility of non-sexual transmission between families 
(Mastromatteo et al.  2001). 
    
Saliva and vaginal secretions from HCV seropositive individuals with 
detectable plasma HCV-RNA showed the unique association of HCV-specific 
humoral immunity directed to viral surface glycoproteins, undetectable free 
viral RNA, and occasional non-replicating strand, cell-associated HCV. These 
observations suggested a resulting poor infectivity of saliva or cervicovaginal 
fluid in chronically HCV-infected individuals, and suggested a biological basis 
for the low risk of non-parenteral transmission of HCV infection. However, 
blood-contamination of body fluids may increase the mucosal shedding of cell 
free HCV, and inflammation of mucosa may increase the mucosal passage of 
mononuclear cell-associated HCV (Belec et al.  2003b). 
    
A study conducted in Cairo found strong correlations in HCV seroprevalence 
between first degree relatives which can be explained by a combination of 
specific modes of intrafamilial viral transmission and genetic predisposition to 
HCV infection. The respective contribution of direct HCV transmission 
between relatives by close contacts or exposure to an unidentified common 
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source of virus to the intrafamilial clustering of viral strains remains to be 
determined. Genetic epidemiological studies based upon genome-wide 
linkage analyses are twice as fast to underly intrafamilial transmission. The 
outcome of further studies could have major implications for the development 
of new HCV control strategies, particularly in developing countries 
(Plancoulaine et al., 2008). 
    
Vertical transmission of HCV is of concern, particularly in women who are co-
infected with HCV and HIV. Polis et al. have conducted a meta-analysis study 
showing that the odds of vertical transmission of hepatitis C virus (HCV) 
infection are approximately 90% higher for HIV-HCV–coinfected women than 
for HCV-monoinfected women (Polis et al., 2007). Schackman et al. previously 
conducted a decision analysis and found that a recommendation for elective 
cesarean delivery among HIV-HCV–coinfected mothers in the United States 
with suppressed HIV RNA levels could avoid up to 90 perinatal HCV 
transmissions per year and incur a risk of 1 additional maternal death per 50 
years (Schackman et al., 2004). On the basis of the findings from both of 
these studies, Schackman et al. suggested that elective cesarean delivery to 
prevent transmission of HCV infection should now be offered to HIV-HCV co-
infected mothers who would not otherwise be offered this delivery option 
(Schackman et al., 2007). 
    
Sexual transmission of HCV among men who have sex with men (MSM) 
appears to be increasing. This was more clearly observed within HIV-HCV co-
infected patients in Amsterdam (van de Laar et al., 2007) but significant 
sexual transmission of HCV to MSM whose HIV status was either negative or 
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unknown at the time of their first HCV test has also been reported, suggesting 
that the sexual transmission of HCV in MSM may not be confined to those 
with HIV infection (Richardson et al., 2008). 
    
Matching sentinel surveillance reports with HIV diagnoses revealed that in 
England and Wales in 2003 nearly 5% of HIV-diagnosed MSM tested HCV 
positive where the only risk was sex with another man. Reports of sexually-
transmitted HCV infection were not confined to London. Enhanced 
surveillance could clarify the exact likelihood of sexual transmission of HCV 
(Dougan et al., 2007). 
 
1.9. Clinical features of HCV 
 
1.9.1. Diagnosis of HCV infection 
 
Chronic HCV infection is usually asymptomatic, although occasionally patients 
may present with nonspecific symptoms such as fatigue or malaise. Some of 
them may have arthralgia and myalgia. Patients with decompensated disease 
may display peripheral manifestations of cirrhosis, such as palmar erythema, 
Dupuytren’s contracture, gynaecomastia, parotid enlargement (see section 
1.12.1), temporal muscle wasting, ascites, hepatosplenomegaly, testicular 
atrophy  and spider nevi (Modi et al., 2008). These signs may be a presenting 
feature of chronic liver disease (Vedamurthy et al., 2008) and are described 
as markers of portal hypertension if more than 6 are present (Sharma et al., 
2009). 
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Clinical course of HCV infection is influenced by several factors. Older age at 
HCV acquisition (patients over 40 years old), male gender, coinfection with 
hepatitis B virus or HIV, steatohepatitis, immunosuppression, and 
predisposing human leukocyte antigen (HLA) haplotypes have all been 
associated with progression of fibrosis and possible development of cirrhosis. 
Alcohol consumption remains the main risk factor for faster progression to 
cirrhosis in HCV infection. Furthermore, many intravenous drug users, the 
main population still at risk of HCV infection in developed countries, consume 
alcohol regularly (Vento et al., 2006). 
 
1.9.2. Staging of HCV infection (grading and staging liver biopsies) 
 
Laboratory tests are the most frequently used means of monitoring and 
grading severity of chronic hepatitis. Histologic examination is stil the gold 
standard for staging chronic liver diseases like HCV infection. 
Notwithstanding, limitations related to sampling and interpretation have to be 
carefully considered. Knodell scoring system (Knodell et al., 1981) was 
published three decades ago (Table 1.2) and is still the current method of 
choice for this purpose. The only modification in the scoring system relates to 
fibrosis (Desmet et al., 1994), which is currently viewed as a dynamic process 
that can progress or regress over time. Even the excess fibrous tissue of 
cirrhotic livers has been found to sometimes regress over time (Germani et al., 
2011). Chronic hepatitis staging relates to its time course and has significant 
prognostic and therapeutic ramifications. Its histological evaluation is based 
on the extent of fibrosis and development of cirrhosis, which is the final and 
irreversible stage of chronic hepatitis (Desmet et al., 1994). 
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Table 1.2. Histology activity index (HAI) numerical scoring of liver biopsy 
specimen used for HCV infection staging (Knodell et al., 1981) 
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1.9.3. Future directions in the staging of HCV infection  
 
Polymorphisms in the region of the interleukin-28B (IL-28B) gene were 
associated with genotype 1 hepatitis C virus (HCV) clearance in patients 
treated with pegylated interferon-alfa and ribavirin. Spontaneous clearance of 
HCV in untreated patients was also associated with IL-28B polymorphisms. IL-
28B genotype and HCV clearance may impact decisions regarding initiation of 
current therapy and the design and interpretation of clinical studies (Afdhal et 
al., 2011).  
 
1.9.4. Hepatic manifestations of HCV infection 
    
HCV causes chronic hepatitis in up to 80% of cases and may give rise to 
hepatic cirrhosis and hepatocellular carcinoma in a significant proportion of 
cases (Lodi et al., 1998). 
    
The incubation time of HCV, defined as the average time from acquisition to 
onset of symptoms, is about 6 to 8 weeks. Antibodies to HCV can be detected 
at the end of or just after, this period. In contrast, circulating HCV RNA 
becomes detectable 1 to 2 weeks after exposure to HCV. Only 60-70% of 
infected individuals have clinically detectable acute symptoms (and only 20-
30% have jaundice) and 10-20% of patients only have non-specific features 
such as anorexia, malaise or abdominal pain. Clinical features of true acute 
hepatitis are very uncommon, but when these do occur, affected individuals 
will have clinical illness that lasts about 3-12 weeks, exhibiting elevated 
alanine transaminase levels, yet low levels of HCV RNA (Zoulim et al., 2003).  
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The vast majority of HCV-infected individuals are thus symptomless carriers of 
the virus (Zoulim et al., 2003). They have only mild fatigue (Freeman et al., 
2001), manifesting the clinical consequences of chronic hepatic disease, 
and/or the extra-hepatic manifestations of HCV infection. It is suggested that 
there are 3 patterns of chronic HCV disease: chronic hepatitis with normal ALT 
levels, mild chronic hepatitis, and moderate to severe chronic hepatitis. The 
first group have persistently normal ALT levels, asymptomatic disease, 
histopathological evidence of mild chronic hepatitis and do not have 
progressive disease. The second group have elevated ALT levels, 
histopathological evidence of mild necroinflammation of the liver and progress 
slowly, if at all, to cirrhosis.  In contrast, however, the third group have marked 
necroinflammation of the liver and are likely to progress to cirrhosis (Zoulim et 
al., 2003). 
    
Hepatic cirrhosis arises in as many as 35% of patients with HCV infection and 
is most likely to occur in those individuals with moderate to severe chronic 
hepatitis. Disease is often asymptomatic, however, the clinical features when 
they do present are not different to hepatic cirrhosis of any other cause. 
Hepatocellular carcinoma (HCC) arises in about 3% of all HCV-infected 
individuals, and is the consequence of the HCV-related cirrhosis (Zoulim et al., 
2003). 
    
Ohki et al (2008) have shown that there is an association between the body 
mass index (BMI) and the risk of hepatocarcinogenesis in chronic hepatitis C 
patients in a wide range of BMIs. Although the mechanism of this phenomenon 
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remains to be investigated, obesity is considered an independent risk factor for 
HCC development in chronic hepatitis C patients (Ohki et al., 2008).  
    
HCV (with the possible exception of HIV) is distinct and somewhat unusual for 
an RNA virus in being able to establish persistent infection in the majority of 
exposed individuals. Furthermore, long-term, chronic infections underlie its 
disease manifestations (Simmonds, 2004). 
 
1.9.5. Extra-hepatic manifestation of HCV infection 
 
HCV infected patients often have extrahepatic manifestations, which 
significantly contribute to HCV-related morbidity (Carrozzo et al., 2002). It is 
well established that HCV can give rise to essential mixed cryoglobulinaemia 
(MC), this association being most common in patients in Italy (Pozzato et al., 
1994). The cryoglobulinaemia may lessen with interferon therapy indicating 
that there is a causal relationship with HCV infection. MC is characterised by a 
B-cell lymphoproliferative disorder. The definition of MC is provided by 
laboratory findings: presence of serum immunoglobulins that precipitate at low 
temperatures (less than 37 degrees Celsius). Type II MC is characterised by 
polyclonal IgG and monoclonal IgM with rheumatoid factor (RF) activity 
(Zignego et al., 2007). Chronic infection with HCV is strongly associated with 
MC type II, which can evolve into overt lymphoma in some patients (De 
Sanjose et al., 2008). HCV may also be causally associated with certain types 
of non-Hodgkin’s lymphoma. Other possible extra-hepatic features of HCV 
infection are indicated in Table 1.2 (Carrozzo, 2008). 
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Table 1.3. Classification of extrahepatic manifestations of HCV infection 
(Carrozzo, 2008) 
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1.10. Treatment of HCV infection 
 
Although HCV infection is a chronic viral infection, an advantage of this 
disorder over many other viral infections is that replication is generally 
confined to the cytoplasm of hepatocytes (Chung, 2006). As a consequence 
delivery of a specific antiviral agent to its site of action should be possible, and 
hence a sustained virological response may be achievable. 
     
There are currently two different treatment regimens for chronic hepatitis C: 
monotherapy (using a single drug, interferon) and combination therapy (using 
two drugs, interferon and ribavirin) recommended by The Food and Drug 
Administration (FDA) from the US and the National Institute for Clinical 
Excellence (NICE) – National Health Service (NHS) from the United Kingdom 
(UK). Interferon alfa, a cytokine with immunomodulatory and antiviral activity 
which is injected into the bloodstream, works by bolstering the immune 
response to HCV (Bren, 2001). Ribavirin, a synthetic guanosine nucleoside 
analogue with in vitro antiviral activity (Freeman et al., 2001) taken orally, may 
work by preventing the virus from reproducing (viral replication) (Bren, 2001).  
    
The goal of antiviral therapy of HCV infection is to induce a sustained 
virological response (SVR) in which there is clearance of serum HCV RNA by 
the end of therapy that is further sustained for the subsequent 6 months 
(Hughes et al., 2006). This is generally thought to represent “cure” of the 
infection, as the vast majority of subjects that reach this therapeutic goal go on 
to have a clinical, biochemical, and sometimes histological remission of their 
chronic hepatitis (Gallegos-Orozco et al., 2008). A variety of factors influence 
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the ability to achieve SVR, these being both viral- or host-associated. In a 
large cohort of chronic hepatitis C patients with an SVR, followed up for up to 
18 years after treatment cessation, HCV RNA remained undetectable in 
serum and PBMCs in all the patients, and was detected in 2 of 114 (1.7%) 
liver tissues tested. SVR was associated with sustained biochemical response 
(94%), stability or regression of fibrosis (88%), and with rare liver-related 
clinical events (3 hepatocelular carcinomas). These results suggest that SVR 
durable regardless of the type of treatment and should be considered to 
represent eradication of HCV infection (Maylin et al., 2008).   
    
A favourable response is likely when the genotype is 2 or 3, the viral RNA 
levels are low, there is lowest quasispecies diversity (Pawlotsky, 2006b) and 
the disease is acute rather than chronic. Genotypes 2 and 3 typically respond 
to treatment in 24 weeks or less (Heathcote and Main, 2005; Hughes and 
Shafran, 2006). Dalgard et al. (2008) have shown in a recent trial that SVR 
rate after 14 weeks of treatment is high, and although longer treatment may 
give slightly better SVR rate there are considerable economical savings, good 
response to retreatment, and fewer side effects making it rational to treat 
patients with genotype 2 or 3 and RVR for only 14 weeks (Dalgard et al.  
2008). 
    
Genotype 1 is more resistant, requiring treatment for 48 weeks and maybe 
more (Heathcote et al., 2005). Variable treatment duration ensures an SVR 
rate similar to that of the standard treatment duration, with significant potential 
reductions in cost and side effects. Approximately a quarter of HCV genotype 
1 patients may be cured by therapy in only 24 weeks and an approximately 
 67 
comparable rate of patients may require extended treatment for 72 weeks. 
HCV RNA should be monitored qualitatively at week 4 to identify patients with 
the highest likelihood of response and at weeks 8 and 12 to determine if 
extended treatment duration may be required (Mangia et al.  2008). 
    
The host factors that favour an SVR are female gender, young age, little 
hepatic fibrosis, low body weight and body mass, and lack of co-morbidity 
(e.g. alcohol abuse, renal disease, HIV infection) (Feld et al., 2005). A 
favourable SVR results in a durable HCV response and an improvement in 
hepatic histology (e.g. lessening of inflammation and fibrosis). Three patterns 
of response to antiviral therapy have been observed: SVR (as detailed above), 
an end of treatment response with subsequent relapse, and non-response.  In 
a typical SVR there is a two-phase virological response in which there is an 
initial drop of HCV RNA levels of 90-99% in the first two days, followed by a 
slower, but sustained decrease in HCV RNA levels (the latter reflecting 
clearance of virus from the hepatocytes) (Feld et al., 2005). 
    
Only patients with low HCV complexity, i.e., a small quasispecies sequence 
repertoire, appear to be able to have sustained HCV clearance after therapy. 
In contrast, patients with a large quasispecies sequence repertoire are very 
unlikely to achieve SVR, probably because there is a higher chance that one 
or several pre-treatment variants will escape the action of interferon alfa 
effectors and will proliferate (Pawlotsky, 2006a). 
    
The attachment of polyethylene glycol to interferon alfa (peginterferon alfa) 
extends the half-life and duration of therapeutic activity of interferon alfa. In 
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contrast to interferon alfa, peginterferon alfa is given only once a week, and 
the individual dose is calculated according to the patient’s weight. Treatment 
with peginterferon alfa results in a higher rate of response than does 
conventional monotherapy with interferon alfa. Large clinical trials are under 
way, at least over the course of the last decade, to evaluate the combination 
of peginterferon and ribavirin (Lauer et al., 2001, Rai et al., 2011). The results 
will determine the role of these agents in the treatment of HCV infection. 
    
Two forms of pegylated (PEG-IFN) interferon alpha are available (PEG-IFN 
alpha 2a and PEG-IFN alpha 2b), each of which have a longer duration of 
action than conventional IFN alpha.  Overall sustained virological response 
(SVR, i.e. the absence of detectable HCV RNA in blood 6 months after end of 
treatment) can be achieved in 25-40% of patients receiving PEG-IFN 
monotherapy, the typical duration of therapy being 24 or 48 weeks (Hughes et 
al., 2006). Interferon alpha exerts its anti-HCV action by inducing IFN-
stimulated genes of the host cell that then interfere in the translation of viral 
proteins (Feld et al., 2005). 
    
A wide of adverse side effects can arise with IFN therapy including fatigue, flu-
like illness, gastrointestinal disturbances, haematological changes, 
neuropsychiatric disturbances (especially depression), thyroid dysfunction, 
cutaneous disease (e.g. alopecia and pruritis) (Pawlotsky, 2006a) and 
lichenoid reaction (Guillermo et al., 2009, Sookoian et al., 1999). 
    
Gurguta et al. (2006) observed lingual hyperpigmentation, an unreported 
condition so far, in 5 of 171 patients participating in two clinical trials with 180 
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μg PEG-Interferon α2a once weekly and various doses of Ribavirin (400–1,200 
mg per day) given for 24–72 wks. All five were dark-skinned patients (out of 
22). No hyperpigmentation occured in the 149 Caucasian patients(Gurguta et 
al., 2006). Although two years later Fernández et al. (2008) reported a tongue 
hyperpigmentation resulting from peginterferon alfa-2a and ribavirin treatment 
in a Caucasian patient with chronic hepatitis C (Fernandez et al., 2008). 
    
Ribavirin will inhibit HCV replication via early chain termination and weak 
inhibition of RNA polymerase. The principal clinical effect of ribavirin is to 
prevent relapses in patients who respond to IFN-alpha (Pawlotsky, 2006b). 
Ribavirin monotherapy may not have a significant effect upon the SVR, but 
may improve the histopathological and biochemical responses in HCV 
infection (Brok et al., 2006). When given in combination with IFN-alpha, 
ribavirin does however improve short-term and long-term outcome, although 
its antiviral action seems to be of greatest impact in the later phases of 
therapy, reducing the likelihood of rebound infection.  As with IFN-alpha, a 
wide variety of adverse side effects can arise with ribavirin and include 
anaemia, dermatitis, anorexia, dyspepsia, insomnia, dyspnoea and malaise 
(Hughes et al., 2006).   
    
An unexpected case of severe pulmonary tuberculosis after 7 month 
combined pegylated interferon-ribavirin for Chronic HCV was observed in a 
patient with a severe underlying immunosuppression caused by the cited 
combination therapy (Sabbatani et al., 2006). 
    
 70 
The long-term effects of IFN alpha and ribavirin are unclear, however, 
certainly many patients do clear HCV from blood and have a fall in markers of 
HCV infection and hepatitis. In addition there may be an improvement in the 
histopathological features of hepatitis. Despite these, perhaps optimistic 
findings, the therapy of HCV infection is expensive and thus unlikely to be 
available to many HCV-infected individuals in the developing world.  In 
addition, co-infection with hepatitis viruses (e.g. HBV, HDV and others) (Gaeta 
et al., 2006) and HIV infection may hinder anti-HCV therapy being effective 
(Hughes et al., 2006). 
    
Weight-based ribavirin dosing must be taken into consideration to maximize 
treatment outcomes (Hrachovec et al., 2003). In addition, certain other factors 
impact upon virological outcomes, such as high viral load, sex, race, weight, 
age at the time of infection, degree of hepatic fibrosis, and adherence 
(Heathcote et al., 2005, Kim et al., 2005). 
    
Amantadine (1-aminoadamantanamine) is a water soluble tricyclic amine that 
has been used clinically to prevent influenza A viral infection, and has known 
antiviral effects against other families of RNA viruses such as togavirus, 
myxovirus, coronavirus and flavivirus, of which hepatitis C is a member, as 
explained before (De Clercq, 2001). Amantadine may be useful as a safe and 
well-tolerated adjunct to combination interferon/ribavirin therapy in the 
treatment of some patients who have failed interferon or interferon/ribavirin for 
chronic hepatitis C infection. The major advantage of amantadine is its 
favourable safety and tolerability profile and low cost. Although it is a weak 
antiviral agent with indirect effects on viral replication, multiple observational 
 71 
studies and randomized trials suggest that combination regimens with 
amantadine may significantly increase rates of sustained viral clearance in 
non responders, responder/relapsers, and breakthrough responders to 
interferon and interferon/ribavirin. In the absence of available therapies which 
target the HCV viral replication cycle, amantadine may represent a suitable 
option in the properly selected patient (Lim et al., 2005).  
    
In a recent randomized clinical trial the sustained virological response (SVR) 
rate was 8% higher in the triple therapy group - pegylated interferon/ribavirin, 
plus amantadine - (24%) compared with the double therapy group - pegylated 
interferon/ribavirin - (16%), although the difference was not statistically 
significant (Maynard et al., 2005). Further clinical trials with a larger population 
group may give us some hope about the benefits that amantadine could 
achieve in terms of effective doses for combined therapy in the future. 
    
Akuta et al. identified amino acid substitutions in the core region and serum 
LDL-C as precursors of early virological response (EVR) and sustained 
virological response (SVR) to Peginterferon-Ribavirin therapy in Japanese 
patients infected with HCV genotype 1b (Akuta et al., 2007).      
Liver transplantation is the only available treatment option for patients with 
decompensated HCV-related cirrhosis and is also indicated for some patients 
with early stages of hepatocellular carcinoma (Lauer et al., 2001). 
    
A large scale Egyptian study provides strong evidence in favour of a higher 
HCV clearance rate in females compared to males, but it’s important to bear in 
 72 
mind that 98,5% of the study population was genotype 4. There would be 
higher chances of spontaneous resolution of infection among females 
compared to males (Bakr et al., 2006).   
       
Histological evaluation of a liver-biopsy specimen remains the gold standard 
for determining the activity of HCV-related liver disease, while histological 
staging remains the only reliable predictor of prognosis and the likelihood of 
disease progression. A biopsy may also help to rule out other concurrent 
causes of liver disease. Therefore, biopsy is generally recommended for the 
initial assessment of persons with chronic HCV infection. However, a liver 
biopsy is not considered mandatory before the initiation of treatment, and 
some recommend a biopsy only if treatment does not result in sustained 
remission (Lauer et al., 2001, Germani et al., 2011). 
    
HCV infection can be treated, but the treatment is still costly and requires 
long-term medical support and follow-up; current therapies are impractical for 
the majority of HCV carriers worldwide. The development of a protective 
vaccine was considered, at best, a distant prospect (Simmonds, 2004). This 
panorama may have started to change when Klade et al. showed that the 
HCV peptide vaccine IC41 can induce HCV-specific Th1/Tc1 responses in a 
subset of difficult to treat HCV nonresponder patients despite persisting 
viremia. However, changes in HCV RNA occurred only in single patients. 
Because strongest T-cell responses were associated with HCV RNA decline, 
further studies with optimized vaccine regimens and combination therapies 
have been initiated (Klade et al., 2008). 
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Recent studies in the LCMV model of infection have also highlighted the key 
regulatory role of the IL-10/IL-10 receptor (R) pathway because IL-10-R 
blockade with specific antibodies was able to restore protective antiviral 
responses, preventing chronic evolution of infection. Also in human HCV 
infection, HCV-specific regulatory CD8 cells that are able to suppress T-cell 
responses by production of IL-10 or TGF-Beta have been isolated from the 
liver and the peripheral blood of patients with chronic hepatitis C. Because the 
impact of IL-10/IL-10-R blockade on LCMV, infection was more dramatic when 
the pathway was blocked at early stages of infection, studies are needed to 
understand whether this strategy can be envisaged for chronic infections in 
humans, where T cells have been exposed to viral antigens for years (Ferrari, 
2008). 
 
The specifically targeted antiviral therapies for hepatitis C (STAT-C) drugs 
target host proteins or influence the intrinsic host antiviral response through 
interferon-responsive pathways. In addition, new interferon compounds have 
been developed in order to further optimize pharmacokinetics, dosing 
frequencies, bioavailability, and potency against HCV. While the development 
of some compounds has discontinued due to safety or efficacy concerns, such 
as taribavirin, a prodrug of ribavirin with decreased haemolytic anemia, many 
promising drugs remain in various stages of development (Amorosa, 2010). 
 
The constant development of new therapeutic approaches reveal promissing 
alternatives such as the traditional path of interferon related systems or 
modified forms of ribavirin, internal ribosome entry site (HCV IRES) inhibitors, 
NS3/4A serine protease (telaprevir and boceprevir) and NS5A inhibitors, novel 
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immunomodulators, specifically targeted anti-viral therapy for hepatitis C 
compounds, caspase inhibitors, anti-fibrotic agents, antibody treatment and 
vaccines (De Clercq, 2001, Feld et al., 2005, Pawlotsky, 2006a, Munir et al., 
2010). Another novel class of agents in development is the entry inhibitors. 
SR-B1 is the hepatocyte membrane protein that is the primary substrate for 
HCV attachment followed by internalization. It is important to target this host 
receptor as well as identify and analyse other compounds that directly target 
the viral envelope (Bartosch et al., 2003). Disadvantageously, no recent 
studies have explored further development of any entry inhibitor compounds. 
 
Anti-NS4B molecules such as the clemizole hydrochloride, an old drug that 
has previously been clinically approved as an antihistamine, have also a great 
potential to be helpful in HCV therapy, either alone or in combination with 
other drugs. Clemizole hydrochloride could be synergistic with protease 
inhibitors and with interferon, ribavirin, nucleoside and non-nucleoside NS5B 
polymerase inhibitors. If clemizole hydrochloride or any other anti-NS4B 
compound further demonstrates efficacy in human clinical trials, evaluating 
their combination with other clinical candidates will considerably broaden the 
potential treatment options for HCV-infected patients (Rai et al., 2011). 
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1.11. Oral aspects of HCV infection 
 
1.11.1. HCV in oral fluids 
 
The epidemiology of HCV disease does not suggest that saliva is a common 
vehicle for the transmission of HCV (Shepard et al., 2005). In addition the 
prevalence of HCV infection among dental health care workers exposed to 
saliva is similar to that of local populations (Leao et al., 2006). While these 
latter observations were made where the local population prevalence of HCV 
was likely to be low and infection control measures likely to be effective, the 
results of a recent study with a large cohort that included HCV-infected 
individuals did not reveal that orogenital contact (and thus contact with saliva) 
was a route of transmission of HCV (Marincovich et al., 2003). Nevertheless 
HCV RNA and antibodies to HCV are present in saliva, HCV binds to, and may 
possibly replicate within oral epithelium and may give rise to salivary gland 
disease (Carrozzo et al., 2003).  
     
It has been more then two decades since eminent papers has been published 
regarding the diagnostic uses of saliva. (Ferguson, 1987; Malamud, 1992; 
Mandel, 1990; Streckfus and Bigler, 2002) It is not one of the popular bodily 
fluids. It “lacks the drama of the blood, the sincerity of sweat and the 
emotional appeal of tears” (Mandel, 1990). However, a growing number of 
health care workers are finding that saliva provides an easily available, non-
invasive diagnostic medium for a rapidly widening range of diseases and 
clinical situations (Ferguson, 1987, Mandel, 1990).  
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Salivary transmission of HCV was suggested by the report of a male 
developing HCV infection one month after receiving a bite injury.  However, 
the HCV status of the aggressor was not known, and thus it cannot be 
concluded that the bite injury lead to HCV acquisition (Dusheiko et al., 1990). 
Certainly saliva may be infective, (as discussed below), and transmission of 
NANBH via innoculation of NANBH-infected saliva into a chimpanzee has 
been demonstrated (Abe et al., 1991). 
    
The salivary antibodies to HCV have immunoreactivity different to that of the 
serum antibodies.  The antibodies of saliva have greatest activity to 
complement component C1, whereas those of serum show greater activity to 
antigen NS3. These differing immunoreactivities might reflect the existence of 
local viral replication, the carriage of viral mutants or the present of viral 
inhibitors in oral fluids (Maticic et al., 2003). 
    
RT-PCR is an accurate assay for the detection of HCV-RNA in saliva (Lins et 
al., 2005). Furthermore, HCV-RNA detection in the saliva of HCV infected 
patients may be independent of the viral load (Fabris et al., 1999, Lins et al., 
2005) and any oral disease. Saliva might, therefore, play a significant role in 
the non-parenteral transmission of HCV (Lins et al., 2005) and explain 
intrafamilial transmission of HCV.  
   
A study in Japan showed that 14 out of 18 patients (78%) whose saliva 
specimens were negative had HCV RNA in their gingival crevicular fluid 
(GCF). Most patients (20 of 26; 77%) also had higher HCV RNA levels in their 
GCF than in their saliva. Although the numbers of specimens were limited, 
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they have quantitatively determined HCV RNA in oral fluids from dental 
patients, including some patients with oral diseases, and demonstrated 
frequent detection of HCV in the saliva and GCF (Suzuki et al., 2005). 
    
There have been many studies of the detection of HCV RNA in oral fluids, 
particularly whole saliva.  The frequency of detection of HCV-RNA in whole 
saliva has ranged from 0-100% (Goncalves et al., 2005, Hermida et al., 2002) 
with a mean of about 50% (Ferreiro et al.  2002; Leao et al.  2006) as detailed 
in chapter 3. The notable variation in the results of these studies probably 
reflects differences in the population groups, country of residence of patients, 
methods of collection of saliva and the assays employed to detect HCV RNA. 
 
The presence of HCV in saliva usually correlates with high load of circulating 
virus.  The HCV genotype in saliva seems to be identical to that in the blood of 
the same individual (Roy et al., 1998). It has been suggested that HCV occurs 
mainly in the cellular element of saliva (Belec et al.  2003b; Chen et al.  1995), 
however, some workers have found HCV RNA to be present in the cell-free 
fraction (Roy et al.  1998; Hermida et al.  2002; Roy et al.  1996).  
    
Hepatitis C virus particles have been detected in oral mucosal epithelial cells 
(Arrieta et al.  2000; Carrozzo et al.  2002).  Both the non-replicating (positive) 
(Belec et al.  2003b) and replicating (negative) strand of HCV have been 
detected in oral epithelial cells (Carrozzo et al., 2002), thus there is no 
conclusive evidence that HCV replicates in the oral epithelium.  It would seem 
logical that HCV in saliva is not the consequence of local replication, but is 
passed to the mouth via gingival crevicular fluid (GCF). However, although 
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HCV RNA has been detected in up to 59% of GCF samples (Maticic et al.  
2001), this cannot be the only local source of HCV as it has been detected in 
saliva of edentate individuals (Roy et al., 1998). HCV is present in circulating 
monocytes – known to pass into GCF – thus it would be expected that the oral 
carriage of HCV would be increased in gingivitis and periodontitis, however, a 
study of patients in Brazil did not find any association between the present of 
HCV in saliva and their dental status (Lins et al., 2005). 
   
In contrast to HCV RNA, antibodies to HCV are frequently detected in saliva, 
indeed at least 90% of viraemic HCV seropositive individuals have detectable 
HCV antibodies in saliva (Lucidarme et al., 2003). Several studies have 
established that the sensitivity of detection of HCV antibodies in saliva can 
approach 98% and recent epidemiological studies have indicated that the 
detection of antibodies to HCV in saliva may be more effective, and less 
invasive, than the detection of antibodies in serum. In particular studies of 
haemodialysis recipients (Yaari et al., 2006), prisoners (Champion et al., 2004) 
and children (Chatzipantazi et al., 2004) have utilised saliva rather than serum 
to estimate the prevalence of HCV infection. 
 
HCV may persist in the mouth despite clearance from blood (Diz et al., 2005). 
This data suggests that there is the need for further studies in order to clarify 
the significance of the HCV virus in the saliva (Hermida et al., 2002, Diz et al., 
2005, Goncalves et al., 2005) as HCV RNA detection in saliva may be useful 
for monitoring anti-viral treatment in the future (Diz et al., 2005). 
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1.12. Oral manifestations of HCV infection 
   
The oral manifestations of HCV disease principally centre upon HCV 
sialadenitis. Associations between HCV and oral lichen planus have been 
extensively investigated and there remains no clear evidence of such an 
association.  Likewise links between HCV infection and Behcet’s disease have 
been proposed, but as of yet there is little evidence that conclusively supports 
such an association (Carrozzo et al., 2002). 
 
1.12.1. Sialadenitis 
 
Sialadenitis presenting as xerostomia and/or salivary gland enlargement – 
usually the parotid glands (Vedamurthy et al., 2008) – can affect up to 80% of 
examined individuals with HCV infection (Carrozzo et al., 2002). Given the 
strong association recently discussed between HCV infection and essential 
MC and the high prevalence of Sjogrën Syndrome (SS) in essential MC, an 
association between HCV infection and the SS has been postulated (Gumber 
et al., 1995). While lacrimal gland dysfunction can also occur, HCV does not 
cause SS (as only 0-19% of patients with SS are HCV infected). The 
histopathology of HCV sialadenitis does not include the same pattern of 
lymphocytic infiltrates as SS.  However, a transgenic mouse model carrying 
HCV envelope genes E1 and E2 did develop sialadenitis with lymphocytic 
infiltrate that resembled that of SS (Haddad et al., 1992). The exact pathogenic 
mechanism of HCV sialadenitis remains unknown.   
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In association with salivary gland tissue inflammation, the decreased 
production of salivary total IgA at a level nearly twofold less than the normal 
could be caused by possible dysfunction of salivary glands related to HCV 
infection itself. In three patients with clinical symptoms resembling primary SS, 
the salivary productions of total IgA and IgG were both decreased, but the 
local inflammation was probably enhanced, resulting in a pattern of highly 
increased salivary levels of HSA and immunoglobulins, a well known feature 
occurring during xerostomia (Belec et al.  2003b). 
    
Even though sialadenitis is frequently observed in chronic hepatitis C, it seems 
to be not directly related to HCV per se. The presence of a common epitope 
between antigenic protein in the salivary gland and the HCV-structured protein 
could be a target for immunological attack (Ohoka et al., 2003). 
  
1.12.2. Oral lichen planus 
 
Oral lichen planus (OLP) has been observed in some patients with HCV 
infection. The exact, if any, aetiological link between HCV-associated OLP and 
this viral infection remains controversial. Circulating HCV RNA has been 
detected in 0-34.7% of examined patients with OLP, while HCV antibodies 
have been detected in 0-55% of examined patients (Carrozzo et al., 2002). 
   
It has been recently suggested that the hepatitis C virus exerts an indirect 
effect, mediated possibly by the modulation of cytokines and lymphokines in 
the pathogenesis of oral erosive lichen planus (Femiano et al., 2005). 
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The frequency of HCV RNA and antibodies is increased in patients with OLP 
in comparison with appropriate controls in some, but not all, studies. In 
particular, a marked relationship between HCV and OLP has been observed in 
studies with patients from Mediterranean coutries, Japan and USA, but not in 
the UK or Brazil (Cunha et al., 2005, Jaber et al., 2003, Lodi et al., 2010). In 
some instances, the association of HCV with OLP is likely to simply reflect the 
high prevalence of HCV disease in local populations, however, a study of 
patients with OLP in Egypt (the country with the highest prevalence of HCV 
disease) did not find any significant association between HCV and OLP 
(Ibrahim et al., 1999). 
    
Associations between OLP and chronic liver disease (e.g. HBV infection) have 
previously been reported (Carrozzo et al., 1996), and cutaneous lichen planus 
can arise following HCV vaccination (Rebora et al., 1999). However, the 
associations between non-HCV-related chronic liver disease have 
predominantly been observed in patients in France, Italy and Spain, but not 
Scandinavia or the UK (el Kabir et al., 1993). 
    
Some instances of OLP associated with chronic liver disease reflect drug 
therapy (e.g. penicillamine) and similarly OLP can arise in HCV infection 
secondary to interferon therapy(Guijarro et al., 2001). 
    
It remains unclear if HCV truly gives rise to OLP.  Anti-epithelial antibodies 
have been detected in patients with HCV-related OLP (Lodi et al., 1997), 
however, these may not be of aetiological relevance as interferon alpha 
therapy can induce such antibodies (Fleischmann et al., 1996). Both positive 
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and negative strands of HCV have been detected in 82-93% and 21-36% of 
examined HCV-associated lesions (Nagao et al., 2000, Carrozzo et al., 2002), 
but HCV RNA has also been detected in normal oral epithelia of HCV infected 
individuals (Arrieta et al.  2000). There may be some compartmentalisation of 
HCV specific CD8+ T cells in OLP (Pilli et al., 2002). 
    
While an association between HCV and OLP might exist, the geographic 
variation in the prevalence of HCV-related OLP is striking. A recent study 
demonstrated that there was an increased frequency of HLA-DR6 in Italian 
individuals with HCV-related OLP when compared with Italians with HIV, but 
not OLP, and UK individuals with OLP only. It has thus been suggested that 
the development of OLP in HCV disease reflects host immunogenetic factors, 
rather than any specific viral factor (Carrozzo et al., 2005). 
 
A recent review with meta-analysis on the prevalence of HCV in lichen planus 
patients and on the prevalence of lichen planus in chronic HCV infected 
patients has shown that HCV positive patients have significantly higher 
chances than controls of being HCV seropositive. In addition, significantly 
higher chances of having lichen planus were found among HCV patients. 
Variability of  HCV/lichen planus association was only partially dependant on 
geographic distribution (Lodi et al., 2010). 
 
1.12.3. Non-Hodgkin’s lymphoma 
 
A study with high statistical power (more than 10000 patients including the 
control group) has confirmed the association between HCV infection and non-
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Hodgkin’s lymphoma and specific B-non Hodgkin’s lymphoma subsets (diffuse 
large B-cell lymphoma, marginal zone lymphoma and lymphoplasmacytic 
lymphoma) (de Sanjose et al.  2008). Thus, perhaps as expected, NHL within 
parotid glands has been observed, but in a small number of patients with HCV 
disease (De Vita et al.  1995; Luppi et al.  1996; Ascoli et al.  1998).  
 
1.12.4. Oral Squamous cell carcinoma 
 
Oral squamous cell carcinoma (OSCC) has been observed in small numbers 
of patients with HCV infection (Nagao et al.  2000; Nagao et al.  1996; Nagao 
et al.  1995), however, as HCV infection is not common in oral epithelial 
dysplasia (Jaber et al., 2003), it seems unlikely that HCV has any aetiological 
relevance to OSCC.   
 
1.12.5. Behcet’s disease 
 
Associations between Behcet’s disease and HCV infection have been 
suggested, but there is no clear evidence of such a link (Farajzadeh et al., 
2005). 
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1.13. Scope of studies and aims 
 
There remains uncertainty as to wether HCV is present in saliva and hence a 
possible source of transmission of the virus. In addition, there is a need for a 
greater understanding of the possible influences upon oral carriage of HCV. 
This present study was thus undertaken to determine the frequency of oral 
carriage of HCV and the influence of oral factors (e.g. oral health status), 
systemic factors (e.g. presence of HCV in plasma and peripheral blood 
mononuclear cells) and viral factors (genotype and quasispecies) upon oral 
carriage. 
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Aims are: 
 
1) To determine the prevalence and viral load of HCV in whole saliva of 
patients with HCV disease attending clinics in Recife in Northeast 
Brazil.  
2) To determine the influence of HCV in plasma and peripheral blood 
mononuclear cells (PBMCs) upon the salivary presence of this virus. 
3) To determine the prevalence and viral load of HCV in peripheral blood 
mononuclear cells (PMBCs) of patients with HCV disease attending 
clinics in Recife in Northeast Brazil. 
4) To determine the influences of oral health on root of transmission and 
treatment. 
5) To determine the influence of HCV in plasma upon the PMBC presence 
of this virus. 
6) To determine if the genotype distribution of HCV of patients resident in 
the Recife area of Northern Brazil is consistent with other studies from 
South America.  
7) To determine if there were any genotype discordances between 
plasma, peripheral blood mononuclear cells and whole saliva taken 
from the same individuals. 
8) To establish if there are different quasispecies of HCV within plasma, 
saliva and peripheral blood mononuclear cells by means of analysing 
the compartments nucleotide changes and aminoacid variabilities. 
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Chapter 2  
 
 
Materials and methods 
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2.1. Patients 
 
The group comprised 86 individuals (52 males, 34 females; mean age 49.2 
years; range 20 to 79 years) who were antibody positive for HCV attending the 
Hospital das Clínicas HC/UFPE, Recife, Brazil and/or the “Nefroclínica” 
(Haemodialysis clinic), Recife, Brazil; 23 of the patients required regular 
haemodialysis. The patients’ gender, age and HCV therapy are described in 
Table 2.1. Sixty six had not received anti-HCV therapy.  
 
The untreated group comprised 40 males and 27 females, with a mean age of 
49.1 years and a range of 20 to 79 years.  
 
The treated group comprised 12 males and 7 females with a mean age of 49.3 
years, and a range of 27 to 69 years. Therapy for the treated patients 
comprised interferon (5 patients), ribavirin (2 patients), interferon plus ribavirin 
(11 patients) and interferon plus amantadine (1 patient). Five patients had had 
retreatment of their HCV disease with interferon (1 patient) or interferon plus 
ribavirin (4 patients). All the samples were collected between July and August, 
2006.  
 
2.1.1. Inclusion criteria 
 
Patients enrolled were either attending the Hospital das Clínicas HC/UFPE or 
Nefroclínica with HCV antibody positive status, and signed an informed 
consent agreeing to take part of the study between July and August, 2006. 
The patients were not necessarily tested for HCV RNA before commencing 
the study. 
 
 
 88 
2.1.2. Oral health status  
 
Each patient had a visual, non-invasive oral examination to detect their oral 
health status.  
 
2.2. Sample Collection and Preparation 
 
2.2.1. Collection and Preparation of whole blood 
 
Peripheral blood was collected from the cubital fossa of each patient into 
EDTA-treated vacutainers and stored, for not more than 24 hours at 4ºC. 
Plasma was separated from blood by centrifugation at 3500 RPM for 15 
minutes with 1 mL of plasma removed and stored at -20 ºC. The remaining 
blood was resuspended for isolation of individual cell types (see section 
2.2.3).  
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        Table 2.1. Details of the gender, age and HCV therapy of 86 patients with known HCV infection 
Patient ID Gender Age Treatment Type (Duration) Comment (re-treatment) 
1 M 50 Yes Peginterferon + Ribavirin   
2 M 34 No N/A  
3 M 47 No N/A  
4 F 37 Yes Interferon + Ribavirin  
5 M 73 No N/A  
6 M 33 No N/A  
7 F 65 No N/A  
8 F 56 Yes Interferon + Ribavirin  Peginterferon +Ribavirin 
9 F 22 No N/A  
10 F 53 Yes Interferon   
11 F 39 No N/A  
12 F 43 No N/A  
13 M 45 No N/A  
14 F 69 Yes Ribavirin  
15 M 55 No N/A  
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16 M 67 No N/A  
17 M 50 No N/A  
18 M 49 Yes Interferon + Ribavirin   
19 M 73 No N/A  
20 M 65 Yes Interferon  
21 F 58 No N/A  
22 F 71 No N/A  
23 M 53 No N/A  
24 M 30 Yes Interferon + Ribavirin   
25 F 62 No N/A  
26 M 52 No N/A  
27 F 37 No N/A  
28 M 36 No N/A  
29 F 64 No N/A  
30 M 57 No N/A  
31 F 25 No N/A  
32 M 27 No N/A  
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33 M 50 Yes Interferon  Interferon + Ribavirin  
34 F 27 No N/A  
35 M 53 Yes Interferon + Ribavirin  
36 F 51 No N/A  
37 F 48 No N/A  
38 F 60 No N/A  
39 F 62 No N/A  
40 M 55 No N/A  
41 M 20 No N/A  
42 M 47 No N/A  
43 M 44 Yes Interferon + Ribavirin   
44 F 30 No N/A  
45 F 65 Yes Ribavirin   
46 M 53 No N/A  
47 F 49 No N/A  
48 M 67 No N/A  
49 M 43 No N/A  
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50 F 28 No N/A  
51 F 64 No N/A  
52 F 38 No N/A  
53 M 45 No N/A  
54 M 54 Yes Interferon + Ribavirin  Interferon  
55 F 61 No N/A  
56 F 53 No N/A  
57 M 45 No N/A  
58 M 47 Yes Interferon + Ribavirin  
59 M 44 Yes Interferon   
60 F 48 No N/A  
61 M 48 No N/A  
62 F 39 No N/A  
63 F 56 Yes Interferon + Ribavirin   
64 F 51 No N/A  
65 F 46 No N/A  
66 M 57 No N/A  
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67 M 43 Yes Interferon + Ribavirin  Peginterferon+ Ribavirin  
68 M 51 No N/A  
N1 M 44 Yes Interferon (10 months)  
N2 M 40 No N/A  
N3 M 52 No N/A  
N4 M 45 No N/A  
N5 F 34 No N/A  
N6 M 73 No N/A  
N7 M 74 No N/A  
N8 M 47 No N/A  
N9 M 26 No N/A  
N10 M 49 No N/A  
N11 F 27 Yes Interferon   Interferon + Ribavirin for 1 year  
N12 M 36 No N/A  
N13 M 63 No N/A  
N14 M 27 No N/A  
N15 M 70 No N/A  
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         * N denotes patients from the renal unit at Nefroclínica private dialysis centre. 
N16 M 73 No N/A  
N17 M 29 No N/A  
N18 M 79 No N/A  
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2.2.2. Preparation of saliva samples 
 
 Unstimulated whole mouth saliva (WMS) was collected in 50 mL sterile 
centrifuge tubes (Sarstedt Ltd.). Samples were frozen immediately and 
shipped to the UK for laboratory analysis. After the arrival in the UK, samples 
were defrosted for analysis and the remaining stored in 2 mL microcentrifuge 
tubes and stored again in -80 degrees freezers. 
 
2.2.3. Dynal Magnetic Bead cell isolation 
 
Immunomagnetic cell isolation using Dynabeads allows isolation of predefined 
subsets directly from heterogeneous cell suspensions, such as whole blood. 
Dynabeads (Dynal A.S., Oslo, Norway) are small magnetically charged 
uniformly shaped beads coated with a specific monoclonal antibody. The 
Dynabeads were supplied as a suspension containing 4x108 beads/mL in 
phosphate buffer saline (PBS), pH 7.4, containing 0.1% bovine serum albumin 
(BSA) and 0.02% sodium azide (NaN3). As NaN3 is a cytotoxic agent the 
beads required to be washed before use with a washing buffer (PBS/0.1 % 
BSA). Fifty microliters (50 µL) of Dynabeads was transferred into a washing 
tube that was then placed on a magnetic particle concentrator (Dynal MPC) 
for 60 seconds and the fluid removed with a pipette. After removing the tube 
from the magnetic device, 1 mL PBS/0.1 Bovine Serum albumin (BSA) was 
added and the beads resuspended. This procedure was repeated another two 
times until the Dynabeads are resuspended back into their original volume (50 
µL) with washing buffer. 
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To separate different leukocyte fractions from the blood, Dynabeads coated 
with antibodies against CD19 (pan B leukocytes), CD14 (macrophages / 
monocytes), CD2 (pan T leukocytes) and CD45 (pan leukocytes) were used. 
To 1 mL of whole blood, 50 µL of dynabeads were added giving an 
approximate final concentration of 2 x 107 beads/mL. The whole blood and 
Dynabead mixture was then incubated at 4ºC for 1 hour with continuous 
rotation of the tubes using a Dynal sample mixer (Dynal A.S., Oslo, Norway). 
The tube was then positioned in the magnetic particle concentrator (Dynal 
MPC) for 3 minutes to collect the rosetted cells. The supernatant was pipetted 
carefully while the rosetted cells remained attached to the wall of the tube by 
the concentrator. The tube was removed from the concentrator, after which 1 
mL of washing buffer was added and the rosetted cells gently resuspended. 
The tube was repositioned into the concentrator and the supernatant 
removed. The rosetted cells were washed three times with 1 mL washing 
buffer, resuspended in 250 µL of nuclease-free water and finally stored at -80 
ºC until required. Figure 2.1 illustrates the process.  
 
2.3. Molecular detection of HCV 
 
2.3.1. Laboratory accommodation 
 
To minimize contamination during polymerase chain reaction (PCR), nucleic 
acid extraction, PCR reagent preparation, thermocycling, and post-PCR 
procedures were conducted in dedicated rooms. Appropriate negative control 
specimens were also included in each PCR. The workflow was strictly 
unidirectional in order to prevent contamination with PCR products. 
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Figure 2.1. cell separation procedure using dynabeads 
   
I) 50 µl of dynabeads in 15ml 
sterile centrifuge tube + 1 ml 
of whole blood.
II) 4ºC for 1 hour at sample mixer.
III) 3 min to collect rosetted cells.V) 3 min again at Dynal MPC.
IV) Remove the tube from the 
concentrator, and add 1 ml of 
washing buffer (PBS/0.1 % 
BSA) and gently resuspend
rosetted cells. 
VI) Repeat step V two more 
times and ressuspend in 250 
µL of nuclease free water. 
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2.3.2. RNA Extraction 
 
2.3.2.1. Manual RNA extraction - Qiagen QIAamp MinElute virus spin kit 
 
Manual RNA extraction was employed for all samples, but CD45 from patients 
1 to 4 due to lack of blood for cell separation. RNA was extracted from two 
hundred microlitres (200 μL) of plasma, whole saliva, as samples of CD19, 
CD14, CD2 or CD45 using the modified QIAamp kit (Qiagen, UK) following the 
manufacturer’s instruction. The extraction was carried out using QIAamp 
MinElute columns in a standard microcentrifuge. The Qiagen protease was 
ressuspended in buffer AVE® (RNase free water containing 0.04% sodium 
azide) instead of the protease ressuspension buffer, which could coagulate 
cells. This modification was carried out to avoid clogging the columns as with 
the exception of plasma, there were cells in all of the analyzed body fluids. 
 
Twenty five microliters (25 µL) of Qiagen protease, 200 μL of sample (plasma, 
whole saliva, CD19, CD14, CD2 or CD45) and then 200 μL of buffer AL 
(containing 28 μg / mL of carrier RNA) were pipetted into a 1.5 mL 
microcentrifuge tube. The microtubes were incubated at 56°C for 15 minutes 
in a heating block. Lysis was performed in the presence of Qiagen protease 
and lysis buffer (buffer AL®) in order to ensure the inactivation of RNAses. 
Samples were lysed under these elevated temperatures which were highly 
denaturing conditions. 
    
The tubes were then briefly placed in a microcentrifuge to remove drops from 
the inside of the lid and 250 µL of ethanol (99.7-100%) added to the tubes. 
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Following thorough pulse-vortexing for 15 seconds the lysate was incubated 
with ethanol for 5 minutes at room temperature. Binding conditions were 
adjusted by adding ethanol to allow optimal binding of the viral RNA and DNA 
to the membrane. Lysates were then transferred onto a QIAamp MinElute 
column and viral nucleic acids were adsorbed onto the silica-gel membrane as 
the lysate was drawn through by centrifugation. 
    
Four centrifugation steps were then performed, starting with the addition of 
500 µL of buffer AW2 to the columns followed by centrifugation for 1 minute at 
8000 RPM. After changing the collection tubes, 500 µL of ethanol was added 
to the columns followed by centrifuge for 1 minute at 8000 RPM. The 
collection tubes were changed and a dry spin at the centrifuge for 3 minutes at 
13000 RPM performed to dry the membrane completely. Salt and pH 
conditions ensured that protein and other contaminants, which can inhibit PCR 
and other downstream enzymatic reactions, were not retained on the QIAamp 
MinElute membrane. The collection tube was replaced for a 1.5 mL 
microcentrifuge tube with a lid for storage purposes. The final elution volume 
added is 60 µL of buffer AVE (RNase free water, containing 0.04% sodium 
azide), after which the column is left at room temperature for 1 minute before 
being placed in the centrifuge at 13000 RPM for 1 minute. Figure 2.2 
proposes a scheme representation of the process. 
 
2.3.2.2. Automated extraction - Qiagen Universal QiAamp96 Virus Kit    
 
Qiagen Universal QIAamp96 Virus nucleic acid purification procedure was 
used to perform RNA extraction for the quantitative Hepatitis C virus (HCV) 
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assay for whole saliva and plasma samples. Three hundred microliters (300 
μL) of the samples were extracted by the Qiagen Universal QIAamp96 Virus 
Nucleic Acid Purification Robot. The HCV standard curve employed was 
based upon a 10 fold dilutions of an in-house 10000000 IU/mL standard 
shown in Table 2.2. One of 96 HCV window phase plasmas from a previous 
study (Tuke et al., 2008) was used as the positive control. This plasma had 
been characterised as containing 3.58 x 107 IU / mL. One millilitre of this 
control was diluted with 2.58 mL of normal human plasma (NHP) to obtain a 
concentration of 107 IU / mL.  
 
Table 2.2. HCV standard 10 fold dilutions of the in-house control for real 
time RT-PCR of HCV RNA 
 
In-house Control Composition 
10000000  IU/mL Plasma “122” diluted 1mL + 2.58 mL NHP 
1000000  IU/mL 50 μL 10000000  IU/mL control + 450 μL NHP 
100000  IU/mL 50 μL 1000000  IU/mL control + 450 μL NHP 
10000  IU/mL 50 μL 100000  IU/mL control + 450 μL NHP 
1000 IU/mL 50 μL 10000  IU/mL control + 450 μL NHP 
100 IU/mL 50 μL 1000  IU/mL control + 450 μL NHP 
10 IU/mL 50 μL 100  IU/mL control + 450 μL NHP 
Negative 450 μL normal human plasma (NHP) 
 
 
The extraction was automated following the same principles as the QIAamp 
MinElute Virus Spin Kit with some modifications. An AW1 (guanidine and 
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ethanol) wash step was added before the AW2 wash, and instead of spinning 
in a centrifuge all fluid passed through the columns using a vacuum.  
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Figure 2.2. MinElute Virus Spin Procedure / 
manual extraction of HCV RNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 103 
2.3.3. Microzone DNA OK Kit 
 
DNA OK kit (Microzone, UK) was the housekeeping assay used for this study. 
It has confirmed the integrity of DNA, therefore highlighting that samples were 
adequate for molecular biology analysis.  
 
In this kit five primer pairs were amplified from 5 different chromosomes to 
verify the integrity of the DNA of the extracts. The kit was used according to 
manufacturer’s criteria testing all the samples. The gel picture (figure 2.3) 
shows results for intact DNA (G), degraded, fragmented or shortened DNA (B) 
and fully degraded DNA (U). 
    
The protocol used comprised mixing 7.5 μL of Human DNAOK mix with 12.5 
μL of MegaMix Gold. Five (5) μl DNA (5 to 50 ng) was then added and the 
reaction tubes were placed in a Thermal Cycler. The cycling profile comprised 
of an initial denaturation step of 95°C for 5 mins. Then this cycle was repeated 
33 times: 
 
Step 1: 95°C for 30 secs. Step 2: 62°C for 30 secs. Step 3: 72°C for 45 secs. 
After cycling, 10 μl was loaded onto a 2% agarose gel and electrophoresed 
alongside a 100 bp DNA Ladder. Expected fragment sizes were 100 bp, 200, 
300, 400, 500 (internal control) and 600 bp. In this assay, the more negative 
bands present, the more DNA is degraded or not present, which was not the 
case in the present study. 
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Figure 2.3. Interpretation of DNAOK results (G, B and U explained above 
in text) 
 
 
 
 
 
 
 
Modified from www.microzone.co.uk/images/HDNA.png. 
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2.3.4. cDNA Generation 
 
RNA was reverse-transcribed using Murine Maloney Leukemia Virus reverse 
transcriptase (Invitrogen, UK), 10X buffer (Invitrogen, UK), 5 mM MgCl2 
(Invitrogen, UK), 10 mM deoxynucleotide triphosphates (dNTP’s - Invitrogen, 
UK), RNasin (Promega, UK) and 20 units / μL random hexamers (Amersham 
Pharmacia, UK). Cycling conditions were as follows: 23°C for 10 min, 37°C for 
45 min and 95°C for 5 min. The mix for the cDNA generation is shown in 
Table 2.3. 
 
Table 2.3. Mix for the cDNA generation 
 
 
 
 
 
 
 
 
 
 
2.3.5. Amplification of HCV 5’ Noncoding Region 
 
This amplification, used for the identification of the virus, was performed in 
order to use final products to run the RFLP genotyping assay (refer to item 
2.3.12). The HCV 5’ noncoding region (5’-NCR) was amplified by nested PCR. 
 Amount 
Nuclease free water 4.06 μL 
10 x PCR Buffer 4  μL 
MgCl2 (50mM) 4 μL 
dNTP’s (10mM) 4 μL 
RH (20 U/ μL) 0.4 μL 
Rnasin (0.34 U / μL) 0.34 μL 
RT (0.02 U / μL) 1 μL 
RNA 22.2 μL 
Final 40 μL 
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Primary amplification was carried out using 1 mM MgCl2 (Invitrogen, UK), 10X 
buffer (Invitrogen, UK),10 mM each of the four dNTPs (Invitrogen, UK), 5 
pmoles of sense primer 57 (P1) and of antisense primer 321 (P2), and 0.625 
units of Taq polymerase (Invitrogen, UK). Reactions were heated to 94°C for 4 
minutes followed by 35 cycles of 94°C for 20 seconds, 62°C for 40 seconds, 
72°C for 35 seconds and final extension at 72°C for 3 minutes. Secondary 
amplification was from 2 µL of primary PCR product using 2 mM MgCl2 
(Invitrogen, UK), 10X buffer (Invitrogen, UK), 0.625 units of Taq polymerase 
(Invitrogen, UK), 20 pmoles of sense primer 126 (P3) and 20 pmoles of 
antisense primer 299 (P4) were used and cycling conditions were as follows: 
25 cycles of 94°C for 20 seconds, 68°C for 40 seconds and 72°C for 30 
seconds. Primer sequences (Lin et al., 1992) as indicated in Table 2.4 and the 
PCR mixs are indicated in tables 2.5 and 2.6. 
 
Table 2.4. NCR PCR primer sequences 
 
57 (sense): 5’-AGCGTCTAGCCATGGCGT 
321 (antisense): 5’ GCACGGTCTACGAGACCT 
126 (sense): 5’-GTGGTCTGCGGAACCGG 
299 (antisense): 5’-GGGCACTCGCAAGCACCC 
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Table 2.5. Mix for the first round HCV NCR PCR 
 
 Amount 
Nuclease free water 30.8 µL 
10 x Buffer 4 µL 
MgCL2 (50mM) 1 µL 
P1 (5 pmoles) 2 µL 
P2 (5pmoles) 2 µL 
Taq 0.2 µL 
cDNA 10 µL 
Final 50 µL 
 
Table 2.6. Mix for the second round HCV NCR PCR 
 
 Amount 
Nuclease free water 37.8 µL 
10 x Buffer 5 µL 
MgCL2 (50mM) 2 µL 
dNTPs (10mM) 1 µL 
P3 (20 pmoles)  1 µL 
299 (20 pmoles) 1 µL 
Taq 0.2 µL 
Total 48 µL 
HCV NCR-1 2 µL 
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2.3.6. Amplification of Non Structural 5 b Region (NS5b)  
 
Non Structural 5 b Region PCR (NS5b) was employed in order to achieve 
direct sequence of plasma, whole saliva and PBMCs genome. 
 
The NS5b was amplified by nested PCR. Primary amplification was carried 
out using 3.5 mM MgCl2, 10X buffer, 10 mM each of the four dNTPs, 20 
pmoles of sense primer P1203 and 20 pmoles of antisense primer P1204 
(Mellor et al., 1995), and 0.625 units of Taq polymerase (Invitrogen, UK). 
Reactions were heated to 94°C for 30 seconds followed by 35 cycles of 94°C 
for 30 seconds, 55°C for 40 seconds, 72°C for 50 seconds and final extension 
at 72°C for 30 seconds. Secondary amplification was from 2 µL of primary 
PCR product using megamix blue® (50 µL reaction – Microzone, UK) plus 20 
pmoles of sense primer NS5bn2 (Reference Laboratory – Health Protection 
Agency, Colindale – UK) and 20 pmoles of antisense primer P1204 (Mellor et 
al., 1995). The cycling conditions were as follows: 94°C for 30 seconds 
followed by 30 cycles of 94°C for 30 seconds, 54°C for 40 seconds, 72°C for 
30 seconds and final extension at 72°C for 30 seconds. The primer sequences 
are indicated in Table 2.7 and the PCR mixs are indicated in Tables 2.8 and 
2.9. 
 
Table 2.7. NS5b PCR primer sequences 
  
P1203 (sense): 5’ ATGGGGTTCTCGTATGATACCCGCTG CTTTGACTC 
P1204 (antisense): 5’ GGAGGGGCGGAATACCTGGTCATAGCCTCCGTGAA 
NS5bn2 (sense): 5’ -  TGATACCCGCTGCTTTGACTCNACNGTCAC 
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 Table 2.8. Mix for the first round HCV NS5b PCR 
 
 
 
 
 
 
 
 
 
 
Table 2.9. Mix for the second round HCV NS5b PCR with megamix blue® 
 
   
 
 
 
 
 
2.3.7. Detection of the PCR product 
 
Ten microliters (10 µL) of PCR product was eletrophoresed immediately after 
removed from the thermal cycler, as megamix blue® already contains the 
loading dye. After cloning and GFX cleanup, 8 µL of the PCR product was 
mixed with 2 µL of Blue/Orange 6X loading dye (Promega, UK) and 
 HCV NS5b-1 
Nuclease free water 27.8 µL 
10 x Buffer 3.5 µL 
MgCL2 (50mM) 2.5 µL 
P1203 (20 pmoles) 0.5 µL 
P1204 (20 pmoles) 0.5 µL 
Taq 0.2 µL 
cDNA 15 µL 
Final 50 µL 
 HCV NS5b-2 
Megamix blue® mastermix 46 µL 
P1204 (20 pmoles) 1 µL 
NS5bn2 (20 pmoles) 1 µL 
HCV NS5b-1 2 µL 
Final 50 µL 
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electrophoresed through a 2% agarose gel along with 1 µg of 1-kb ladder 
molecular weight marker (Invitrogen, UK) on either side of the test samples to 
assess the size of the amplified product. A positive and a negative control 
were also added. Electrophoresis was undertaken in a 1X tris-borate EDTA 
buffer (Invitrogen, UK). The gels were then stained with 10 mg/mL ethidium 
bromide solution (Invitrogen, UK) in TBE buffer (concentration of 5 µg / mL). 
DNA fragments were visualized using a short wave ultra-violet trans-
illuminator and photographed using a photo printer. 
 
2.3.8. Restriction Fragment Length Polymorphism (RFLP) and Analysis 
 
The amplification product obtained in the 5’-NCR PCR was used for 
genotyping via RFLP. A 10 µL final volume restriction digestion assay was 
done for each enzyme, adding nuclease free water (NFW) and the appropriate 
buffer for each enzyme. The enzymes and the tubes in which they were mixed 
remained on ice, as 3 of these 4 enzymes work at 37oC (very close to room 
temperature). The tubes were incubated individually (for each enzyme) with 
10U of the enzymes for 1.5 hour at 37oC for ScrfI, MvaI and HinfI and 60oC for 
BstUI and then at 80oC for 10 minutes. The following restriction enzymes were 
added in two different reactions: 1: ScrfI (New England Biolabs, UK) /MvaI 
(Roche, UK); 2: HinfI /BstUI (New England Biolabs, UK) for electrophoresis. 
The mix for the RFLP in indicated in Table 2.10.  
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Table 2.10. Mix of the restriction fragment length polymorphism 
 
 Amount 
Nuclease free water 4 μL 
10 X Buffer 1 μL 
Restriction enzyme 0.5 μL 
DNA 4.5 μL 
Final 10 μL 
 
2.3.9. Detection of the RFLP product 
 
Four microliters of the each restriction digestion product was mixed following 
the previous pattern (ScrfI+MvaI and HinfI+BstUI) with 2 µL of Blue/Orange 6X 
loading dye (Promega, UK) and electrophoresed through a 3% agarose gel 
along with 1 µg of 100-bp ladder molecular weight marker (Invitrogen, UK) on 
either side of the test samples to assess the size of the cleaved amplicons. A 
positive and a negative control were also added. Electrophoresis was 
undertaken with a 1X tris-borate EDTA buffer (Invitrogen, UK). The gels were 
then stained with 10mg/mL ethidium bromide solution (Invitrogen, UK) in TBE 
buffer (concentration of 5µg / mL). DNA fragments were visualized using a 
short wave ultra-violet trans-illuminator and photographed using a photo 
printer. A diagram of genotype specific patterns found with RFLP is indicated 
in Figure 2.5.  
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Figure 2.4. Diagrammatic representation of most representative bands 
determining the digestion pattern observed with RFLP for HCV 
genotyping 
 
*Based on Pohjanpelto et al. 1996. Numbers from 1a to 6 refer to genotypes 
and from 32 to 174 refer to base pairs. SM refers to the mixture of ScrfI and 
MvaI enzymes and HB to the mix of HinfI and BstUI enzymes for 
electrophoresis. 
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2.3.10. Purification of NS5b PCR products for sequencing (GFX Cleanup) 
 
In order to prepare samples for sequencing, second-round PCR products 
were purified using a spin column based purification kit (Amersham 
Pharmacia, UK) following the manufacturer’s instructions. Five hundred micro 
litres of capture buffer was added to a GFX column together with the second 
round PCR product. After mixing thoroughly by pipetting the sample up and 
down 6 times the GFX, the columns were placed in a microcentrifuge at full 
speed for 30 seconds. Following discard of the flow-through by empting the 
collection tube, 500 μL of wash buffer was added to the column and 
centrifuged at 8000 RPM for 30 seconds. The columns were transferred to a 
fresh microcentrifuge tube followed by the addition of 50 μL of elution buffer 
(nuclease free water). The samples were incubated at room temperature for 1 
minute followed by centrifugation at 8000 RPM for 1 minute to recover the 
purified DNA. 
    
Samples that did not sequence on the first attempt were cloned. These 
samples required purification of DNA from gel bands. The PCR product was 
run down a gel and the product cut out of the gel. The gel slice was weighted 
(maximum of 300 mg) and the same amount of capture buffer added to it in a 
1.5 mL microcentrifuge tube, and incubated at 60°C until the agarose was 
completely dissolved (approximately 15 minutes). The sample was then 
transferred to the GFX column and incubated at room temperature for 1 
minute. The procedure then followed that for the purification of DNA from a 
solution. 
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To confirm that the purification had been successful and to estimate the 
quantity of DNA recovered, 1 µL of the supernatant was run on a 2% agarose 
gel alongside a 1µg of 1-Kb ladder (Invitrogen, UK), stained and visualised 
before subsequent cloning or sequencing. 
 
2.3.11. Cloning  
 
Cloning was undertaken for some positive samples that were difficult to 
sequence. The TOPO-TA Cloning® kit (Invitrogen, UK) was used. TOPO-TA 
Cloning® reaction mix is indicated in Table 2.11. 
 
Table 2.11. Mix for chemically competent E. coli reaction 
 
Chemically competent E. coli reaction 
1 µL of salt solution. 
2 µL of PCR fresh product. 
Sterile water added to a final volume of 5 µL. 
0.9 µL of vector. 
5.9 µL of final volume. 
 
E. coli was used to transform the cloning reaction. The constituents were 
incubated for 5 minutes at room temperature and then placed on ice for the 
addition of 2 µL of this reaction to separate vials of competent cells (OneShot® 
Top10 cells). The transformation mixture was placed in a thermostatic bath 
circulator at 42°C for 30 seconds and then left on ice for 2 minutes. Two 
hundred and fifty (250) µL of S.O.C. Medium (2% tryptone, 0.5% yeast extract, 
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10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) 
was added to each cell / ligation tube. The tubes were left in an orbital 
incubator for 1 hour, at 200 RPM and at 37°C. Finally, 270 µL of the cell / 
ligation was spread on an L agar plate. The cloning reaction was left overnight 
on L agar (Luria agar: 1.0% tryptone, 5.0% yeast extract, 1.0% 0.17% MNaCl, 
1.5% agar, pH 7.0) containing 50 mg/mL ampicillin at a 37°C incubation to 
allow for growth of the E. coli containing the HCV RNA amplicon. PCR using 
second-round primers was performed directly on the resulting colonies prior to 
sequencing. The cycling conditions were as follows: 94°C for 2 minutes 
followed by 30 cycles of 94°C for 30 seconds, 55°C for 30 seconds, 72°C for 
40 seconds. 
 
2.3.12. DNA sequencing 
 
The samples were sequenced using the Beckman CEQ2000 automated 
capillary array sequencer.  
     
Purified DNA was added to the PCR sequencing reaction consisting of the 
following components: 2-8 µL of DNA (400 ng calculated for sequencing 
reaction), 3 µL of inner (P1204 or NS5bn2) PCR primers (2 pmoL), and 8 µL 
of Beckman dye terminator cycle quick start master mix (Beckman Coulter, 
UK), the volume adjusted with sterile water to a total volume of 20 µL. The 
cycling conditions were as follows: 30 cycles of 96°C for 20 sec, 50°C for 20 
sec and 60°C for 4 minutes. 
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Sequencing PCR reactions were purified using the CleanSEQ® Sequencing 
Reaction Clean-Up System (Agencourt, USA). CleanSEQ® contains magnetic 
particles in an optimized binding buffer to selectively capture sequencing 
extension products.  
    
The CleanSEQ® procedure (Figure 2.4) was performed in three stages. 
Selective binding of sequencing extension products to paramagnetic beads 
and separation of the beads with a magnetic field, followed by washing of the 
beads with 85% ethanol to remove unincorporated dyes, nucleotides, salts 
and other contaminants and finally the elution of the purified sequencing 
product from the paramagnetic beads using formamide. 
    
The Agencourt CleanSEQ reagent and ethanol was added to the sequencing 
reaction and the sequencing products bind to the magnetic beads. The 
sequencing products were then separated from the contaminants with a 
magnetic plate. After the washing step with ethanol, the elution from magnetic 
particles was achieved with the addition of 40 µL of formamide. After the 
incubation of the plate for 5 minutes to elute, a drop of mineral oil was added 
to each sample. 
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Figure 2.5. Overview of the CleanSEQ® Process overview 
 
 
http://www.agencourt.com/products/spri_reagents/cleanseq/ 
    
The sequencing products were then immediately loaded onto the automated 
sequencer. The Beckman CEQ-2000 uses a capillary system to 
electrophorese the samples through a polyacrylamide gel contained in a 
capillary tube. In the sequencing PCR mix, chain terminating nucleotide bases 
with different fluorescent tags are present and are incorporated into the DNA 
during PCR amplification. During electrophoresis a laser reads these 
fluorescent bases to determine the sequence of the sample. 
    
Raw chromatograph data were analysed using the SeqMan sequence 
analysis software, and multiple alignments were made in Megalign. Both 
programs are from the LASERGENE sequence analysis package (DNAstar 
Inc.). A cluster V alignment was produced in Megalign to construct a guide 
tree using the UPGMA method of clustering analysis. Further analysis was 
undertaken using the blast search, using HCV databanks: 
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http://hcv.lanl.gov/content/hcv-db/BASIC_BLAST/basic_blast.html, 
http://www.ncbi.nlm.nih.gov/BLAST/. 
 
2.3.13. Quantitative Real Time PCR 
 
The quantitative Hepatitis C virus (HCV) assay was used for all the whole 
saliva, plasma, CD19, CD14, CD2 and CD45 samples. ABI Prism 7000 real-
time PCR was used with QIAGEN TaqMan-PCR reagents (QIAGEN, UK). The 
quantification is based on a standard curve with a calibrated in house 
standard, calibrated by comparison to the NIBSC HCV standard 96/798. The 
assay used Brome mosaic virus (BMV) RNA as an internal control (IC), which 
was introduced at the extraction stage. BMV could not be added for the 
quantitative real time PCR of CD19, CD14, CD2 and CD45 samples, as they 
had been performed using extractions from the Qiagen QIAamp MinElute 
virus spin kit. 
    
The multiplex real time PCR detects both HCV and BMV with differently 
labelled TaqMan probes. An in-house ‘run control’ was used as a monitor of 
performance (see Table 2.2 and section 2.3.2.2 for details). This assay is 
intended for detection of HCV RNA in serum or plasma, and quantification of 
HCV RNA between 100 and 10000000 IU/mL, and was adapted for use in the 
detection of HCV RNA in the whole saliva. 
    
The master mix volume added into each well of an optical PCR plate 
consisted of 15 μL in total, and includes the Absolute quantitative RT-PCR 
mastermix, the HCV/BMV primer/probe mix, the enzyme and nuclease free 
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water. To this, 10 μL of RNA extraction of the sample was added. The tray 
was then sealed with an optical adhesive sealer (Applied Biosystems, UK). 
Tables 2.12, 2.13 and 2.14 indicate the mix of the real time PCR HCV assay 
and the primers and probes used, respectively. 
 
 Table 2.12. Mix for the real time PCR HCV assay 
 
 
 
 
 
 
 
 
Table 2.13. Primers used for the HCV/BMV quantitative PCR (100 
pMol/µL) 
HCV Primer 1:  5'- GTCTAGCCATGGCGTTAGTA -3' 
HCV Primer 2:  5'- GTACTCACCGGTTCCGC -3' 
BMV Primer 1:  5’- GTTCACCGATAGACCGCTG-3’ 
BMV Primer 2:  5’- AAGAGCCCGGAATGTCAAGA-3’ 
 
Table 2.14. Probes used for the HCV/BMV quantitative PCR (100 pMol/µL) 
 
HCV: 5'FAM- CCCTCCCGGGAGAGCCATAGTG-3'TAMRA   
BMV: 5’-VIC- CCTCAAGCTGAAATGGCACGGATG -3'TAMRA 
 
 
 
Reagent Amount/sample 
ABsolute quantitative RT-PCR mastermix 12.5 μL 
HCV/BMV primer/probe mix 0.5 μL 
Enzyme 0.25 μL   
Nuclease free water 1.75 μL 
RNA 10 μL 
Total 25 μL 
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2.3.14. Pyruvate dehydrogenase (PDH) Quantitative Real Time PCR 
    
Pyruvate dehydrogenase (PDH) was undertaken in order to quantify the 
average number of cells present in the extract in order to achieve also a viral 
number per cell on the top of the neat value.  
 
The quantitative PDH PCR was used for all the PBMCs extracts (other than 
that of one patient) and for all saliva samples extracts (Koike et al., 1990).  
    
Quantification was made with a standard curve using a Human male DNA 
dilution. The human male DNA was diluted in a 1:10 with buffer AVE with 
carrier RNA (6 µL of carrier RNA added to 594 µL of buffer AVE, which is 
constituted of RNAse free water containing 0.04% of sodium azide). Ten fold 
dilutions of this standard are shown in Table 2.15. 
 
Table 2.15. Ten fold dilution of human male DNA 
 
Human male DNA Composition 
1666 copies 2μL Human male DNA (10ng/ μL) + 18 μL AVE* 
166 copies 2μL 1666 copies/mL control + 18 μL AVE* 
16.6 copies 2 μL 166 copies/mL control + 18 μL AVE* 
1.6 copies 2 μL 16.6 copies/mL control + 18 μL AVE* 
0.16 copies 2 μL 1.6 copies/mL control + 18 μL AVE* 
Buffer AVE with carrier RNA 20 μL Buffer AVE with carrier RNA 
 
The master mix volume added into each well of an optical PCR plate 
constituted 15 μL in total, and included the Absolute quantitative RT-PCR 
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mastermix, the PDH primer/probe mix, the enzyme and nuclease free water. 
To this, 10 μL of RNA extraction of the sample was added. The tray was then 
sealed with an optical adhesive sealer (Applied Biosystems, UK). Table 2.16 
shows the mix for the real time PCR PDH assay. The primers and probe for 
PDH quantification via Real Time PCR are indicated in Tables 2.17 and 2.18, 
respectively. 
 
Table 2.16. Mix for the real time PCR PDH assay 
 
 
 
 
 
 
 
 
Table 2.17. Primers for the real time PCR PDH assay (concentration 25 
pMol/µL) 
 
 
 
 
Table 2.18. Probe (concentration 100pMol/µL) 
 
PDH: 5’ VIC-CCCCCAGATACACTTAAGGGATCAACTCTTAATTGT-3’TAMRA 
 
 
Reagent Amount/sample 
ABsolute quantitative RT-PCR mastermix 12.5 μL 
PDH primer/probe mix 0.5 μL 
Enzyme 0.25 μL   
Nuclease free water 1.75 μL 
RNA 10 μL 
Total 25 μL 
PDH Taq 1: 5’-TGAAAGTTATACAAAATTGAGGTCACTGTT-3’ 
PDH Taq 2: 5’- TCCACAGCCCTCGACTAACC -3’ 
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Table 2.19. Preparation of HCV Taqman primer/probe mix 
 
Primer/probe Concentration 
(pmol/ μL) 
Half plate 
(48 wells) 
Full plate 
(96 wells) 
HCV primer 1 100 10 μL 20 μL 
HCV primer 2 100 10 μL 20 μL 
HCV probe 100 5 μL 10 μL 
BMV primer 1 100 10 μL 20 μL 
BMV primer 2 100 10 μL 20 μL 
BMV probe 100 5 μL 10 μL 
 
Table 2.20. Preparation of PDH Taqman primer/probe mix 
 
Primer/probe Concentration 
(pmol/ μL) 
Half plate 
(48 wells) 
Full plate 
(96 wells) 
BMV primer 1 100 10 μL 20 μL 
BMV primer 2 100 10 μL 20 μL 
BMV probe 100 5 μL 10 μL 
PDH primer 1 25 10 μL 20 μL 
PDH primer 2 25 10 μL 20 μL 
PDH probe 100 5 μL 10 μL 
 
2.3.15. Statistical analysis 
 
Data entry and analysis were performed using the SPSS for Windows 
(Statistical Package of Social Science) software, version 17.0. Frequency 
distributions and cross-tabulation tables were constructed in order to analyze 
the demographic, clinical and virological information. In an attempt to detect 
possible risk factors, both logistic regression and chi-squared testing (the P 
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value for statistical significance was set at <0.05) were used. The independent 
samples t-test, ANOVA, Mann Witney U and Bivariate correlation (Spearman’s 
rank correlation) were used as appropriate.  
 
Fisher’s exact test was employed to compare the expected amino acid 
sequences within the dominant quasispecies of individual HCV genotypes 
between the different compartments detecting the presence of non-
synonymous mutations within the NS5b region of the HCV genome. 
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Chapter 3 
 
 
 Prevalence of HCV RNA in Whole Saliva 
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Several studies have been published with regards to the aspects of the 
prevalence of HCV RNA in the saliva (Goncalves et al., 2005, Diz et al., 2005, 
Hermida et al., 2002, Fabris et al., 1999, Belec et al., 2003b, Suzuki et al., 
2005, Roy et al., 1998, Roy et al., 1996, Arrieta et al., 2001, Rey et al., 2001, 
Harle et al., 1993, Couzigou et al., 1993, Jorgensen et al., 1996, Sugimura et 
al., 1995, Mariette et al., 1995, Young et al., 1993, Caldwell et al., 1996, 
Komiyama et al., 1995, van Doornum et al., 2001, Liou et al., 1992, 
Mastromatteo et al., 2001, Eirea et al., 2005, Wang et al., 2006, Wang et al., 
1992b, Hsu et al., 1991, Puchhammer-Stockl et al., 1994, Takamatsu et al., 
1990, Wang et al., 1991, Roy et al., 1995, Taliani et al., 1997, Becheur et al., 
2000, Ustundag et al., 1997, Biasi et al., 1995, Roy et al., 1999, Pastore et al., 
2006, Nakano et al., 1992, Kage et al., 1997, Savoldi et al., 2001, Fried et al., 
1992, Ogasawara et al., 1993, Toussirot et al., 2002, Chen et al., 1995, Lins et 
al., 2005, Maticic et al., 2001). Nevertheless, only three of the cited papers 
involved the quantification of HCV RNA in saliva (Suzuki et al., 2005, Rey et 
al., 2001, Belec et al., 2003b). The HCV RNA prevalence in the saliva ranges 
from 0% (van Doornum et al., 2001, Hsu et al., 1991, Fried et al., 1992) to 
100% (Lins et al., 2005, Arrieta et al., 2001, Harle et al., 1993, Takamatsu et 
al., 1990, Wang et al., 1991, Biasi et al., 1995). 
    
The first study involving HCV RNA quantification was positive for 20 cases 
(62.5%) in the saliva and could only quantify 18 cases in plasma (56%) from all 
the 32 HCV seropositive patients. They claimed that the hybridization method 
used (”branched DNA” technique – Chiron, as opposed to RT-quantitative 
PCR in most other cases including our study) was probably unable to detect 
the virus in these two patients that were HCV RNA positive for the saliva and 
 126 
not for plasma. The virus concentration of the only study that used branched 
DNA hybridization for HCV RNA quantification had an average of 38.8 ± 22.4 
copies / mL in plasma and 67 ± 60.8 copies / mL in saliva (Savoldi et al., 
2001). Another study later at the same year performed HCV RNA 
quantification in the saliva showing a 37.3% rate of detection of the virus in the 
saliva. The mean viral RNA level was 1150000 copies / mL and the mean viral 
RNA level for plasma was 25200000 copies / mL, also using a branched DNA 
assay for HCV RNA quantification (Rey et al. 2001). Two years later, Belec et 
al. (2003) detected HCV RNA in 42% of the saliva pellet samples (cell 
associated whole saliva), 4% (only one patient) of saliva  supernatant and in 
none of the cell free gingival crevicular fluid. Viral load was performed for the 
only positive patient with both whole saliva supernatant (1134 copies / mL) and 
cell associated whole saliva positivity (251 copies / mL). Viral load was also 
measurable in only 2 other patients from the 12 HCV RNA positives at the cell 
associated whole saliva. Measures were 198 copies / mL and 133 copies / mL 
(Belec et al.  2003a). Suzuki et al. (2005) found no significant association 
between viral RNA levels in plasma and viral RNA levels in the saliva or 
gingival crevicular fluid (GCF). HCV RNA was detected in 31% of the saliva 
samples and 85% of the GCF specimens using real-time RT-PCR and the 
mean viral RNA level was 19000 copies / mL for the saliva and 31000 copies / 
mL for the GCF (Suzuki et al., 2005). 
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3.1. Aims 
 
The aim of the present chapter is to determine the prevalence and viral load of 
HCV in whole saliva of patients with HCV disease attending clinics in Recife in 
Northeast Brazil. In addition, the influence of HCV in plasma and peripheral 
blood mononuclear cells (PBMCs) upon the salivary presence of this virus was 
examined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 128 
3.2. Patients and samples 
 
3.2.1. Study population 
  
Samples were collected from two different locations: a general public hospital 
and a private dialysis clinic in Recife, Northeast Brazil (details in Section 2.1). 
All participants were of Brazilian nationality. Clinical data on all patients were 
obtained from standard medical records and documented onto standardized 
forms, which were linked to patient samples by numerical code. These forms 
were used during anamnesis undertaken before clinical examination. Oral 
findings and route of HCV acquisition can be found in Table 3.2. 
  
3.2.2. Sample collection 
 
Matched oral and blood samples were obtained from all patients as described 
in Sections 2.2.1 and 2.2.2.  
 
3.2.3. Sample processing  
 
After separation of plasma from the blood, the CD19+, CD14+, CD2+ and 
CD45+ cell subsets were immunomagnetically fractionated as described in 
Sections 2.2.3. WMS was not subjected to centrifugation and it was stored at -
80°C until required. RNA was extracted from blood cell subsets and oral 
samples as described in Section 2.3.2. The presence of DNA in randomly 
selected extracts was verified by using the Microzone DNA OK kit as 
described in Section 2.3.3. 
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3.2.4. Molecular detection of HCV 
 
3.2.4.1. RNA extraction 
 
RNA extraction was performed both manually (Section 2.3.2.1) for all 
samples, but CD45 from patients 1 to 4 due to lack of blood for cell separation 
and automatically for whole saliva and plasma samples (Section 2.3.2.2). 
 
3.2.4.2. Polymerase Chain Reaction (PCR) 
 
Reverse transcription was carried out to generate cDNA for all samples 
(Section 2.3.4) followed by PCR of the 5’-noncoding region for plasma 
samples only (Section 2.3.5) and NS5b region for all samples (Section 2.3.6). 
 
3.2.4.3. RFLP and direct sequencing 
 
RFLP was performed for all plasma samples (Sections 2.3.8 and 2.3.9) and 
direct sequencing was performed for all samples (Section 2.3.12). 
 
3.2.4.4. Quantitative real time PCR 
 
Quantitative Hepatitis C virus (HCV) assay was used for all the whole saliva, 
plasma, CD19, CD14, CD2 and CD45 samples in order to obtain HCV viral 
load of the respective sites (Section 2.3.13). 
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3.3. Results 
 
3.3.1. Hepatic function of patients 
 
The Mann Witney U test established that there were no statistically different 
results in the levels of aspartate aminotransferase (P=0.563), alanine 
aminotransferase (P=0.367), alkaline phosphatase (P=0.212) and gamma-
glutamyl transpeptidase (P=0.509) between patients treated and not treated 
for their HCV infection.  
 
3.3.2. HCV prevalence in plasma 
Seventy one (82.5%) of the total patient group of 86 patients had detectable 
HCV RNA in plasma. Within the untreated group 59 (88%) had detectable 
RNA while 6 (33%) of the treated group had detectable HCV RNA. Fisher’s 
exact test established that there was no statistically significant difference in 
the prevalence of HCV RNA between these 2 groups (P=0.66).  
 
3.3.3. HCV load in plasma 
 
The median plasma HCV load in the total group was 483000 IU/ml (range 0 to 
30800000). The median HCV loads in the treated and untreated patients was 
93550 (range 0 to 19600000) and 562000 IU/ml (range 0 to 30800000)  
respectively however the Mann Witney U test revealed that there was no 
statistically significant difference in the plasma HCV loads between these two 
groups (P= 0.101).  
 
3.3.4. HCV prevalence in whole saliva 
 
Twenty seven (31.8%) of the 85 patients had detectable HCV RNA in whole 
saliva. HCV RNA was detected in 31.3% of the treated and 33.3% of the 
untreated patients, hence there were no statistically significant differences in 
the prevalence of saliva between these groups.  
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3.3.5. HCV load in whole saliva 
 
The median salivary HCV load in the total group was 0 IU/mL (range 0 to 
3910). The median HCV loads in the treated and untreated patients were 0 
IU/mL (range 0 to 95) and 0 IU/mL (range 0 to 3910) respectively. Only 1 of 
the 27 HCV RNA positive samples was above the lowest level of quantification 
(100 IU/mL).  
 
It should be noted that 5 of the positive salivary samples using block-based 
PCR were negative with real time PCR while 14 of the positives with block 
based PCR were negative with real time PCR. A positive result in one of the 
two assays was considered to indicate the presence of HCV RNA. 
 
3.3.6. Correlation of prevalence of HCV RNA in whole saliva and plasma 
 
Fisher’s exact test revealed that there was a strong correlation (P=0.004) 
between the prevalence of HCV RNA in whole saliva and plasma of the total 
group. There were no instances of HCV being present in saliva and not 
plasma. These same trends were observed in the treated (P=0.049) and 
untreated groups (P= 0.054) separately.  
 
3.3.7. Correlation of HCV load in whole saliva and plasma 
 
In contrast to the above finding Spearman’s test indicated that there was no 
correlation between the salivary and plasma HCV RNA loads in the total group 
and in the treated and untreated groups.  
 
3.3.8. Influence of Oral Health 
 
3.3.8.1. Presence of oral mucosal disease 
 
Forty seven (47) out of 86 patients from this study had detectable oral 
mucosal disease during examination, only looking for gingival status with 
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probing depth measurement (Table 3.2). Twenty seven point seven per cent 
(27.7%) of patients with oral mucosal disease had detectable HCV RNA in 
saliva while 35.9% of those without oral mucosal disease had salivary HCV 
RNA. There were no statistically significant differences in the salivary HCV 
RNA load between the 2 groups (P=1.00). Lichen planus was not identified in 
any patient. 
 
3.3.8.2. Presence of teeth 
 
Thirty one point two per cent (31.2%) of 78 patients with teeth (i.e. dentate) 
and 37.5% of 8 patients without teeth (i.e. edentulous) had detectable HCV 
RNA in saliva respectively. There were no statistically significant differences in 
the salivary HCV RNA load between the 2 groups (P=0.705). 
 
3.3.9. Correlation of route of possible acquisition of HCV and salivary 
carriage of HCV RNA 
 
According to Pearson’s Chi Square test, there were no statistically significant 
differences in the prevalence of salivary HCV RNA between the probable 
routes of acquisition of HCV of all patients (P=0.712, Table 3.1) 
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Table 3.1. Prevalence of detectable HCV RNA in patients according to 
the possible route of acquisition 
 
Possible route 
No virus detected in 
saliva (%) 
Virus detected in saliva 
(%) 
Total 
None listed 25 (67.6) 12 (34.2) 37 (100) 
Sexual 2 (100) 0 (0) 2 (100) 
Transfusion 20 (62.5) 12 (37.5) 32 (100) 
IV drug user 2 (100) 0 (0) 2 (100) 
Dialysis 8 (72.7) 3 (27.3) 11 (100) 
Other* 1 (100) 0 (0) 1 (100) 
Total 58 (68.2) 27 (31.8) 85 (100) 
* Possible occupational acquisition. 
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          Table 3.2. Details of likely route of acquisition of HCV and oral health status of 86 patients with known HCV infection 
 
Patient 
ID 
Route of HCV acquisition Oral Health Status Oral Lesions 
1 Unknown Healthy None 
2 Unknown Healthy None 
3 Via contaminated glass syringe Healthy None 
4 Sexually acquired with partner Healthy None 
5 Unknown Gingivitis None 
6 Blood transfusion Gingivitis Mucocele 
7 Blood transfusion Edentulous, xerostomia None 
8 Unknown Periodontitis None 
9 Blood transfusion Gingivitis Aphthous ulcer 
10 Blood transfusion Xerostomia Candidiasis 
11 Unknown Periodontitis None 
12 Dialysis Periodontitis None 
13 Unknown Periodontitis None 
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14 Sexually acquired with partner Periodontitis Mucolece 
15 Unknown Periodontiti None 
16 Unknown Periodontitis None 
17 Blood transfusion Periodontitis None 
18 Injecting drug user Periodontitis None 
19 Unknown Periodontitis Tonsilitis 
20 Unknown Edentulous Denture-associated stomatitis 
21 Blood transfusion Periodontitis,xerostomia Fibrous hyperplasia, xerostomia 
22 Blood transfusion Gingivitis Fibrous hyperplasia 
23 Unknown Periodontitis, roots left None 
24 Blood transfusion Gingivitis None 
25 Unknown Edentulous None 
26 Unknown Healthy None 
27 Unknown Caries, periodontitis None 
28 Unknown Healthy Aphthous ulcer 
     29 Unknown Edentulous, xerostomia Hairy tongue 
30 Blood transfusion Healthy Fibrous hyperplasia, caries 
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31 Blood transfusion Caries, gingivitis None 
32 Dialysis Gengivitis, xerostomia Hairy tongue 
33 Unknown Edentulous Denture-associated stomatitis 
34 Blood transfusion Healthy None 
35 N/A Periodontitis, caries Hairy tongue 
36 Blood transfusion Healthy Frictional keratosis 
37 Blood transfusion Healthy Denture-associated stomatitis 
38 Dialysis Periodontitis, caries Hairy tongue 
39 Blood transfusion Healthy Aphthous ulcer 
40 Unknown Healthy Bilateral morsicatium buccarum 
41 Unknown Healthy Hiperplasia of stenon ducts 
42 Unknown Healthy Denture-associated stomatitis 
43 Unknown Healthy None 
44 Dialysis Healthy None 
45 Unknown Xerostomia Erythroplakia 
46 Blood transfusion Healthy Morsicatio linguarum 
47 Unknown Periodontitis None 
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48 Unknown Periodontitis Hairy tongue 
49 Blood transfusion, cocaine Healthy Leuco/erythroplakia 
50 Blood transfusion Healthy None 
51 Blood transfusion Edentulous Denture-associated stomatitis 
52 Unknown Health Frictional keratosis, hyperplasia of stenon 
duct (erythematous) 
53 Unknown Healthy Denture-associated stomatitis, mucocele 
54 Unknown Healthy Epulis suggestive of peripheral giant cell 
granuloma (purple coloured) 
55 Unknown Healthy Aphthous ulcers 
56 Unknown Healthy None 
57 Unknown Roots left to be pulled None 
58 Blood transfusion Gengivitis, caries None 
59 Blood transfusion Caries Geographic tongue 
     60 Blood transfusion Caries, periodontitis Denture-associated stomatitis 
     61 Unknown Caries Herpes simplex 
62 Unknown Gengivitis, caries None 
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63 Unknown Edentulous BMS 
64 Unknown Periodontitis Hemorrhagic petechias 
65 Unknown Healthy Denture-associated stomatitis 
66 Unknown Caries, periodontitis Hairy tongue 
67 Blood transfusion Healthy Hairy tongue 
68 Blood transfusion Gingivitis None 
N1 Dialysis Healthy None 
N2 Blood transfusion Caries, gingivitis Hairy tongue 
N3 Blood transfusion Caries, periodontitis Hairy tongue 
N4 Dialysis Healthy Denture-associated stomatitis 
N5 Blood transfusion Healthy Linea alba 
N6 Blood transfusion Xerostomia, edentulous None 
N7 Blood transfusion Healthy None 
N8 Blood transfusion, Dialysis Periodontitis Hairy tongue 
N9 Blood transfusion, Dialysis Healthy None 
N10 Dialysis Gingivitis None 
N11 Blood transfusion Healthy Linea alba, traumatic ulcer 
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* N denotes patients from the renal unit at Nefroclínica private dialysis centre. 
N12 Dialysis Healthy Aphthous ulcers 
N13 Blood transfusion, Dialysis Healthy None 
N14 Dialysis Periodontitis Hairy tongue 
N15 Injecting drug user, Dialysis Edentulous with just one root to be pulled out None 
N16 Blood transfusion Caries, periodontitis and roots to be pulled out None 
N17 Dialysis Healthy Traumatic ulcer, linea alba 
N18 Dialysis Gingivitis None 
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3.3.10. Correlation of HCV RNA detection in saliva versus treatment 
status 
 
There was no statistically significant difference in the prevalence of HCV in 
whole saliva of patients who had received HCV therapy when compared with 
those who had not received such therapy (P=1.00, Table 3.3). 
 
Table 3.3. Prevalence of detectable HCV RNA in patients according to 
whether or not they have received therapy 
 
Treatment status 
No virus detected in 
saliva (%) 
Virus detected in saliva 
(%) 
Total 
Untreated 46 (68.7) 21 (31.3) 67 (100) 
Treated 12 (66.7) 6 (33.3) 18 (100) 
Total 58 (68.2) 27 (31.8) 85 (100) 
 
The salivary load ranged from 0 to 3940 IU per mL (median 0 IU / mL, mean 
54 IU / mL) and only 1 out of the 27 HCV RNA positive saliva samples was 
above the lowest level of quantification (100 IU / mL) with 3940 IU / mL. Three 
of the 27 HCR RNA saliva positive patients are edentulous. All of them were 
below the level of quantification for the quantitative real time PCR assay. Five 
of the positives for the block based PCR came up as negatives at the real time 
PCR assay and fourteen of them came up as positives at the real time PCR 
assay despite negative results at the block based PCR. 
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3.3.11. Correlation of HCV RNA detection between whole saliva and 
plasma. 
 
The relative risk for the association between whole saliva HCV RNA and 
plasma HCV RNA detection was 1.614 (95% CI 1.345-1.936). The relative risk 
for these parameters was 2 (95% CI 1.135-3.522) for treated and 1.553 (95% 
CI 1.284-1.877) for untreated patients (Table 3.4). 
 
Table 3.4. Relative risk for detectable HCV RNA in plasma according to 
therapy status 
 
Therapy 
group 
Plasma virus 
status 
Virus not 
detected in 
saliva 
Virus 
detected in 
saliva 
RR (95%CI) 
Untreated No virus detected 8 0  
 Virus detected 38 21 1.553 (1.284, 1.877) 
Treated No virus detected 6 0  
 Virus detected 6 6 2.000 (1.136, 3.522) 
Combined No virus detected 14 0  
 Virus detected 44 27 1.614 (1.345, 1.936) 
 
3.3.12. Relationship to Cellular Viral Load (CD19, CD14, CD2, CD45) 
 
Spearman’s nonparametric correlations have shown that there is a strong 
correlation of the HCV salivary detection in relation to all the studied cell 
compartments (CD19, CD14, CD2 and CD45). The correlation was very 
similar when using the same statistics test for the salivary viral load per 1000 
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cells as opposed to compartments loads (CD19, CD14, CD2 and CD45) per 
1000 cells.  
 
3.4. Discussion 
 
To date, only four studies analysing the quantitative detection of HCV RNA in 
oral fluids in comparison to plasma could be found after a literature search on 
the subject (Rey et al., 2001, Suzuki et al., 2005, Belec et al., 2003b, Savoldi 
et al., 2001). This would thus appear to be the first study to address the HCV 
RNA viral load in oral fluids, plasma and PBMCs and it’s aspects with regards 
to compartmentalization of HCV. 
    
In the present study whole saliva has been utilized as preliminary studies did 
not verify any significant difference between HCV presence in the saliva 
supernatant and saliva pellet after separation by centrifugation (data not 
shown). Similarly, it has been shown in a previous study that centrifugation did 
not modify HCV-RNA concentration in saliva (Savoldi et al., 2001). GCF was 
not collected as the present study was focused on the presence of HCV in 
whole saliva, as the likely route of any non-sexual and non-parenteral 
transmission. Peripheral blood mononuclear cells (PBMCs), which is one of 
the likely sources for the virus presence at the GCF, was also also examined 
for the presence of HCV RNA (refer to Chapter 4).  
 
In the present study approximately one third of all patients had detectable 
HCV RNA in saliva, there being no statistically significant difference between 
those treated and not treated with anti-HCV antivirals. The present HCV 
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genoprevalence in whole saliva is in general agreement with the mean 
prevalence of HCV RNA of all previous studies of untreated patients and 
certainly indicates that HCV can be present in oral fluids regardless of the 
treatment status of patients. The present HCV genoprevalence of untreated 
patients (31.3%) is higher than that of a similar study of patients from the 
Espírito Santo region of Brazil, where only 20% of HCV seropositivy patients 
had detectable HCV RNA in saliva (Goncalves et al., 2005). The reasons for 
the different genoprevalences of the two studies are unclear as both employed 
essentially similar methods of collection although the present study may have 
employed a much more sensitive method of detection of HCV RNA than that 
of the Espírito Santo patients.    
    
Maticic et al. (2001) have mentioned that the HCV RNA presence in whole 
saliva was significantly related to the presence of blood in the cited 
compartment (Maticic et al., 2001), although it had been previously 
demonstrated that the presence of blood in the saliva samples does not 
correlate with the presence of HCV RNA in the respective fluids (Komiyama et 
al., 1995, Liou et al., 1992). Traces of blood within saliva samples have been 
detected in around 10% (Caldwell et al., 1996) or 20% of cases from all 
studies involving HCV RNA detection in the saliva (Belec et al., 2003b, Hsu et 
al., 1991, Komiyama et al., 1995, Liou et al., 1992, Maticic et al., 2001, 
Sugimura et al., 1995) with the HCV RNA detection ranging from 0% (Hsu et 
al., 1991) to 66% (Komiyama et al., 1995) with an average of approximately 
31%. This average percentage is much lower when compared to studies that 
have excluded saliva samples with traces of haemoglobin (Diz et al., 2005, 
Eirea et al., 2005, Hermida et al., 2002) or much lower (Lins et al., 2005) and 
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exactly the same (Suzuki et al., 2005) when all saliva samples were 
macroscopically negative for the presence of blood. Thus, we have not tested 
our samples for blood presence in our study, but only macroscopically 
checked for the presence of blood.     
    
In the present study the discrepancies on the detection of HCV in the saliva 
via block-based PCR and real time PCR are likely to be due to the low level of 
the virus that was detected within the saliva samples. As mentioned before, 
just one of the HCV positive patients for the saliva had a viral load above the 
lower level of quantification, although, it was still below 5000 IU / mL. 
    
As it was previously discussed in Chapter 1, HCV is typically transmitted via 
parenteral routes (Shepard et al., 2005), however while the majority of 
infections have arisen as a consequence of injecting recreational drug use, 
receipt of blood or blood products or other iatrogenically associated 
exposures, 20 – 40% of HCV infected persons have no identifiable route of 
acquisition of the virus. It is thus possible that body fluids other than blood 
may be vehicles for the transmission of HCV (Belec et al., 2003a, Belec et al., 
2003b, Briat et al., 2005, Minosse et al., 2006, Nowicki et al., 2005, Pekler et 
al., 2003). 
    
Saliva is a potential vehicle for non-parenteral transmission of HCV but the 
supporting evidence remains inconsistent. Prior to the discovery of HCV, 
experimental transmission of non-A non-B Hepatitis via saliva was achieved in 
chimpanzees (Abe et al., 1987) with later demonstration of HCV transmission 
via inoculation of HCV-infected saliva in non-human primates (Abe et al., 
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1991). HCV transmission via human bites has been reported, all be it very 
rarely (Figueiredo et al., 1994, Dusheiko et al., 1990). Vertical transmission, 
potentially as a result of exposure to oral fluids has apparently never been 
reported, but although HCV is rarely observed  or not detected at all in breast 
milk (Kurauchi et al., 1993) it may be present in the whole saliva in 36% (Kage 
et al., 1997) to 50% (Ogasawara et al., 1993) of breast-feeding HCV infected 
mothers. Nevertheless, it is important to consider that both studies on whole 
saliva detection in pregnant women had a low number of patients enrolled – 
11 and 10 patients, respectively. Similarly, children with malignancy may have 
acquired HCV as a consequence of patient-to-patient non-parenteral routes 
(Fink et al., 1993). Intrafamilial transmission (e.g. via kissing shared utensils, 
toothbrushes and razors) is not common, the prevalence of HCV infection of 
household contacts of HCV-infected individuals being approximately 3.6% 
(Everhart et al., 1990, Hou et al., 1995, Mastromatteo et al., 2001). Evidence 
for the sexual transmission of HCV has been shown since the early nineties 
(Tedder et al., 1991). Vaginal shedding of HCV has been demonstrated, 
where the RNA detection ranged from ~30% in HIV co-infected women (Belec 
et al., 2003b, Belec et al., 2003a, Minosse et al., 2006, Nowicki et al., 2005) to 
50% of HCV mono-infected women (Gameiro et al., 2001).  
    
The HCV seroprevalence of Dental health care workers is not consistently 
higher than that of appropriate control populations although early reports did 
suggest that those who frequently undertook surgical procedures may be at 
increased risk of nosocomial acquisition of HCV (Klein et al., 1991), with the 
higher risk of infection extending to the health-care workers in general 
(Jochen, 1992, Cummins et al., 1992), when a case presentation of an acute 
 146 
hepatitis C infection due to a needlestick after occupational exposure 
highlights this increased risk (Sulkowski et al., 2002). On the other hand, other 
authors described a higher (twice as high antibody presence than in health 
care workers) risk related to socioeconomic variables after a comparative 
study with factory workers as controls (De Luca et al., 1992). 
    
The results of previous studies of the prevalence of HCV in oral fluids add 
weight to the notion that HCV transmission via saliva may be possible, 
although not frequent. There have been a substantial number of relevant 
studies with increasingly larger groups of study patients indicating that the 
prevalence of detection of HCV RNA in saliva may from 0 to 100% (Table 
3.5). The study groups have predominantly comprised individuals with 
untreated HCV-induced chronic hepatic disease. The varying prevalence of 
difference in the prevalence of salivary carriage of HCV of previous studies 
has been suggested to reflect variable methods of collection of saliva (e.g. 
oropharyngeal washes, stimulated versus non-stimulated saliva, use of 
sponges) but it is striking that despite these different methods only when 
sponges have been used (van Doornum et al., 2001) HCV has almost always 
been detected, all be it with different prevalences. The virological methods for 
detection of HCV have become more sensitive in recent years although this 
has not lead to a consistent increase in the detected salivary HCV 
genoprevalence. 
   
The present study represents the most extensive of HCV genoprevalence in 
oral fluids. In particular with the exclusive use of PDH real time PCR for cell 
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quantification, thus, providing us with a viral load per 1000 cells present in 
each saliva extract, together with the absolute viral load.   
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            Table 3.5. All studies regarding the prevalence of HCV RNA in the saliva 
First author & 
year 
N Clinical data Methods Type of saliva / GCF HCV-RNA 
in plasma  
N (%) 
HCV-RNA in 
saliva 
N (%) 
(Takamatsu et al., 
1990) 
5 Chronic hepatitis C (1); liver 
cirrhosis (2) ; liver cirrhosis & 
hepatocellular carcinoma (2) 
NS3 nested PCR Saliva supernatant N/A 5 (100) 
(Hsu et al., 1991) 19 Chronic hepatitis C 
 
5’-NCR nested 
PCR 
Whole saliva 19 (100) 0 (0) 
(Wang et al., 
1991) 
3 Post-transfusion chronic hepatitis C NS3 and 5’-NCR 
nested PCR 
Whole saliva 3 (100) 3 (100) 
(Wang et al., 
1992b) 
14 Post-transfusion chronic hepatitis 
 
5’-NCR nested 
PCR 
Whole saliva 10 (71.4) 7 (50) 
(Liou et al., 1992) 31 Chronic hepatitis C 
 
5’-NCR nested 
PCR 
Whole saliva 31 (100) 15 (48.3) 
(Nakano et al., 
1992) 
10 
 
Chronic hepatitis C 
 
5’-NCR nested 
PCR 
Whole saliva 10 (100) 6 (60) 
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(Fried et al., 1992) 14 Chronic hepatitis C males 
 
5’-NCR nested 
PCR 
Saliva supernatant 
 
14 (100) 0 (0) 
(Ogasawara et al., 
1993) 
10 Pregnant HCV RNA positive 
patients 
5’-NCR nested 
PCR 
Whole saliva 10 (100) 5 (50) 
(Young et al., 
1993) 
50 Chronic hepatitis C 
 
5’-NCR nested 
PCR 
Whole saliva 41 (82) 25 (50) 
(Harle et al., 1993) 30 Patients suspected to be infected 
by HCV but seronegative for the 
virus 
PCR (no details) Whole saliva 5 (16.7) 14 (46.7) 
(Couzigou et al., 
1993) 
37 Chronic hepatitis C 5’-NCR nested 
PCR 
Whole saliva N/A 23 (62) 
(Numata et al., 
1993) 
23 HCV seropositive patients 
 
Single round 5’-
NCR PCR 
Whole saliva 23 (100) 8 (34.8) 
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(Puchhammer-
Stockl et al., 
1994) 
46 
 / 
35 
Chronic hepatitis C children with 
malignant diseases who received 
blood 
 
5’-NCR nested 
PCR and line 
probe 
hybridization for 
some amplified 
samples 
Throat wash supernatant 35/46 (73) 7/35 (20) 
(Roy et al., 1995) 14 Chronic hepatitis C 5’-NCR nested 
PCR and 
quantitative 
branched DNA on 
plasma 
1 – Whole saliva;  
2 – Saliva pellet;  
3 – Saliva supernatant;  
4 – Salivette (sponges) 
 
13 (93) 1 – 11 (78.6) 
2 – 7 (50) 
3 – 7 (50) 
4 – 10 (71.4) 
(Komiyama et al., 
1995) 
32 Chronic hepatitis C with liver 
cirrhosis or hepatoma, patients 
HCV seropositive 
 
Single round 5’-
NCR PCR 
followed by 
southern blot 
hybridization 
Whole saliva N/A 21 (66) 
(Mariette et al., 
1995) 
28 Chronic hepatitis C, 13 HIV 
coinfected 
Amplicor HCV 
test (Roche) and 
Whole saliva 28 (100) 17 (61) 
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 branched DNA on 
plasma 
(Sugimura et al., 
1995) 
76 Elderly Chronic hepatitis C patients 
 
5’-NCR and 
envelope (E1) 
nested PCR 
Whole saliva 24 (44) 27 (35.5) 
(Chen et al., 1995) 26 Anti-HCV positive patients, 11 of 
them co-infected with HIV-1  
5’-NCR nested 
PCR 
1 – Saliva pellet;  
2 – Saliva supernatant;  
3 – Saliva pellet  
4 – supernatant of 
submaxillary glands 
23 (88) 1 – 4/23 
(17.4);  
2 – 0 (0);  
3 – 0 (0);  
4 – 0 (0) 
(Biasi et al., 1995) 1 HCV seropositive, chronic 
sialadenitis 
5’-NCR nested 
PCR 
Saliva supernatant 
 
0 (0) 1 (100) 
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(Caldwell et al., 
1996) 
33 Chronic hepatitis C, 21 of them 
undergone liver transplantation 
 
5’-NCR nested 
PCR and 
quantitative 
branched DNA on 
plasma 
Whole saliva 33 (100) 4/21 (19); 
0/12 (0) 
 
(Jorgensen et al., 
1996) 
16 Chronic hepatitis C and Sjögren 
Syndrome 
 
Single round 5’-
NCR PCR 
followed by 
southern blot 
hybridization 
Whole saliva 15 (93) 13 (83) 
(Roy et al., 1996) 21 Haemophiliac HCV-seropositive 
patients 
5’-NCR nested 
PCR 
1 – Whole saliva;  
2 – Saliva pellet;  
3 – Saliva supernatant;  
4 – Salivette (sponges) 
 
 
21 (100) 1 – 5 (23);  
2 – 5 (23);  
3 – 4 (19);  
5 – 5 (23%) 
(Taliani et al., 
1997) 
20 Chronic hepatitis C (11) and 
cirrhosis (9) 
5’-NCR nested 
PCR and 
Whole saliva 20 (100) 3 (15) 
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 quantitative 
branched DNA on 
plasma 
(Ustundag et al., 
1997) 
10 HGBV-C and HCV co-infected, 
haemodialysis 
5’-NCR nested 
PCR 
Whole saliva 10 (100) 3 (30) 
(Kage et al., 1997) 
 
11 Hepatitis C carriers (HCV RNA and 
antibody positive), pregnant 
patients 
5’-NCR nested 
PCR 
Whole saliva 11 (100) 4 (36) 
(Roy et al., 1998) 50 HCV seropositive intravenous drug 
users, 27 of them also HIV  
Seropositive 
 
5’-NCR nested 
PCR, quantitative 
branched DNA on 
plasma 
1 – Whole saliva;  
2 – Salivette (sponges) 
33 (66) 1 and/or 2 –  
19/33 (57.6) 
(Fabris et al., 
1999) 
45 Chronic hepatitis C 5’-NCR nested 
PCR 
1 – Whole saliva;  
2 – Saliva pellet;  
3 – Saliva supernatant 
39 (81.2) 22/39 (56.4) 
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(Roy et al., 
1999) 
50 HCV seropositive intravenous drug 
users 
5’-NCR nested 
PCR 
1 – Whole saliva;  
2 – Salivette (sponges);  
3 – Omni-Sal (sponges) 
33 (66) 1 – 17 (34);  
2 – 9 (18);  
3 – 13 (26) 
(Becheur et al., 
2000) 
15 Untreated chronic hepatitis C 
 
Amplicor HCV 
test (Roche) 
Whole saliva 15 (100) 4 (26.6) 
(Arrieta et al., 
2001) 
9 HCV seropositive (4) and 
seronegative (5), xerostomia 
Amplicor HCV 
test (Roche) 
Whole saliva 4/4 (100); 
0/5 (0) 
4/4 (100); 0/5 
(0) 
(Mastromatteo 
et al., 2001) 
45 / 
138 
Chronic hepatitis C (45) and 
cohabitants (138) 
 
5’-NCR nested 
PCR 
Whole saliva 23/45 
(52.6); 
7/138 (5.1) 
13/45 (28.8); 
5/138 (3.6) 
(van Doornum 
et al., 2001) 
102 HCV seropositive, HIV infected illicit 
drug users 
 
 
 
 
Amplicor HCV 
test (Roche) 
Salivette and Omni-Sal 
(sponges) 
76 (74.5) 0 (0) 
(Maticic et al., 50 Chronic hepatitis C Amplicor HCV 1 – Whole saliva;  50 (100) 1 – 17/48 
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2001) test (Roche) 2 – Gingival crevicular fluid 
 
(35.4);  
2 – 29/49 
(59.2) 
(Savoldi et al., 
2001) 
32 HCV seropositive geriatric patients 
with odontostomatologic problems 
 
Quantitative 
branched DNA on 
plasma and saliva 
Whole saliva 18 (56.3) 20 (62.5) 
(Rey et al., 
2001) 
59 HIV-HCV co-infected patients 
 
5’-NCR nested 
PCR and 
quantitative 
branched DNA on 
saliva and plasma 
positives 
 
Whole saliva 45/56 
(80.4) 
22/59 (37.3) 
(Hermida et al., 
2002) 
61 Chronic hepatitis C 5’-NCR nested 
PCR 
Whole saliva 61 (100) 32 (52.4) 
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(Toussirot et al., 
2002) 
5 Chronic hepatitis C and Sjögren 
Syndrome 
 
Amplicor HCV 
test (Roche), 
quantitative 
branched DNA on 
plasma 
Whole saliva 5 (100) 5 (100) 
(Belec et al., 
2003b) 
28 Hospitalized HCV seropositive 
patients 
Quantitative 
amplicor HCV test 
(Roche), Single 
round 5’-NCR 
PCR followed by 
southern blot 
hybridization 
1 – Saliva pellet;  
2 – Saliva supernatant;  
3 – cell free gingival crevicular 
fluid 
 
28 (100) 1 – 12 (42.9); 
2 – 1 (3.6);  
3 – 0 (0) 
(Eirea et al., 2005) 75 Chronic hepatitis C co-infected with 
HIV 
 
 
5’-NCR nested 
PCR 
Whole saliva 75 (100) 49 (65.3) 
(Diz et al., 2005) 44 Chronic hepatitis C Quantitative 
amplicor HCV test 
Whole saliva 44 (100) 26 (59.1) 
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(Roche) for 
plasma and 5’-
NCR nested PCR 
for saliva 
 
(Goncalves et al., 
2005) 
39 HCV seropositive 5’-NCR nested 
PCR 
Saliva supernatant 32 (82.5) 8 (20.5) 
(Lins et al., 2005) 50 HCV seropositive Quantitative 
amplicor HCV test 
(Roche), 5’-NCR 
nested PCR 
Whole saliva 50 (100) 50 (100) 
(Suzuki et al., 
2005) 
26 HCV seropositive Quantitative 5’-
NCR core 
reagents HCV 
test (Applied 
Biosystems) 
1 – Whole saliva;  
2 – Gingival crevicular fluid 
 
20 (76.9) 1 – 8 (30.8); 
2 – 22 (84.6) 
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(Wang et al., 
2006) 
23 Chronic hepatitis C Quantitative 
amplicor HCV test 
(Roche) for 
plasma and 
transcription-
mediated 
amplification 
Versant HCV test 
(Bayer) 
Whole saliva 23 (100) 22 (95.7) at 
least in 1 day 
of 21 
consecutive 
days tested 
 
(Pastore et al., 
2006) 
46 Chonic hepatitis C Quantitative 
amplicor HCV test 
for plasma and 
Cobas amplicor 
HCV test for 
saliva (Roche) 
 
Saliva supernatant 
 
46 (100) 18 (39.1) 
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A striking feature of the present study is the absence of any significant 
difference in the salivary HCV genoprevalence rates between treated and 
non-treaded patients. While this is a cross-sectional study, and thus did not 
examine the HCV genoprevalance longitudinally, the present absence of any 
significant difference in the prevalence or load of HCV in saliva between the 
two patient groups is of clinicopathological significance. One previous 
longitudinal study of HCV-infected patients in Spain reported that 
approximately 10% of patients may have persistence of HCV in saliva for at 
least 6 months despite clearance of HCV from blood following interferon and 
ribavirin (Diz et al., 2005). The present results, together with those of Diz Dios 
and co-workers (2005) raise the possibility that there is some 
compartmentalized extrahepatic HCV replication, e.g., in the salivary glands 
(Arrieta et al., 2001), that is resistant to anti-HCV therapy.  
    
In the present study there was no correlation between the salivary prevalence 
or load of HCV with those of plasma. HCV loads have been found in some 
(Fabris et al., 1999, Hermida et al., 2002, Mariette et al., 1995, Numata et al., 
1993) but not all (Rey et al., 2001, Roy et al., 1995) similar studies. This lack 
of correlation may point towards the mouth or salivary glands being a site of 
extra-hepatic HCV replication. Indeed in some instances HCV has been more 
frequent in saliva than in blood (Biasi et al., 1995, Harle et al., 1993, Savoldi et 
al., 2001). Adding weight to this argument, no association was observed 
between the dental status (i.e., dentate versus edentate) in the present group 
of patients. Previous studies have not found consistent correlations between 
dental disease (e.g. gingival and periodontal disease markers, the presence of 
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oral mucosal disease and/or number of teeth) and the presence or load of 
HCV RNA in saliva of HCV infected patients (Lins et al., 2005). Similarly, 
although gingival crevicular fluid may have higher frequencies and levels of 
detectable HCV RNA than whole saliva, no significant association between 
GCF levels of HCV RNA and gingival disease has been observed (Maticic et 
al., 2001, Suzuki et al., 2005).  
    
Likewise HCV has been detected in the saliva of edentulous individuals in the 
present and previous studies. Eleven per cent (11%) of the HCV RNA saliva 
positive patients were edentulous, making it more questionable the possible 
leakage of the virus via the GCF and rising again the possibility that the virus 
could indeed replicate within the oral mucosa (Carrozzo et al., 2002) or maybe 
in salivary glands, where both positive and negative sense RNA were 
detected by in situ hybridization at the epithelial cells of the acini structures 
(Arrieta et al., 2001). Nevertheless, both studies have detected the virus in 
patients affected by lichen planus and Sjögren's syndrome or chronic 
sialadenitis, respectively. Lins et al. (2005) have also detected HCV RNA in 
the saliva of 2 edentulous patients with no oral lesions (Lins et al., 2005). 
Elderly persons were the subject of one study, some of whom would be 
expected to be edentulous (Sugimura et al., 1995), hence, suggesting that 
while HCV-infected peripheral blood mononuclear cells may allow HCV to 
infiltrate the GCF and saliva (as a consequence of transmigration from blood 
to the gingival crevice) it is unlikely that these are a major source of HCV in 
oral fluids (Suzuki et al., 2005). 
    
 161 
There was no significant difference in the prevalence of salivary HCV RNA of 
patients with different routes of possible HCV acquisition. This accord with the 
findings of a previous study of patients from another region of Brazil 
(Goncalves et al., 2005). It is possible that the carriage of HCV in oral fluids 
might be influenced by sexually- or parenterally-acquired factors although 
HIV-related immunodeficiency does not influence salivary carriage of HCV 
(Rey et al., 2001) and unless a particular route of acquisition was to favour 
infection by an HCV variant that is notably tropic for salivary gland tissue or 
oral epithelium it seems most unlikely that the route of acquisition is a 
predictor of oral carriage in the mouth. 
 
The present results confirm that HCV RNA is present in saliva of 
approximately one third of all patients with HCV infection and that salivary 
genoprevalence is not influenced by local factors such as dental status nor 
recent anti-HCV therapy. Oral carriage of HCV may however be influenced by 
genetic variation of the infecting virus. 
 
There was no correlation of IgG levels in saliva and high viral load in plasma 
of the respective patients. That is another indication of no viral leakage from 
the gingival crevicular fluid. The other finding that reinforces this hypothesis is 
that we could detect HCV RNA in the saliva of edentulous patients.  
 
Whatever the mechanism is, the presence of HCV RNA in saliva, regardless 
of the viral load levels detected, could have important implications for hepatitis 
C epidemiology, as the origin of infection remains unknown in up to 40% of 
cases. (Rey et al., 2001) In the other hand, our study is only the fourth study 
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to evaluate the quantitative presence of HCV RNA in the saliva, and we have 
analysed a higher number of patients, showing a much lower HCV RNA 
titration in the saliva in comparison to the other studies. This could mean that 
chance of transmission of the virus via the saliva could be lower than 
previously expected. Nevertheless, further studies are needed with regards to 
HCV RNA quantification in the oral fluids.     
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Chapter 4  
 
 
Compartmentalization of HCV in Saliva and Blood 
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4. 1. Introduction 
 
The presence of Hepatitis C virus (HCV) within oral fluids may be the 
consequence of local carriage or replication within leukocytes that are 
trafficking to the oral mucosa, gingivae or salivary glands. Alternatively there 
may be local replication of HCV within oral mucosal and gingival keratinocytes 
or salivary gland acinar cells (see Chapter 1). 
 
Compartmentalisation of HCV within extra-hepatic sites certainly does occur 
as HCV RNA has been detected in a number of extra-hepatic sites including 
peripheral blood mononuclear cells (PBMC; see below), dendritic cells, CNS 
(Morsica et al., 1997, Bagaglio et al., 2005, Laskus et al., 2002), salivary 
glands (Arrieta et al., 2001, Takamatsu et al., 1992) – see Chapter 1, oral 
mucosa (Carrozzo et al., 2002) – see also chapter 1, female genital tract 
(Nowicki et al.  2005), lymph nodes (Sansonno et al.  1996) and kidneys 
(Widell et al., 1995, Rodriguez-Inigo et al., 2000). The detection of negative-
stranded RNA (intermediary of HCV replication) and demonstration of 
quasispecies compartmentalisation additionally support the concept of 
compartmentalisation and extra-hepatic HCV replication (Blackard et al.  
2006; Laskus et al.  2007; Roque Afonso et al.  1999).   
 
Some of the studies that have demonstrated compartmentalisation of HCV 
have involved patients who are immunocompromised, e.g. with HIV co-
infected patients (Morsica et al., 1997, Nowicki et al., 2005) perhaps 
suggesting that there is simply non-permissive HCV infection, however many 
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of the studies that have found HCV RNA within PBMC have been in 
immunocompetent individuals suggesting strongly the existence of extra-
hepatic HCV replication, even in occult infection, when HCV RNA is found 
only within PBMC (Castillo et al.  2005; Cavalheiro et al.  2007).  
 
Hepatitis C virus RNA has been detected in the PBMC of up to 79% of 
examined patients with chronic hepatitis (Table 4.1). HCV RNA in PBMC has 
been detected in different groups liable to HCV acquisition and is thus 
independent of any route of acquisition of HCV (Azzari et al.  2008). The 
presence of HCV RNA within PBMC is not consistently correlated with plasma 
or serum levels of HCV RNA (Lerat et al.  1998; Meier et al.  2001), indeed as 
patients with occult disease have no serum HCV yet HCV RNA can be 
detected in PBMC. HCV RNA is not consistently influenced by HCV genotype 
(Kao et al.  1997; Mazur et al.  2001). Significantly HCV RNA can be detected 
in PBMC for years after complete clinical and virological resolution of clinical 
disease suggesting that PBMC may be a natural reservoir of HCV (Radkowski 
et al.  2005; Pham et al.  2005).  
 
There is limited evidence that HCV replicates within keratinocytes nor salivary 
gland acinar cells (see Chapter 1) and as noted in Chapter 3 HCV is not 
consistently present in oral fluids and when present is in low concentration. 
However the consistent finding of HCV RNA within PBMC does suggest that 
any extra-hepatic compartmentalisation of HCV within circulating PBMC is 
likely to influence the carriage of HCV within oral fluids.  To date there have 
been no studies that have examined the association of salivary carriage with 
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HCV compartmentalisation in PBMC and plasma. Knowledge of the likely 
influence of HCV compartmentalisation of HCV between blood and oral fluids 
would provide insight into source of HCV in oral fluid and the likely impact of 
HCV therapy upon clearance of HCV from saliva. 
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Table 4.1. Results of previous studies of the prevalence of HCV RNA in peripheral blood mononuclear cells 
 
First author 
& year 
N Clinical data Methods Type of PBMC HCV-RNA in plasma 
N (%) 
HCV-RNA in PBMC 
N (%) 
(Bouffard et 
al., 1992) 
24 HCV-infected patients 
(all HCV antibody 
positive, 8 chronic 
active hepatitis, 3 
chronic persistent 
hepatitis, 3 cirrhosis 
with chronic active 
hepatitis, 10 without 
biopsy) 
5’-NCR 
nested 
PCR 
Total PBMCs “+” strand – 19 (79.2);  
“-“ strand – 0/5 (0) 
“+” strand – 17 (70.8);  
“-“ strand – 1/5 (20) 
(Takehara 
et al., 1992) 
9 Chronic hepatitis C, 6 
with chronic active 
hepatitis and 3 with 
cirrhosis 
5’-NCR 
single 
round PCR 
Total PBMCs “+” strand – 9 (100);  
“-“ strand – 0 (0) 
 
“+” strand – 7 (77.8);  
“-“ strand – 0 (0) 
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  (Wang et 
al., 1992a) 
7 Posttransfusion 
hepatitis C 
5’-NCR 
nested 
PCR 
Total PBMCs “+” strand – 7 (100); 
 “-“ strand – 0 (0) 
“+” strand – 7 (100);  
“-“ strand – 3 (42.9)  
 
(Zignego et 
al., 1992) 
5 Chronic active 
hepatitis anti-HCV 
positive drug addicts 
  
5’-NCR and 
NS5 
regions 
nested 
PCR 
1 – Total PBMCs;  
2 – T-lymphocytes;  
3 – B-lymphocytes;  
4 – Macrophage monocytes 
“+” strand - 4 (80);  
“-“ strand – 3 (60) 
“+” and “-“ strands 
(same results) – 1 – 5 
(100); 2 – 3/3 (100); 3 
– 3/3 (100); 4; 2/3 
(66.7); 
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(Gil et al., 
1993) 
20 Histologically proven 
chronic hepatitis and 
positive and negative 
strand of HCV RNA 
present in plasma of all 
patients; samples 
analysed after 12 
months of therapy (6 
untreated patients) 
5’-NCR 
nested 
PCR; semi-
quantitative 
titration of 
HCV RNA 
Total PBMCs “+” strand – 6/14 
(42.9);  
“-“ strand – 5/14 (35.7) 
“+” strand – 12/18 
(66.6);  
“-“ strand – 8/18 (44.4) 
(Muller et 
al., 1993) 
5 Two post-transfusional 
hepatitis C and three 
orthotopic liver 
transplantation due to 
chronic hepatitis C 
5’-NCR and 
NS3/NS4 
region 
nested 
PCRs 
1 – B lymphocytes;  
2 – T lymphocytes;  
3 – NK cells 
5 (100) “+” strand – 1 – 3 (60); 
2 – (0); 3 – 0 (0); “-“ 
strand (southern blot) 
– 1 – 4 (80); 2 – (0); 3 
– 0 (0); 
 
 
(Gabrielli et  Type II (10) and type 5’-NCR Total PBMCs A – 7 (63.6); B – 10 A – 6 (54.5); B – 1 
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  al., 1994) III (1) mixed cryoglobu-
linemia - MC (A) – 6 
under interferon-alpha 
therapy and 11 chronic 
hepatitis without MC 
(B) – 3 under 
interferon-alpha 
therapy 
single 
round PCR 
(90.9) (9.1) 
(Willems et 
al., 1994) 
47 Hemophiliacs  with 
chronic hepatitis C 
5’-NCR 
nested 
PCR 
Total PBMCs “+” strand – 35 (74.5); 
“-“ strand – 16/29 
(55.2) 
“+” strand – 36 (76.6); 
“-“ strand – 22/29 
(75.9) 
(Berenguer 
et al., 1995) 
1– 
5; 2 
– 
16 
1 – non-responders to 
anti-HCV therapy; 2 – 
responders to HCV 
therapy 
5’-NCR 
nested 
PCR 
Total PBMCs 1 – 5 (100); 2 – 0 (0) 
 
1 – Not tested; 2 – 
6/13 (46.2) 
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(Biasi et al., 
1995) 
1 HCV seropositive, 
chronic sialadenitis 
5’-NCR 
nested PCR 
Lympho-monocytes 
 
0 (0) 1 (100) 
(De 
Maddalena et 
al., 1995) 
1 – 
39; 2 
– 11 
Type II (24) and 
type III (15) mixed 
cryoglobulinemia - 
MC (1) and 11 
chronic hepatitis 
without MC (2) 
 
5’-NCR 
nested PCR 
and 5’-NCR 
Amplicor 
(Roche) 
Total PBMCs 34/37 (91.9) 1 – 14/20 (70); 2 – 
8/11 (72.7) 
(Lanford et 
al., 1995) 
1 – 
5; 2 
– 10  
1 – 2 acutely 
infected 
chimpanzees and 3 
chronically infected 
chimpanzees; 2 – 
HCV-infected 
humans 
5’-NCR 
single round 
rTth PCR 
followed by 
southern blot  
hybridization 
Total PBMCs “+” strand – 1 –  5 
(100); 2 – 2/2 (100); “-” 
strand – 1 – 5 (100); 
2/2 (100) 
   
“+” strand – 1 – 4 (80); 
2 – 7 (70); “-” strand – 
1 – 0 (0); 2 – 0 (0) 
(Oesterreiche 67 Chronic 5’-NCR Total PBMCs 10 (14.9) 6 (8.9) 
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  r et al., 1995) hemodialysis 
 
nested PCR 
(Taliani et al., 
1995) 
20 Histologically 
proven chronic 
hepatitis C 
5’-NCR 
nested PCR 
Total PBMCs “+” strand – 18 (90); 
 “-“ strand – 0 (0) 
“+” strand – 15 (75); “-“ 
strand – 13 (65) 
(Zignego et 
al., 1995) 
34 HCV seropositive 
for more than 1 
year 
 
5’-NCR 
nested PCR 
Fresh (1) and mitogen-
stimulated (2) total PBMC 
 
22 (64.7) “+” strand – 1 – 20 
(58.8); 2 – 22 (64.7);  
“-“ strand – 1– 12 
(35.3); 2 – 19 (55.9) 
(Chang et al., 
1996) 
1 –
11; 2 
– 48 
1 – Acute 
posttrans-fusion 
hepatitis C; 2 – 
Chronic Hepatitis C 
5’-NCR 
nested PCR; 
quantitative 
branched 
DNA on 
plasma 
Total PBMCs 1 – 10 (90.9); 2 – 41 
(85.4) 
1 – “+” strand – 0 (0); 
“-“ strand – 0 (0); 2 – 
“+” strand – 12 (25); “-“ 
strand – 6/12 (50)  
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(Lerat et al., 
1996) 
32 Chronic hepatitis C (A) 
and liver transplant-
tation (B) 
“+” strand – 
5’NCR 
nested PCR; 
“-“ strand – 
5’NCR, 5’ 
tagged NCR 
and 
nucleocap-
sid nested 
PCRs 
Total PBMCs “+” strand – 32 (100); 
“-“ strand – 0 (0) 
“+” strand – A – 15/23 
(652); B – 3/3 (100); “-“ 
strand – A – 1/23 (4.3); 
B – 3/3 (33.3); 
 
(Zehender 
et al., 1997) 
15 Chronic hepatitis C, 4 
with mixed cryoglobu-
linemia 
5’-NCR 
nested PCR; 
semi-
quantitative 
titration of 
HCV cDNA 
1 – B cells CD19;  
2 –  T cells CD3;  
3 – T cells CD14 
15 (100) 1 – 15(100); 2 – 5/14 
(35.7); 3 – 5/12 (41.6) 
 
(Kao et al., 106 Chronic hepatitis C 5’-NCR Total PBMCs “+” strand – 89 (84.0); “+” strand – 83 (78.3); 
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  1997) nested PCR “-“ strand – 0 (0) “-“ strand – 33 (31.1) 
(Laskus et 
al., 1997) 
27 Chronic hepatitis C 5’-NCR (1) 
and NS5 
region (2) 
single round 
PCR 
followed by 
southern blot 
hybridization 
Total PBMCs 1 – 27 (100); 2 – 20 
(74.1); all “-“ strand 
RNA negative 
1 – 17 (63);  2 – 12 
(44.4); all “-“ strand 
RNA negative 
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(Lerat et al., 
1998) 
38 HCV RNA positive and 
seropositive 
 
INNO-LIPA 
(Inno-
genetics) 5’-
NCR (A) and 
nucleo-
capsid 
nested PCRs 
(B) and 
quantitative 
branched 
DNA on 
plasma 
1 – Monocytes;  
2 – B lymphocytes;  
3 – granulocytes 
38 (100) (A) “+” strand – 1 – 21 
(56); 2 – 24 (63); 3 – 
34 (89); (B) “-“ strand – 
1 – 1/10 (10); 2 – 2/9 
(22.2); 3 – 3/10 (30) 
 
(Morsica et 
al., 1999) 
4 Chronic hepatitis C 5’-NCR 
nested PCR 
1 – Total PBMCs;  
2 – B cells CD19;  
3 – T cells CD4;  
4 – T cells CD8 
4 (100); all “-“ strand 
RNA negative 
1 – 3 (75); 2 – 3 (75); 3 
–  1 (25); 4 – 1 (25); all 
“-“ strand RNA 
negative 
(Roque 9 HCV antibody positive HVR1 nested 1 – B cells CD19;  9 (100) 1 – 7 (77.7); 2 – 3/8 
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  Afonso et 
al., 1999) 
PCR; 
quantitative 
Amplicor for 
plasma 
(Roche) 
2 – T cells CD8;  
3 – T cells CD4;  
4 – Negatively selected 
cell fraction (NF) 
  
(37.5); 3 – 1 (11.1); 4 – 
7/8 (87.5) 
(Azzari et 
al., 2000) 
1 – 
13; 
2 – 
53 
1 – Mothers whose 
babies became 
infected; 2 – Mothers 
whose babies did not 
become infected 
5’-NCR 
nested PCR 
Lymphocytes 
 
1 – 13 (100); 
2 – 53 (100); ; all “-“ 
strand RNA negative 
 
“+” strand – 1 – 13 
(100); 
2 – 13 (24.5) ; “-“ 
strand – 1 – 5 (38.5); 2 
– 0 (0) 
(Garcia et 
al., 2000) 
22 Chronic hepatitis C NS3 region 
nested PCR 
Total PBMCs 22 (100) “+” strand – 8/21 
(38.1); “-“ strand – 2/8 
(25)  
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(Takyar et 
al., 2000) 
8 HCV carriers 5’-NCR 
nested PCR; 
quantitative 
Amplicor for 
plasma 
(Roche) 
Total PBMCs 8 (100) “-“ strand – 4 (50) 
 
(Gameiro et 
al., 2001) 
14 HCV infected women 
 
5’-NCR PCR 
and 9 cases 
quantitative 
Amplicor for 
plasma 
(Roche) 
Total PBMCs 14 (100) 8 (57.1) 
(Mazur et 
al., 2001) 
45 8 anti-HCV positive 
haemodialysis patients 
(1) and 37 anti-HCV 
negative (2)  
5’-NCR 
nested PCR 
Total PBMCs 1 – 2 (4.4); 2 – 2 (4.4) “+” strand – 1 – 4 (8.8); 
2 – 3 (6.6); “-“ strand – 
1 – 4 (8.8); 2 – 1 (2.2) 
 
(Meier et 15 Chronic hepatitis C 5’-NCR Total PBMCs 1 – 15 (100); 2 – 14/14 1 – 15 (100); 2 – 0/14 
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  al., 2001) before (1), during (2) 
and after interferon 
alfa therapy examined 
when it was present in 
both sites (3), and 
present  in plasma but 
not in PBMC (4) later 
nested PCR;  
quantitative 
Amplicor for 
plasma 
(Roche) 
(100); 3 –  8 (53.3); 4 – 
4/11 (36.4) 
(0); 3 – 8 (53.3); 4 – 
0/11 (0)  
(Ye et al., 
2001) 
583 Chronic hepatitis C Nested PCR Total PBMCs 112 (19.2) 143 (24.5) 
 
(Laskus et 
al., 2002) 
13 HCV seropositive 
undergoing nontrau-
matic lumbar puncture 
for diagnostic 
purposes 
5’-NCR 
nested PCR 
Total PBMCs 13 12 (92.3) 
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(Mazurek et 
al., 2002) 
1 – 
154
; 2- 
54 
Chronic liver disease 
with hepatitis C 
infection (1) and 
HCV/HBV coinfected 
(2) 
5’-NCR 
nested PCR 
Lymphocytes “+” strand – 1 – 98 
(63.6); 2 – 49 (90.7); “-
“ strand –  
1 – 70 (45.5); 2 –  
16 (29.6) 
“+” strand – 1 – 126 
(81.8); 2 – 21 (38.8); “-
“ strand – 1 – 
98 (63.6); 2 – 14 (25.9) 
(Ducoulombi
er et al., 2004) 
14 Chronic hepatitis C HVR1 nested 
PCR and 
quantitative 
real time 
PCR (Roche) 
1 – Total PBMCs;  
2 – CD19;  
3 – CD8;  
4 – CD4;  
5 – CD14 
14 (100) 1 – 3/3 (100); 2 – 
11/11 (100); 3 – 10/11 
(90.9); 4 – 4/11 (36.4); 
5 – 0/11 (0) 
 
(Fernandez et 10 HCV RNA positive 5’-NCR Total PBMCs 1 – 10 (100); 2 – 10 1 – 7 (70); 2 – 7 (70); 3 
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al., 2004) under hemodialysis; 
samples collected 
before Dialysis (1), 5 
minutes after the 
session (2) and 2 days 
later – before next 
Dialysis session (3) 
nested PCR; 
quantitative 
branched 
DNA on 
plasma 
(100); 3 – 10 (100) – 7 (70) 
(Castillo et 
al., 2005) 
18 Occult hepatitis C, 
PBMC RNA positive  
5’-NCR 
nested PCR 
detected by 
fluorescent in 
situ 
hybridisation 
 
 
 
 
Total PBMCs 0 (0) “+” strand – 18 (100); 
“-“ strand – 11 (61)  
 
(Blackard et 48 HCV seropositive 5’-NCR Total PBMCs 1 – 42/47 (89); A – 23 “+” strand – 1 – 20 
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al., 2005) women (IDU as main 
risk factor) 28 HCV 
monoinfected (A) and 
20 HCV-HIV 
coinfected (B) before 
(1) and after ART 
treatment for HIV 
started (2). 
 
single round 
PCR 
(82); B – 19/19 (100); 
2 – 43/47 (91); A – 26 
(93); B – 17/19 (89) 
 
(42); A – 9 (32); B – 11 
(55); 2 – 20/45 (44); A 
– 8 (29); B – 
12/17 (71); “-” strand – 
1 – 17 (35); A – 9 (32); 
B – 8 (40); 2 – 17/45 
(38); A – 7 (25); B –  
10/17 (59) 
(Cavalheiro et 
al., 2007) 
54 Chronic hepatitis C 
after combined therapy 
 
5’-NCR 
single round 
PCR 
Amplicor 
(Roche) 
Total PBMCs  35 (65) 38 (70.6) 
(Di Liberto et 
al., 2006) 
119 Chronic hepatitis C 5’-NCR 
nested PCR 
 
Total PBMCs  113 (94) 113 (94) 
(Carreno et 12 HCV antibody positive, Amplicor Total PBMCs 0 (0) “+” strand – 6 (50);  
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al., 2006) normal ALT levels and 
serum HCV RNA 
negative for at least 12 
months 
 
(Roche), 5’-
NCR single 
round PCR 
followed by 
in situ 
hybridizati-
on, real time 
PCR 
“-“ strand – 5 (41.7)  
 
(Azzari et al., 
2008) 
1 – 
48; 
2 – 
122 
1 – mothers whose 
babies became 
infected; 2 – mothers 
whose babies did not 
become infected 
 
5’-NCR 
nested PCR, 
quantitative 
Amplicor for 
plasma 
(Roche) 
Lymphocytes 
 
1 – 48 (100) 
2 – 122 (100) 
1 – 48 (100) 
2 – 66 (54.1) 
(Barria et al., 
2008) 
47 HCV seropositi-ve for 
more than 6 months 
Single round 
5’-NCR and 
NS5b PCR 
Total PBMCs 47 (100) 34 (72.3) 
(Bernardin et 56 Blood donors viremic Cell Total PBMCs 56 (100) 43 (76.8) 
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 al., 2008) patients 
 
associated – 
transcrip-tion 
mediated 
amplificati-on 
(GenPro-be), 
Core region 
nested PCR 
(Thongsawat 
et al., 2008) 
11 Individuals who had 
transitioned from 
plasma RNA positive 
to plasma RNA 
negative 
Core/E1 
nested PCR 
Total PBMCs 11 (100), then 0 (0), 
between 24 and 36 
month follow up 
 
2 (18.2), from the 30th 
month follow up 
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(Gallegos-
Orozco et al., 
2008) 
25 Chronic hepatitis C 
after SVR to combined 
therapy 
 
Qualitative 
real-time 
nested 
5’NCR PCR 
Total PBMCs 0 (0) 5 (20) 
(Inokuchi et 
al., 2009) 
75 HCV antibody positive 
and HCV RNA positive 
 
 
“+” strand – 
Quantitative 
real-time 
single round  
5’NCR PCR; 
“-” strand – 
NS5b single 
round PCR 
1 – B cells;  
2 –  T cells CD8;  
3 – T cells CD4;  
4 – remaining PBMCs 
 
75 (100) “+” strand – 1 – 47 
(63); 2 – 12 (16); 3 – 
11 (15); 4 – 17 (23); “-” 
strand – 1 – 4 (5.3) 
 
(Vera-Otarola 
et al., 2009) 
45 Chronic hepatitis C 
(HCV antibody positive 
and HCV RNA positive 
for more than 6 
months) 
 
Qualitative 
single round 
5’NCR PCR; 
added tag 
sequence for 
“-” strand 
detection 
Lymphocytes 
 
45 (100) “+” strand – 33 (73); 
 “-” strand – 0/33 (0) 
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4.2. Aims 
 
The aim of the present chapter is to determine the prevalence and viral load 
of HCV in peripheral blood mononuclear cells (PMBCs) of patients with HCV 
disease attending clinics in Recife in Northeast Brazil. In addition, the 
influence of HCV in plasma upon the PMBC presence of this virus was 
examined. 
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4.3. Patients and samples 
 
4.3.1. Study population 
  
Samples were collected from two different locations: a general public hospital 
and a private dialysis clinic in Recife, Northeast Brazil (details in Section 2.1). 
All participants were of Brazilian nationality. Clinical data on all patients were 
obtained from standard medical records and documented onto standardized 
forms, which were linked to patient samples by numerical code. These forms 
were used during anamnesis undertaken before clinical examination. Oral 
findings and route of HCV acquisition can be found in Table 3.1. 
  
4.3.2. Sample collection 
 
Matched oral and blood samples were obtained from all patients as 
described in Sections 2.2.1 and 2.2.2.  
 
4.3.3. Sample processing  
 
After separation of plasma from the blood, the CD19+, CD14+, CD2+ and 
CD45+ cell subsets were immunomagnetically fractionated as described in 
Sections 2.2.3. WMS was not subjected to centrifugation and it was stored at 
-80°C until required. RNA was extracted from blood cell subsets and oral 
samples as described in Section 2.3.2. The presence of DNA in randomly 
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selected extracts was verified by using the Microzone DNA OK kit as 
described in Section 2.3.3. 
 
4.3.4. Molecular detection of HCV 
 
4.3.4.1. RNA extraction 
 
RNA extraction was performed both manually (Section 2.3.2.1) for all 
samples, but CD45 from patients 1 to 4 due to lack of blood for cell 
separation and automatically for whole saliva and plasma samples (Section 
2.3.2.2). 
 
4.3.4.2. Polymerase Chain Reaction (PCR) 
 
Reverse transcription was carried out to generate cDNA for all samples 
(Section 2.3.4) followed by PCR of the 5’-noncoding region for plasma 
samples only (Section 2.3.5) and NS5b region for all samples (Section 2.3.6) 
with the exception of patients 1, 2, 3 and 4 for CD45 (not available). 
 
4.3.4.3. RFLP and direct sequencing 
 
RFLP was performed for all plasma samples (Sections 2.3.8 and 2.3.9) and 
direct sequencing was performed for all samples (Section 2.3.12). 
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4.3.4.4. Quantitative real time PCR 
 
Quantitative Hepatitis C virus (HCV) assay was used for all the whole saliva, 
plasma, CD19, CD14, CD2 and CD45 samples (with the exception of patients 
1, 2, 3 and 4 for CD45) in order to obtain HCV viral load of the respective 
sites (Section 2.3.13). 
 
4.4. Results 
 
4.4.1. HCV RNA in CD19 leukocytes 
 
4.4.1.1. Prevalence of HCV RNA in CD19 leukocytes 
 
All patients were tested for HCV RNA detection in CD19 cells. The 
prevalence of HCV RNA in CD19 leukocytes is summarized in Table 4.2. 
HCV RNA was detected in 81.2% of the CD 19 cells of the total group, and 
was present in 86.6% of the untreated group and 61% of the treated group. 
Fisher’s exact test revealed that the prevalence of HCV RNA in CD19 cells 
was significantly greater in the untreated group compared with the treated 
group (P=0.036).   
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Table 4.2. Prevalence of HCV RNA in CD19 leukocytes 
 
  
CD19 
 
Group  No HCV RNA 
detected 
HCV RNA 
detected Total 
Untreated Number 9 58 67 
% 13.4% 86.6% 100.0% 
Treated Number 7 11 18 
% 38.9% 61.1% 100.0% 
Total Number 16 69 85 
% 18.8% 81.2% 100.0% 
 
4.4.2. Total HCV load and load per 1000 cells in CD 19 cells  
 
All patients were tested for HCV RNA viral load per 1000 cells in CD 19 
leukocytes. The total HCV load and load per 1000 cells in CD19 leukocytes 
in the total patient group and the untreated and treated groups are 
summarized in Table 4.3. The HCV load in the total group ranged from 0 to 
17770000/IU/ml while the load per 1000 cells ranged form 0 to 15807.1.  
 
The Mann Witney U test revealed that there no statistically significant 
difference in the total HCV load (P=0.186) or HCV load per 1000 CD 19 cells 
(P=0.278 between the treated and untreated patients). 
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Table 4.3. Total HCV load in CD19 cells and load per 1000 HCV cells  
 
 Group CD19_Load CD19_1000 
Untreated Mean 26182.87 19048.158 
N 67 67 
Std. Deviation 71224.949 118319.5830 
Minimum 0 .0 
Maximum 412000 967528.0 
Median 2573.00 458.400 
Treated Mean 114027.22 3743.267 
N 18 18 
Std. Deviation 416850.595 7107.6069 
Minimum 0 .0 
Maximum 1770000 23766.5 
Median 977.00 101.800 
Total Mean 44785.20 15807.122 
N 85 85 
Std. Deviation 201136.593 105116.1954 
Minimum 0 .0 
Maximum 1770000 967528.0 
Median 2370.00 432.300 
 
 
4.4.3. HCV RNA in CD14 leukocytes 
 
4.4.3.1. Prevalence of HCV RNA in CD14 leukocytes 
 
All patients were tested for HCV RNA detection in CD 14 leukocytes. The 
prevalence of HCV RNA in CD14 leukocytes is summarized in Table 4.4. 
HCV RNA was detected in 76.5% of the CD 14 cells of the total group, and 
was present in 82.1% of the untreated group and 55.6% of the treated group. 
Fisher’s exact test revealed that the prevalence of HCV RNA in CD14 cells 
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was significantly greater in the untreated group compared with the treated 
group (P=0.028).   
 
Table 4.4. Prevalence of HCV RNA in CD14 leukocytes 
 
 
  
CD14 
 
Group  No HCV RNA 
detected 
HCV RNA 
detected Total 
Untreated Number 12 55 67 
% 17.9% 82.1% 100.0% 
Treated Number 8 10 18 
% 44.4% 55.6% 100.0% 
Total Number 20 65 85 
% 23.5% 76.5% 100.0% 
 
4.4.4. Total HCV load and load per 1000 cells in CD 14 cells  
 
All patients were tested for HCV RNA viral load and viral load per 1000 cells 
in CD 14 leukocytes. The total HCV load and load per 1000 cells in CD14 
leukocytes in the total patient group and the untreated and treated groups are 
summarized in Table 4.5. The HCV load in the total group ranged from 0 to 
523000 while the load per 1000 cells ranged form 0 to 46283.2.  The Mann 
Witney U test revealed that there was no statistically significant difference in 
the total HCV load (P=0.098) or HCV load per 1000 CD 14 cells (P=0.255) 
between the treated and untreated patients. 
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Table 4.5. Total HCV load and load per 1000 cells in CD 14 cells  
 
Group CD14_Load CD14_1000 
Untreated Mean 11398.49 1049.918 
N 67 67 
Std. Deviation 64616.829 5763.6263 
Minimum 0 .0 
Maximum 523000 46283.2 
Median 594.00 27.000 
Treated Mean 15203.22 1630.961 
N 18 18 
Std. Deviation 51008.829 5322.5500 
Minimum 0 .0 
Maximum 215000 22751.3 
Median 1.00 .650 
Total Mean 12204.20 1172.962 
N 85 85 
Std. Deviation 61722.283 5647.2411 
Minimum 0 .0 
Maximum 523000 46283.2 
Median 456.00 21.100 
 
4.4.5. HCV RNA in CD2 leukocytes 
 
4.4.5.1. Prevalence of HCV RNA in CD2 leukocytes 
 
All patients were tested for HCV RNA detection in CD2 leukocytes. The 
prevalence of HCV RNA in CD2 leukocytes is summarized in Table 4.6. HCV 
RNA was detected in 77.6% of the CD2 cells of the total group, and was 
present in 82.1% of the untreated group and 61.1% of the treated group. 
Fisher’s exact test revealed that there was no statistically significant 
difference in the prevalence of HCV RNA between the CD2 cells of the two 
groups (P = 0.107).  
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Table 4.6. Prevalence of HCV RNA in CD2 leukocytes 
 
Group  No HCV RNA 
detected 
HCV RNA 
detected Total 
Untreated Number 12 55 67 
% 17.9% 82.1% 100.0% 
Treated Number 7 11 18 
% 38.9% 61.1% 100.0% 
Total Number 19 66 85 
% 22.4% 77.6% 100.0% 
 
4.4.5.2. Total HCV load and load per 1000 cells in CD 2 cells  
 
All patients were tested for HCV RNA viral load and viral load per 1000 cells 
in CD2 cells. The total HCV load and load per 1000 cells in CD2 leukocytes 
in the total patient group and the untreated and treated groups are 
summarized in Table 4.7. The HCV load in the total group ranged from 0 to 
452000 while the load per 1000 cells ranged form 0 to 5415.6049. The Mann 
Witney U test revealed that there was no statistically significant difference in 
the total HCV load (P=0.245) or HCV load per 1000 CD 2 cells (P=0.258) 
between the treated and untreated patients. 
 
 
 
 
 
 
 
 
 
 194 
Table 4.7. Total HCV load and load per 1000 cells in CD2 cells  
 
 Group  CD2_Load CD2_1000 
Untreated Mean 11097.49 636.781 
N 67 67 
Std. Deviation 58375.167 2344.4382 
Minimum 0 .0 
Maximum 452000 14675.3 
Median 127.00 2.800 
Treated Mean 10182.22 2631.329 
N 18 18 
Std. Deviation 31447.175 10966.2891 
Minimum 0 .0 
Maximum 129000 46570.4 
Median 4.00 .350 
Total Mean 10903.67 1059.156 
N 85 85 
Std. Deviation 53644.462 5415.6049 
Minimum 0 .0 
Maximum 452000 46570.4 
Median 100.00 2.800 
 
4.4.6. HCV RNA in CD45 leukocytes 
 
4.4.6.1. Prevalence of HCV RNA in CD45 leukocytes 
 
All patients, with the exceptions of patients 1, 2, 3 and 4, were tested for 
prevalence of HCV RNA in CD 45 leukocytes. The prevalence of HCV RNA 
in CD45 leukocytes is summarized in Table 4.8. HCV RNA was detected in 
76.5% of the CD45 cells of the total group, and was present in 81.5% of the 
untreated group and 56.3% of the treated group. Fisher’s exact test revealed 
that the prevalence of HCV RNA in CD45 cells was just significantly greater 
in the untreated group compared with the treated group (P=0.048).   
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Table 4.8. Prevalence of HCV RNA in CD45 leukocytes 
 
Group  No virus 
detected Virus detected Total 
Untreated Number 12 53 65 
% 18.5% 81.5% 100.0% 
Treated Number 7 9 16 
% 43.8% 56.3% 100.0% 
Total Number 19 62 81 
% 23.5% 76.5% 100.0% 
 
4.4.6.2. Total HCV load and load per 1000 cells in CD45 cells  
 
All patients, with the exceptions of patients 1, 2, 3 and 4, were tested for HCV 
RNA viral load and viral load per 1000 cells in CD 45 leukocytes. The total 
HCV load and load per 1000 cells in CD45 leukocytes in the total patient 
group and the untreated and treated groups are summarized in Table 4.9. 
The HCV load in the total group ranged from 0 to 747000 while the load per 
1000 cells ranged form 0 to 41270.7. Spearman’s test revealed that there 
was no statistically significant difference in the total HCV load (P=0.559) or 
HCV load per 1000 CD 2 cells (P=0.719) between the treated and untreated 
patients. 
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Table 4.9. Total HCV load and load per 1000 cells in CD45 cells  
 
 Group  CD45_Load CD45_1000 
Untreated Mean 20638.03 593.179 
N 65 65 
Std. Deviation 94946.913 2648.2927 
Minimum 0 .0 
Maximum 719000 19861.9 
Median 372.00 7.000 
Treated Mean 54390.75 2674.800 
N 16 16 
Std. Deviation 186288.636 10295.2111 
Minimum 0 .0 
Maximum 747000 41270.7 
Median 334.00 7.050 
Total Mean 27305.23 1004.364 
N 81 81 
Std. Deviation 117905.356 5116.5993 
Minimum 0 .0 
Maximum 747000 41270.7 
Median 372.00 7.000 
 
4.4.7. Correlations of plasma load versus total HCV load in the 4 
different leukocytes – total patient group 
 
Correlations between the log plasma load and log total HCV load of the 4 
examined leukocytes in the total group and the untreated and treated groups 
are summarized in Tables 4.10, 4.11 and 4.12. There were strong 
correlations between plasma load and the load within each cell type, these all 
being significant at the 0.01 level (as determined by Spearman’s test). In 
addition it was evident that there were similarly strong correlations between 
the HCV loads of each of the examined cell types.  
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Table 4.10. Correlations of plasma load versus total HCV load in the 4 
different leukocytes – total patient group 
 
  
Log plasma load Log CD19 load Log CD14 load Log CD2 load Log CD45 load 
Log plasma load Correlation 
Coefficient 
1.000 .595** .534** .523** .554** 
Sig. (2-
tailed) 
. .000 .000 .000 .000 
N 71 71 71 71 68 
Log CD19 load Correlation 
Coefficient 
.595** 1.000 .631** .553** .663** 
Sig. (2-
tailed) 
.000 . .000 .000 .000 
N 71 71 71 71 68 
Log CD14 load Correlation 
Coefficient 
.534** .631** 1.000 .683** .600** 
Sig. (2-
tailed) 
.000 .000 . .000 .000 
N 71 71 71 71 68 
Log CD2 load Correlation 
Coefficient 
.523** .553** .683** 1.000 .644** 
Sig. (2-
tailed) 
.000 .000 .000 . .000 
N 71 71 71 71 68 
Log CD45 load Correlation 
Coefficient 
.554** .663** .600** .644** 1.000 
Sig. (2-
tailed) 
.000 .000 .000 .000 . 
N 68 68 68 68 68 
 
**. Correlation is significant at the 0.01 level (2-tailed) 
 *. Correlation is significant at the 0.05 level (2-tailed) 
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Table 4.11. Correlations of plasma HCV load versus total HCV load in 
the 4 different leukocytes – untreated patient group 
 
  
log_plasma_load log_CD19_load log_CD14_load log_CD2_load log_CD45_load 
log_plasma_load Correlation 
Coefficient 
1.000 .542** .429** .475** .505** 
Sig. (2-tailed) . .000 .001 .000 .000 
N 59 59 59 59 57 
log_CD19_load Correlation 
Coefficient 
.542** 1.000 .611** .507** .624** 
Sig. (2-tailed) .000 . .000 .000 .000 
N 59 59 59 59 57 
log_CD14_load Correlation 
Coefficient 
.429** .611** 1.000 .662** .559** 
Sig. (2-tailed) .001 .000 . .000 .000 
N 59 59 59 59 57 
log_CD2_load Correlation 
Coefficient 
.475** .507** .662** 1.000 .614** 
Sig. (2-tailed) .000 .000 .000 . .000 
N 59 59 59 59 57 
log_CD45_load Correlation 
Coefficient 
.505** .624** .559** .614** 1.000 
Sig. (2-tailed) .000 .000 .000 .000 . 
N 57 57 57 57 57 
 
**. Correlation is significant at the 0.01 level (2-tailed) 
 *. Correlation is significant at the 0.05 level (2-tailed) 
 
 
 
 
 
 199 
Table 4.12. Correlations of plasma HCV load versus total HCV load in 
the 4 different leukocytes – treated patient group 
 
  
Log plasma load Log CD19 load Log CD14 load Log CD2 load Log CD45 load 
Log plasma 
load 
Correlation 
Coefficient 
1.000 .755** .852** .701* .633* 
Sig. (2-tailed) . .005 .000 .011 .036 
N 12 12 12 12 11 
Log CD19 load Correlation 
Coefficient 
.755** 1.000 .669* .746** .770** 
Sig. (2-tailed) .005 . .017 .005 .006 
N 12 12 12 12 11 
Log CD14 load Correlation 
Coefficient 
.852** .669* 1.000 .727** .715* 
Sig. (2-tailed) .000 .017 . .007 .013 
N 12 12 12 12 11 
Log CD2 load Correlation 
Coefficient 
.701* .746** .727** 1.000 .779** 
Sig. (2-tailed) .011 .005 .007 . .005 
N 12 12 12 12 11 
Log CD45 load Correlation 
Coefficient 
.633* .770** .715* .779** 1.000 
Sig. (2-tailed) .036 .006 .013 .005 . 
N 11 11 11 11 11 
 
**. Correlation is significant at the 0.01 level (2-tailed) 
 *. Correlation is significant at the 0.05 level (2-tailed) 
 
4.7.8. Correlations of the prevalence of HCV RNA in saliva and 4 
different leukocytes 
 
Spearman’s non-parametric test established that there were significant 
associations between the prevalence of HCV RNA in saliva and all the 4 
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studied cell compartments CD19, CD14, CD2 and CD45 (Table 4.13). In only 
3 instances was HCV not in saliva yet present in the circulating CD 14 (one 
instance) or CD 2 (two instances) cells.  
 
Table 4.13. Relative risk for detectable HCV RNA in saliva according to 
cell type 
 
Cell type Cell virus status 
Virus not 
detected in 
saliva 
Virus 
detected in 
saliva 
RR (95%CI) 
CD19 No virus detected 16 0  
 Virus detected 42 27 1.643 (1.360, 1.985) 
CD14 No virus detected 19 1  
 Virus detected 39 26 12.667 (1.596, 100.502) 
CD2 No virus detected 17 2  
 Virus detected 41 25 5.183 (1.103, 24.353) 
CD45 No virus detected 19 0  
 Virus detected 35 27 1.771 (1.424, 2.204) 
 
4.7.9. Correlations of salivary HCV load versus total HCV load in the 4 
different leukocytes 
 
No significant correlations between salivary HCV load and the 4 examined 
leukocytes in the total group and the untreated and treated groups were 
found when using Spearman’s test. There were strong correlations between 
plasma load and the load within each cell type, these all being significant at 
the 0.01 level (as determined by Spearman’s test). In addition it was evident 
that there were similarly strong correlations between the HCV loads of each 
of the examined cell types.  
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4.5. Discussion 
 
The present investigation is the first to examine potential 
compartmentalisation of HCV between blood and salivary compartments by 
determining the load as well as the prevalence of HCV RNA within oral and 
blood compartments. An understanding of this is essential to determine 
factors that may influence potential oral carriage of the virus. In addition by 
estimation of HCV load within cells it is possible to clearly determine the cells 
that truly harbour HCV and thus are potential sites of HCV replication and 
reservoirs capable of leading to nosocomial transmission and/or rekindling 
systemic infection (Radkowski et al., 2005, Pham et al., 2005).  
 
In the present study HCV RNA was present in up to 85% of examined 
PBMCs. Although previous studies of HCV RNA within PBMC examined a 
range of different patient groups, patients with treated and untreated HCV 
disease or had had variable responses to therapy or different manifestations 
of disease, the present high frequency of HCV in PBMC is in general 
agreement with the results studies that examined patients with chronic HCV 
disease. The present investigation utilised real time PCR as opposed to most 
studies that have not even quantified HCV RNA. Some have used branched 
DNA assays for HCV quantification – which is an old technique that is not as 
reliable as the assay presently employed – or only the automated Amplicor 
without quantification, as used in many studies (Azzari et al., 2008, 
Cavalheiro et al., 2007, De Maddalena et al., 1995, Gameiro et al., 2001, 
Meier et al., 2001, Roque-Afonso et al., 2005, Takyar et al., 2000).  
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Previous studies have found HCV RNA within macrophage/monocytes, 
CD2+, CD3+, CD4+, CD8+, CD14+, CD19+ and CD45+ cells (Bouffard et al., 
1992, Ducoulombier et al., 2004, Gabrielli et al., 1994, Muller et al., 1993, 
Zehender et al., 1997). However HCV RNA has been more frequently 
detected in CD19+ B lymphocytes and CD14+ monocytes than T 
lymphocytes such as CD4+ and CD8+ (Ducoulombier et al., 2004). In the 
present study HCV RNA was detected in similar frequencies and had similar 
loads in cells of monocyte/macrophage lineage (CD14+), B lymphocytes 
(CD19+) as well as CD2+ T lymphocytes and CD45+ pan leukocytes. 
Additionally as there was no difference in the frequency or load of HCV within 
the PBMCs between patients with or without treatment for HCV disease 
(Tables 4.3 and 4.4) the present observations for the cellular distribution of 
HCV RNA are consistent. In agreement with previous studies the presence of 
HCV RNA within PBMC was not influenced by the route of acquisition or 
genotype of HCV (data not shown).  
 
In the present study HCV RNA was more frequent in plasma than in PBMC 
(Table 4.2), an observation reported by many others (Table 4.1). This could 
suggest that PBMC acquire HCV from plasma or that the PBMC are a site of 
replication of HCV. The notion that PBMC may be a potential reservoir of 
infection (and hence source of plasma HCV) is supported by knowledge that 
primary lymphoid cells are susceptible to ex-vivo infection and the virus 
derived from these ex-vivo cultures are infectious (Bare et al., 2005, Kato et 
al., 1995, Bronowicki et al., 1998, Cribier et al., 1995, Macparland et al., 
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2006, Sung et al., 2003). In support of the contrasting argument that PBMC 
secondarily acquire HCV from plasma, monocytes may acquire HCV via 
phagocytosis or infection of antibody-bound HCV particles (Bouffard et al., 
1992) while HCV enter CD19+ B lymphocytes via HCV E2 envelope protein 
binding to  CD81, a tetraspanning receptor on B lymphocytes (Pileri et al.  
1998).   
 
Regardless of the mechanism that underlies any interplay of HCV between 
plasma and PBMC there remains the concern as to whether HCV RNA within 
any extrahepatic compartment (e.g. blood or oral fluids) is infectious and 
capable of replication. Extra-hepatic replication of infectious virus remains 
controversial. HCV replicates by the synthesis of a complimentary negative 
RNA strand that serves as a template for the positive strand, hence the 
presence of a negative strand could be considered to be the most reliable 
marker of ongoing viral replication. This is supported by a rise in levels of the 
negative strand of HCV within PBMC following mitogenic stimulation (Muller 
et al., 1993). The rate of detection of the negative strand in PBMC has 
ranged from 0 to 61%, in comparison with the liver where the rate may be of 
the order of over 75% (Castillo et al., 2005, Laskus et al., 1997, Lerat et al., 
1996, Lerat et al., 1998, Mazur et al., 2001, Wang et al., 1992a) and is thus 
less than that of the positive RNA strand. The present study did not examine 
the presence of the negative strand hence it is not possible to truly determine 
if HCV RNA in blood or saliva is a potential source of sustained HCV 
infection. However the presence of HCV RNA (not the negative strand) within 
PBMC may be associated with accelerated progress of hepatic cirrhosis 
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(Barria et al., 2008), and patients with HCV RNA within PBMC have greater 
hepatic dysfunction than those without HCV RNA in PBMC (Bernardin et al., 
2008), thus HCV RNA within PBMC is at least a marker of probable 
sustained HCV replication and disease.  
 
As noted in the previous chapter although HCV RNA was infrequently 
detected in saliva, there was however a wide range in the HCV load, thus 
allowing analysis of the possible impact of HCV compartmentalisation within 
blood upon oral carriage. As noted in Table 4.5 there was strong correlation 
between HCV RNA and each of the 4 cellular compartments (or plasma), the 
same happening when the rank correlation was done using HCV RNA per 
1000 cells (table 4.6) and HCV RNA in whole saliva (see chapter 3, table 
3.2).  
 
The strong correlation between salivary HCV RNA and that of plasma and 
cellular HCV RNA point towards likely routes by which HCV passes into 
saliva. HCV may passively migrate from plasma via gingival crevicular fluid 
(GCF) into saliva as GCF represents a transudate of serum (Lamster et al., 
2007). Additionally it has previously been found that HCV load is higher in 
GCF than whole saliva and that there is a (non-significant) trend for salivary 
HCV levels to reflect those of serum (Suzuki et al., 2005). Of perhaps greater 
significance is the present finding that there was a significant correlation 
between the presence of HCV in PBMC and whole saliva thus raising the 
possibility that HCV is carried into the mouth via PBMC. It is known that 
PBMC, particularly neutrophils and monocytes, traffic into GCF (Lamster et 
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al., 2007) hence it might be expected that HCV within such cells will 
eventually pass into whole saliva. Although some groups have not found any 
association between gingival health and the presence of HCV in saliva (Lins 
et al., 2005), others have found that the likelihood of HCV RNA being present 
in saliva correlates with the presence of GCF HCV (Maticic et al.  2001) and 
that levels of HCV RNA in GCF are higher than those of saliva – pointing 
towards a dilution effect (Suzuki et al., 2005). The striking observation of the 
present study is the very high correlation between HCV in saliva and CD14+ 
cells. These are circulating monocytes capable of differentiation into dendritic 
cells and macrophages within tissues (Geissmann et al., 2010), where they 
could be fagocyting HCV particles. Although there are no studies of their 
precise presence within the GCF in health, they constitute up to 2% of the 
cellular component of GCF (Suzuki et al., 1997) and it would be expected 
that monocytes will easily migrate from blood into GCF (Attstrom et al., 
1970). In addition HIV RNA in GCF has been found within CD14+ 
macrophages (Suzuki et al., 1997) suggesting that they are a haematological 
source of at least HIV, although loss of CD14 occurs rapidly during migration 
through the vascular endothelium or within the gingival tissues.  
 
The relatively low correlation between CD19+ PBMC and salivary HCV could 
be intriguing as the levels of B lymphocytes in GCF are considered to be 
slightly greater than that of monocytes. This can be understood by the low 
sampling number used at the referred statistical analysis. Even if levels of 
correlation differ widely between both compartments and there is presence or 
absence of saliva, the correlation of B lymphocytes and saliva have a very 
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narrow confidence interval, whereas the correlation between macrophages 
and monocytes has a very wide confidence interval. 
 
CD19 is associated with CD81, a putative receptor for HCV, which is 
considered to be a possible strategy to help HCV achieve persistent infection 
(Roque Afonso et al.  1999). Neverthless consistent HCV replication in B 
cells could not be achieved in vitro, even if the highest viral load found in 
PBMCs was found in these respective cells (Boisvert et al., 2001). Another 
study also reported B cells to present higher viral load than other PBMCs 
(Inokuchi et al., 2009). 
 
Azzari et al. have shown evidence that the HCV infection of PBMCs (Azzari 
et al., 2000, Azzari et al., 2008) and HCV replication within PBMCs (Azzari et 
al., 2000) were highly associated with HCV transmission to newborns. Viral 
load at delivery was shown to be a risk factor of vertical transmission of HCV 
to newborns (Ohto et al., 1994) and had relatively higher titers of HCV when 
babies were infected in another study (Moriya et al., 1995). Notwithstanding, 
there was no statistically significant difference in the viral load of HCV either 
in plasma of mothers who gave birth to infected children as opposed to 
mothers whose babies were not HCV infected after birth. Viral load was also 
similar in mothers whose PBMCs harboured the virus and mothers whose 
PBMCs were negative for HCV (Azzari et al., 2008).  
 
In addition, the finding of retention of HCV RNA despite clearance in blood of 
chronic infected patients in PBMCs (Cavalheiro et al., 2007) and/or liver (Gil 
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et al., 1993) and PBMC in HCV infected patients in the hemodialysis setting 
(Thongsawat et al., 2008) may suggest that mononuclear cell investigation 
for HCV RNA could be added to confirm sustained virological response. On 
the other hand, clearance of HCV from PBMCs when HCV RNA levels 
started to become low in plasma has been demonstrated (Meier et al., 2001).  
 
Of notice, patient 53 mixed infection of genotype 3a detected in plasma, 
CD19, CD14, CD45 cells, and genotype 4o in CD2 cells was highly unusual. 
Contamination is unlikely to account for, as apart from all preventive 
measures to avoid it (see chapter 2), this genotype is not seen usually at the 
VRD reference lab of the Health Protection Agency - UK. Another unusual 
case was detected in patient 63, where genotype 4d was detected only in 
CD14 cells of a patient that was under interferon plus ribavirin treatment for 
around 5 month at the time of examination. All the other PBMCs analysed 
were negative, so were saliva and plasma of this patient. Given that this later 
patient was under treatment, what could give an idea of a possible EVR, it is 
possible to infer that there was compartmentalization of the virus in 
macrophages of patient 63. It was confirmed only few years ago that HCV 
RNA can not only be detected in PBMCs of occult and chronic HCV infected 
patients, but so was its negative strand in both recipients, suggesting that 
these are site of HCV replication even in occult patients (Pham et al., 2008). 
Both patients had unknown route of acquisition and low biochemical markers 
(AST, ALT, ALP and GGT). 
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There was one HIV-co-infected patient (28) in the present study that apart 
from having a high viral load in plasma (around 5 millions IU/mL) and 
moderate viral load in all PBMCs (below 100000 IU/mL) had HCV RNA levels 
in saliva below the level of quantification (<100 IU/mL). This patient was an 
injecting drug user (IDU) and has stopped injecting 6 months before 
examination. A further patient was known to be HIV seropositive (although 
HIV viraemia had not been assessed) (7). His HCV load in plasma was 
around 1000000 IU/mL and the load in PBMCs was around the same range 
as the previous patient, although it was negative for CD2 cells. HCV was 
genotyped in this latter patient’s saliva, even though the viral load could not 
be quantified, the opposite of the earlier patient.  
 
An eminent role of PBMCs in pathophysiology and viral persistence of HCV 
is highly likely if we take into account that higher HCV titres in CD19, CD14, 
CD2 and CD45 were observed in treated as opposed to untreated patients. 
Other findings such as HCV RNA detection in PBMCs in patients with SVR 
(Radkowski et al., 2005), detection of HCV negative strand RNA in PBMCs 
(Kao et al.  1997; Mazur et al.  2001; Bouffard et al.  1992) and even a higher 
HCV titre detection after PBMC stimulation (Pham et al., 2005) reinforce that 
possibility. 
 
The present results indicate that the presence of HCV in saliva is influenced 
(or at least correlated with) the presence of HCV in plasma and PBMC. 
Despite the high frequency and load of HCV in blood compartments, HCV is 
rarely observed in high loads within whole saliva. Hence, it would suggest 
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that parenteral transmission of HCV is way more likely than transmission via 
oral fluid such as whole saliva. 
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Chapter 5 
 
 
Genotypic distribution of HCV between oral and blood compartments 
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5.1. Introduction 
 
As discussed in Chapter 1, there are six main HCV genotypes and molecular 
epidemiological studies indicate that there are marked geographic 
differences in the genotypic distribution across the globe. Genotypes 1, 2, 
and 3 are widely distributed throughout the USA, Europe, Australia and East 
Asia, while genotype 4 tends to be confined to the Middle East, Egypt and 
central Africa (Antaki et al, 2009; Kamal and Nasser, 2008). Genotype 5 is 
predominantly found in South Africa while genotype 6 in South East Asia 
(Lee et al, 2008; Antaki et al, 2009). 
 
Studies of the genotype of HCV can provide insight into the spread of HCV 
within and between communities and countries (Magiorkinis et al, 2009) but 
additionally may have a clinical relevance. The genotype of HCV does not 
seem to greatly influence the clinical presentation of disease, although 
individuals with genotype 1b may be at greater risk factor hepatocellular 
carcinoma (HCC) (Lee et al, 2008) as may genotype 4 (Abdel Hamid et al, 
2007) – which may also increase the risk of recurrence following liver 
transplantation (Zylberberg, Chaix and Brechot, 2000). With regards to oral 
disease there are few studies that have examined the impact of HCV 
genotype. Present evidence indicates that no specific HCV genotype 
correlates with the presence of possible HCV-associated oral lichen planus 
(Imhof et al, 1997; Lodi et al, 1997). 
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Certainly the genotype influences response to therapy. A sustained 
virological response (SVR) can be achieved in 81 to 84% of patients infected 
with genotypes 2 or 3 after 24 weeks of interferon alpha and ribavirin, 
however only 34 to 52% of those infected with genotype 1 will achieve SVR 
after 48 weeks of therapy. Hence genotype is the major contributing factor in 
treatment length and therapeutic response (Farnick et al, 2009; Webster et 
al, 2009).  
 
HCV genotyping has been widely reported in studies involving individuals 
from South American countries. Most studies have been conducted in Brazil 
and Argentina although there has been a small number from Chile, 
Colombia, Peru and Venezuela (Table 5.1). To date, only about a third of the 
South American countries have published data on HCV genotype 
prevalence. Most of the studies undertaken in South American countries 
have used restriction fragment length polymorphism (RFLP) as the 
genotyping method (Table 5.1). This is a cheap and effective method for 
genotyping HCV but does not allow high resolution subtyping that HCV 
sequencing can and is discussed in more detail later in this chapter.  
 
Genotype 1 is generally the most prevalent in South American countries 
(Table 5.1). There are some exceptions but these studies may not be 
representative of the population due to the cohorts of individuals being 
studied (Re et al., 2003, Oubina et al., 1995). Genotypes 4 and 5 are rarely 
detected in South American patients. Genotype 4 was seen in a number of 
studies but only in a few patients when detected in Argentina (Re et al., 2007, 
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Oubina et al., 1995), Brazil (Perone et al., 2008, Oliveira et al., 1999b, 
Mendes-Correa et al., 2008, Campiotto et al., 2005, Bassit et al., 1999) and 
Chile (Barria et al., 2008). Only a few cases of genotype 5 were detected in 
Argentina (Re et al., 2003, Re et al., 2008), Brazil (Campiotto et al., 2005, 
Levi et al., 2002) and Chile (Barria et al., 2008), with the exception of one 
Argentinean study that detected 10 cases (over 30%) of genotype 5 HCV in 
their study group (Oubina et al., 1995). Genotype 6 has not been detected in 
any genotyping study from South America (Table 5.1). 
 
5.1.1. Genotype prevalence in Brazil 
 
Genotype 1 is most prevalent in all Brazilian studies (Table 5.1). The first 
publication to enroll Brazilian patients for HCV genotyping was performed by 
researchers from Innogenetics in Belgium and used sera of 61 patients from 
Brazil (Stuyver et al., 1993). Three years later, the first HCV genotyping study 
was carried out on Brazilian samples in Porto Alegre, Southern Brazil (Krug 
et al., 1996).  
 
5.1.2. Genotype distribution in Venezuela 
 
Genotype 1b used to be the most prevalent in Venezuela (Pujol et al., 1997), 
but it was replaced by genotype 2 over a 10-year period. There was no 
increase in frequency of genotype 3 and an insignificant increase in genotype 
1a (Pujol et al., 2007). Anti-HCV testing in blood banks since 1994 in 
Venezuela is thought to have contributed to this reduction in frequency of 
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HCV genotype 1b infection. As the prevalence of each genotype was not 
detailed in this study (Pujol et al., 2007) it is not listed in Table 5.1. One year 
after the first study in Venezuela, the same group have published a 
theoretical genotype turnover in 6 patients under hemodialysis (Pujol et al., 
1998). This could mean reinfection with a different genotype, especially in a 
hemodialysis setting.  
 
5.1.3. Genotype Distribution in Peru 
 
There is only one study reporting genotypes associated with HCV infection in 
Peru, which was based in the capital city of Lima. Residents of the 
metropolitan area were enrolled if they were blood donors, patients 
undergoing hemodialysis, had haemophilia, had been admitted with acute or 
chronic hepatitis or were individuals undergoing drug abuse rehabilitation. 
From 2827 samples tested, 384 were anti-HCV positive in the referred risk 
groups tested (13.6 %). After randomly choosing 50 patients for genotyping 
from these 384, Genotype 1a was more prevalent, followed by genotypes 1b, 
3 and 2a (Sanchez et al. 2000). 
 
 
. 
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           Table 5.1. Table summarising papers written on HCV genotyping in South American countries 
Country of 
population 
studied (first 
author and 
year)  
 
 
 
Number of 
patients 
 
 
 
Clinical data 
 
 
 
Methods 
 
 
Genotypes in 
Plasma – N (%) 
 
 
 
Genotypes in 
Saliva - N (%) 
 
 
Genotypes in 
PBMC – N (%) 
Brazil 
(Stuyver et 
al., 1993) 
61 23 hemodyalisis 
patients or blood 
donors with NANB 
liver disease, 24 
positive or 
indeterminate for 
line immunoassay, 
14 randomly 
chosen 
 
 
Nested 5’-NCR PCR 
followed by RFLP and 
Reverse hybridization 
line probe assay - Inno-
Lipa (Innogenetics) 
 
1 – 20 (33);  
1b – 23 (38);  
2 – 1 (1.5);  
3 – 15 (24.5);  
1b/3 mix – 2 (3) 
 
N/A N/A 
 216 
Argentina 
(Oubina et al., 
1995) 
31 10 hemophiliac and 
4 polytransfused 
children, 19 adults 
(3 polytransfused, 7 
dialyzed and 9 
sporadic cases) 
 
 
RFLP analysis of nested 
5’-NCR and if positive, 
core-based genotyping 
with PCR using specific 
primers 
1 – 16 (48.4); 
 2 – 21 (63.6);  
4 – 1 (3);  
5 – 10 (30.3) 
N/A N/A 
Brazil (Krug 
et al., 1996) 
100 HCV RNA positive 
patients in 
Southern Brazil 
 
 
RFLP analysis of 5’-
NCR nested PCR 
 
1 – 55 (55);  
2 – 8 (8);  
3 – 37 (37) 
N/A N/A 
  
 217 
Argentina 
(Picchio et 
al., 1997) 
48/59 HCV seropositive 
Hemophiliac 
patients with HIV 
(A=23/29) and 
without HIV 
(B=25/30) 
RFLP analysis of nested 
5’-NCR followed by 
Reverse hybridization 
line probe assay - Inno-
Lipa (Innogenetics) for 
confirmation in 11 
patients 
 
A 
1a – 13 (56.5); 
1b – 5 (21.7);  
1 – 1 (4.3);  
2b – 1 (4.3);  
3a – 1 (4.3);  
3b – 1 (4.3); 
mixed – 1 (4.3);  
B 
1a – 10 (40);  
1b – 9 (36);  
3a – 4 (16);  
4/5 mix – 2 (8) 
 
 
 
N/A N/A 
Venezuela 122 19 blood donors, RFLP analysis of nested 1a – 28 (29);  N/A N/A 
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  (Pujol et al., 
1997) 
43 chronic patients, 
47 hemodialyzed, 
13 hemophiliac 
patients 
5’-NCR 1b – 45 (37);  
2a – 18 (15);  
2b – 7 (5);  
3a – 3 (2.5); 
mixed – 12 (10) 
Venezuela 
(Pujol et al., 
1998) 
14 Hemodialysis 
patients 
RFLP and SSCP 
following nested  5’-
NCR  
1a – 3 (21.4);  
1b – 5 (35.7); 
mixed – 6 (42.9) 
N/A N/A 
Argentina 
(Quarleri et 
al., 1998) 
82 HCV chronically 
infected patients, 
71 adults and 11 
children (mean age 
27.5 years-old, 
range 2 - 71 years) 
RFLP analysis of nested 
5’-NCR followed by 
direct sequencing in 50 
cases  
 
1a – 29 (35.3); 
1b- 29 (35.3);  
2a -16 (19.5);  
2b – 2 (2.4);  
3 – 6 (7.3) 
 
N/A N/A 
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Brazil (Bassit 
et al., 1999) 
348 34 blood donors, 
23 hemophiliacs, 
40 renal-transplant 
and 251 Chronic 
hepatitis C patients 
from São Paulo, 
Brazil 
5’-NCR single round 
PCR followed by 
southern blot  
hybridization 
 
1a – 65 (18.7); 
1b – 109 (31.3); 
1 – 45 (12.9);  
2 – 15 (4.3);  
3 – 109 (31.3); 
4a – 1 (0.3) 
 
N/A N/A 
Brazil 
(Oliveira et 
al., 1999a) 
43 39 chronic hepatitis 
C haemophiliacs 
(A) and 4 patients 
with other 
hematologic 
diseases (B) from 
Minas Gerais State 
– Brazil 
 
RFLP analysis of nested 
5’-NCR 
A  
1 – 33 (82.5);  
3 – 6 (15);  
 
B 
1 – 4 (100) 
N/A N/A 
Brazil 150 Chronic hepatitis C Nested 5’-NCR PCR 1 – 108 (72);  N/A N/A 
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(Oliveira et 
al., 1999b) 
blood donors, 
haemophiliacs, 
cirrhotic patients, 
infectable drug 
users and under 
hemodialysis 
followed by RFLP and 
Reverse hybridization 
line probe assay - Inno-
Lipa (Innogenetics) 
for 60 samples 
 
2 – 3 (2);  
3 – 38 (25.3);  
4 – 1 (0.7) 
Brazil 
(Martins et 
al., 2000) 
90 39 haemophiliacs 
(A) and 33 blood 
donors (B) from 
Goiânia City, Brazil 
Nested 5’-NCR PCR 
followed by Reverse 
hybridization line probe 
assay - Inno-Lipa 
(Innogenetics) 
 
A: 1a – 16 (41);  
1b – 10 (25.6); 
3a – 3 (7.7); 
2/3a mix – 1 
(2.6);  
B: 1a – 18 
(54.6); 1b – 4 
(12.1);  
2b – 1 (3);  
3a – 10 (30.3)  
N/A N/A 
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Brazil (Parana 
et al., 2000) 
232 HCV carriers 
candidates for 
antiviral therapy 
Reverse hybridization 
line probe assay - Inno-
Lipa (Innogenetics) 
 
1a – 75 (32.3); 
1b – 72 (31); 
2a/b – 14 (6);  
3a – 61 (26.3); 
mixed – 5 (2.2); 
ND – 5 (2.2) 
N/A N/A 
Argentina 
(Quarleri et 
al., 2000) 
243 Three groups of 
viremic patients: 
with parenteral risk 
factors for viral 
infection, with 
nonparenteral risk 
and sporadic or 
community-
acquired cases 
 
RFLP analysis of nested 
5’-NCR followed by 
direct sequencing for 
selected cases also for 
NS5b 
  
1 – 130 (53.5);  
2 – 56 (23);  
3 – 21 (8.6); 
mixed – 36 
(14.8) 
 
N/A N/A 
Peru 50 Randomly RFLP analysis of nested 1a – 37 (74);  N/A N/A 
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(Sanchez et 
al., 2000) 
genotyped from 
384 anti-HCV 
positives from 
several different 
risk groups (see 
text) from the 
metropolitan are of 
Lima, Peru 
5’-NCR  1b – 6 (12);  
2a – 1 (2);  
3 – 5 (10); 
unresolved – 1 
(2) 
 
Argentina 
(Oubina et al., 
2001) 
18 Patients with 
histologically 
proven chonic 
hepatitis C and 
porhyiria cutanea 
tarda 
RFLP analysis of nested 
5’-NCR 
1a – 2 (11.1)  
1b – 9 (50); 
2a/c– 1 (5.5);  
3a – 1 (5.5); 
1a/1b mix – 4 
(22.2); 2b/c/3a 
mix – 1 (5.5) 
 
N/A N/A 
Venezuela 16 HCV Urban, rural and RFLP analysis of nested 1a – 6 (37.5); 1 N/A N/A 
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(Aguilar et al., 
2001) 
RNA + / 
2592 
Amerindian 
populations from 
Venezuela 
5’-NCR b – 4 (25);  
2b – 3 (18.8); 
1a/1b mix– 1 
(6.3);  
1b/2a mix – 1 
(6.3) 
Brazil (Levi et 
al., 2002) 
3 HCV carriers Single round 5’-NCR 
PCR followed by direct 
sequencing 
5 – 3 (100) N/A N/A 
Colombia 
(Yepes et al., 
2002) 
40 Anti-HCV positive 
patients from 
Medellín 
 
 
 
 
RFLP analysis of nested 
5’-NCR 
1a, followed by 
1b, then 2  
N/A N/A 
Argentina (Re 96 Anti-HCV positive RFLP of the 5´NCR, and 1 – 23 (38.3);  N/A N/A 
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 et al., 2003) patients (60 
patients were HCV 
RNA positive) 
 
a nested PCR with type 
specific primers 
following RT-PCR - core 
region 
2 – 33 (55); 
3 – 3 (5); 
unresolved – 1 
(1.7) 
Chile (Soza et 
al., 2004) 
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HCV seropositive 
patients from Chile 
RFLP – HCV region not 
shown 
1a – 1/17 (6);  
1b – 14/17 (82); 
3a – 2 (12) 
N/A N/A 
Brazil (Vogler 
et al., 2004) 
61 7 blood donors, 8 
HCV chronic and 
46 HIV-seropositive 
patients 
Nested 5’-NCR PCR 
followed by direct 
sequencing 
 
1 – 47 (77.1);  
2 – 1 (1.6);  
3 – 13 (21.3) 
N/A N/A 
Brazil 
(Campiotto et 
al., 2005) 
1688 Viremic chronic 
hepatitis C patients 
 
Nested 5’-NCR PCR 
followed by direct 
sequencing 
 
1 – 1095 (64.9); 
2 – 78 (4.6);  
3 – 510 (30.2);  
4 – 3 (0.2);  
5 – 2 (0.1) 
N/A N/A 
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Argentina (Cusumano et 
al., 2005) 
7 HCV 
RNA+ / 16 
Patients 
undergoing 
peritoneal dialysis 
RFLP analysis of nested 
5’-NCR, quantiplex HCV 
RNA branched DNA for 
viral load 
 
1a – 3 (42.9);  
1b – 4 (57.1) 
N/A N/A 
Brazil (Lins et al., 2005) 50 HCV seropositive 
patients 
5’-NCR genotype 
specific nested PCR 
(detection of genotypes 
1, 2, 3, and 4) 
 
1 – 32 (64);  
3 – 17 (34);  
1/3 mix – 1 (2) 
1 – 32 (64);  
3 – 17 (34);  
1/3 mix – 1 (2) 
 
N/A 
Brazil (Martins et al., 
2006) 
165 Blood donors Reverse hybridization 
line probe assay - Inno-
Lipa (Innogenetics) 
 
1 – 112 (67.9);  
2 – 5 (3);  
3 – 51 (29.1) 
 
N/A N/A 
Argentina (Picchio et al., 
2006) 
93 
positives 
out of 1637 
Seventy one 
percent of a rural 
town in Argentina 
enrolled to 
investigate HCV 
prevalence 
RFLP analysis of nested 
5’-NCR 
1b – 92 (98.9); 
1a/1b mix – 1 
(1.1) 
 
N/A N/A 
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 Brazil (Bezerra et al., 
2007) 
 
119 HCV seropositive 
patients 
5’-NCR nested PCR and 
RFLP 
 
1 – 45/95 (47.3); 
2 – 8/95 (8.4);  
3 – 33/95 (34.7); 
ND – 9/95 (9.5) 
N/A N/A 
Brazil (Cavalheiro et al., 
2007) 
54 Chronic hepatitis C 
patients from the 
western Brazilian 
Amazon region 
(Acre) after 
combined therapy 
5’-NCR single round 
PCR Amplicor (Roche) 
1 – 31 (57);  
2 – 2 (3.7);  
3 – 11 (20); 
 ND – 10 (19) 
N/A 1 – 31 (57);  
2 – 2 (3.7);  
3 – 11 (20); 
ND – 10 (19) 
Brazil (Parana et al., 
2007) 
24 HCV antibody 
positives health 
care workers 
 
Amplicor (Roche) with 
Inno-Lipa (Innogenetics) 
– HCV region not shown 
 
1 – 16 (66.7); 
2 – 1 (4.1);  
3 – 6 (25);  
ND – 1 (4.1) 
N/A N/A 
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Argentina (Re 
et al., 2007) 
36 Chronic hepatitis 
(26), hemophiliacs 
(2), intravenous 
drug users (3), 
blood donors (5) 
Nested core region PCR 
followed by direct 
sequencing  
1a – 4 (11.1);  
1b – 12 (33.3); 
2c – 18 (50);  
3a – 1 (2.7);  
4a – 1 (2.7) 
N/A N/A 
Chile (Barria 
et al., 2008) 
47 HCV seropositive 
patients for more 
than 6 months 
Single round 5’-NCR 
and NS5b PCR followed 
by direct sequencing 
1b – 39 (83);  
2a – 1 (2.1);  
3a – 5 (10.6);  
4 – 1 (2.1);  
5a – 1 (2.1) 
N/A 1b – 39 (83); 
2a – 1 (2.1); 
3a – 5 (10.6); 
4 – 1 (2.1);  
5a – 1 (2.1) 
Brazil 
(Mendes-
Correa et al., 
2008) 
100 HIV-HCV co-
infected patients 
5’-NCR nested PCR 
followed by direct 
sequencing 
1 – 68 (68.7);  
2 – 4 (4);  
3 – 26 (26.3);  
4 – 1 (1) 
N/A N/A 
Brazil (Matos 
et al., 2009) 
5/878 Seropositive Afro-
Brazilians from 
Goiás State 
Reverse hybridization 
line probe assay - Inno-
Lipa (Innogenetics) 
 
1a – 3/3 (100) N/A N/A 
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Brazil 
(Perone et al., 
2008) 
788 Chronic hepatitis C 
patients 
 
Direct sequencing of 5’-
NCR 
 
1a – 291 (37.5); 
1b – 314 (40.4); 
1a/b – 4 (.5); 
2a/c – 3 (0.4); 
2b – 24 (3.1);  
3a – 139 (17.9); 
4 – 2 (0.2) 
N/A N/A 
Argentina (Re 
et al., 2008) 
37 HIV infected 
patients from 
Cordoba, Argentina 
RFLP analysis of nested 
5’-NCR 
1 – 27 (73);  
2 – 1 (2.7);  
3 – 5 (13.5) 
N/A N/A 
Chile (Vera-
Otarola et al., 
2009) 
45 Chronic hepatitis C  
patients (HCV 
antibody positive 
and HCV RNA 
positive for more 
than 6 months)  
Reverse hybridization 
line probe assay - Inno-
Lipa (Innogenetics) 
 
1 – 37 (82);  
2 – 1 (2);  
3 – 7 (15);  
5 – 1 (2) 
N/A 1 – 31 (94);  
3 – 2 (6) 
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5.1.4. Genotype distribution in Colombia 
 
The only published genotyping study from Colombia reports the prevalence 
of HCV genotypes in Medellín, the capital of Colombia. It did not specify the 
genotyping prevalence of HCV, although it is known that genotype 1a was 
the most prevalent and that 66.5% of these patients were younger than 44 
years (Yepes et al., 2002). 
   
5.1.5. Genotype distribution in Argentina 
 
Although genotype 1 is the most prevalent in Argentina (Picchio et al., 2006, 
Quarleri et al., 1998, Quarleri et al., 2000, Re et al., 2008), HCV genotype 2 
was the most prevalent genotype in two studies with patients from Córdoba, 
Central Argentina. In the first study 55% of the patients were genotype 2 
followed by genotype 1 (38.3%). Thirty nine samples could be sequenced 
(65% of the total samples), and genotype 2b was present in 16 (41%), 1b in 
16 (41%), 1a in 5 (12.8), 3 in 1 (2.6%) and indeterminate in 1 (2.6%) of 
patients (Re et al. 2003). The same research group reported the following 
results: genotype 2c in 50%, 1b in 33.3%, 1a in 11.1%, 3a in 2.7% and 4a in 
2.7% of patients (Re et al. 2007). These two studies are the only ones from 
outside East Argentina, and Córdoba is the second most populous city in the 
country, after Buenos Aires.  
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5.2. Aims 
 
The first aim of this chapter was to determine if the genotype distribution of 
HCV of patients resident in the Recife area of Northern Brazil is consistent 
with other studies from South America. The second aim of this study was to 
determine if there were any genotype discordances between plasma, 
peripheral blood mononuclear cells and whole saliva taken from the same 
individuals. The effect of age on genotype carriage was also evaluated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 231 
5.3. Patients and samples 
 
5.3.1. Study population 
 
Samples were collected from two different locations: a general public hospital 
and a private dialysis clinic in Recife, Northeast Brazil (details in Section 2.1). 
All participants were of Brazilian nationality. Clinical data on all patients were 
obtained from standard medical records and documented onto standardized 
forms, which were linked to patient samples by numerical code. These forms 
were used during anamnesis undertaken before clinical examination. Oral 
findings and route of HCV acquisition can be found in Table 2.1. 
  
5.3.2. Sample collection 
 
Matched oral and blood samples were obtained from all patients as 
described in Sections 2.2.1 and 2.2.2.  
 
5.3.3. Sample processing  
 
After separation of plasma from the blood, the CD19+, CD14+, CD2+ and 
CD45+ cell subsets were immunomagnetically fractionated as described in 
Sections 2.2.3. WMS was not subjected to centrifugation and it was stored at 
-80°C until required. RNA was extracted from blood cell subsets and oral 
samples as described in Section 2.3.2. The presence of DNA in randomly 
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selected extracts was verified by using the Microzone DNA OK kit as 
described in Section 2.3.3. 
 
5.3.4. Molecular detection of HCV 
 
5.3.4.1. RNA extraction 
 
RNA extraction was performed both manually (Section 2.3.2.1) for all 
samples except CD45 from patients 1 to 4 due to lack of blood for cell 
separation and automatically for whole saliva and plasma samples (Section 
2.3.2.2). 
 
5.3.4.2. Polymerase Chain Reaction (PCR) 
 
Reverse transcription was carried out to generate cDNA for all samples 
(Section 2.3.4) followed by PCR of the 5’-noncoding region for plasma 
samples only (Section 2.3.5) and NS5b region for all samples (Section 2.3.6). 
 
5.3.4.3. RFLP and direct sequencing 
 
RFLP was performed for all plasma samples (Sections 2.3.8 and 2.3.9) and 
direct sequencing was performed for all samples (Section 2.3.12). 
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5.4. Genotyping results 
 
5.4.1 Genotypes of HCV isolated from plasma 
 
In the present study group, 71 patients were positive (83.5%) by HCV NS5b 
PCR in plasma and therefore could be genotyped. From these RNA positive 
patients, genotype 1a was detected in plasma of 16 patients (22.5%). 
Genotype 1b was detected in plasma of 39 patients (54.9%), whereas 
genotype 2b was only detected in one patient (1.4%) and genotype 3a in 15 
patients (21.1%). The genotype distribution amongst plasma samples are 
shown in Figure 5.1. Genotyping of this compartment was also performed by 
RFLP. HCV RNA prevalence was again 83.5% and the genotyping results for 
the 71 patients were concordant with the NS5b sequencing, however there 
was a discordance at the subtype level in 3 patients which were genotyped 
as 1a by RFLP as opposed to 1b genotype via NS5b (patients 2, 34, N7), but 
the NCR region is told to be not accurate enough to predict differences 
between subtypes 1a and 1b (Verma et al., 2008). 
 
 
 
 
 
 
 
 234 
Figure 5.1. Genotype distribution of 71 HCV RNA positive plasma 
samples 
  
5.4.2. Genotypes of HCV isolated from saliva 
 
In the present study group, only 11 patients were positive (12.9%) for HCV 
NS5b PCR in saliva and therefore could be genotyped. From these RNA 
positive patients, genotype 1a was detected in plasma of 3 patients (22.5%), 
genotype 1b was detected in plasma of 4 patients (54.9%) and genotype 3a 
was detected in 4 patients (21.1%). The genotype distribution amongst saliva 
samples is shown in Figure 5.2. 
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Figure 5.2. Genotype distribution of 11 HCV RNA positive saliva 
samples 
 
5.4.3. Genotypes of HCV isolated from CD19  
 
In the present study group, 68 patients were positive (80%) for HCV NS5b 
PCR in CD19 cells and therefore could be genotyped. From these RNA 
positive patients, genotype 1a was detected in CD19 cells of 15 patients 
(22.1%), genotype 1b was detected in CD19 cells of 38 patients (55.9%), 
genotype 2b (1.5) was detected only in one patient whereas genotype 3a in 
14 patients (21.1%). Genotype distribution amongst CD19 samples is shown 
in a pie chart enclosed in Figure 5.3. 
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Figure 5.3. Genotype distribution of 68 HCV RNA positive CD19 
samples 
 
5.4.4. Genotypes of HCV isolated from CD14 cells 
 
In the present study group, 60 patients were positive (70.6%) for HCV NS5b 
PCR in CD14 cells and therefore could be genotyped. From these RNA 
positive patients, genotype 1a was detected in CD14 cells of 15 patients 
(22.1%). Genotype 1b was detected in CD14 cells of 38 patients (55.9%), 
genotype 2b (1.7%) was detected only in one patient whereas genotype 3a in 
14 patients (21.1%) and genotype 4d in only one patient (1.7%). Genotype 
distribution amongst CD14 samples are shown in a pie chart enclosed in 
Figure 5.4. 
 
 237 
 
Figure 5.4. Genotype distribution of 60 HCV RNA positive CD14 cells  
 
 
5.4.5. Genotypes of HCV isolated from CD2 cells 
 
In the present study group, 58 patients were positive (68.2%) for HCV NS5b 
PCR in CD2 cells and therefore could be genotyped. From these RNA 
positive patients, genotype 1a was detected in CD2 cells of 15 patients 
(25.9%). Genotype 1b was detected in CD2 cells of 29 patients (50%), 
genotype 2b (1.7) was detected only in one patient whereas genotype 3a in 
12 patients (20.7%) and genotype 4o in only one patient (1.7). Genotype 
distribution amongst CD2 samples are shown in a pie chart enclosed in 
Figure 5.5.    
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Figure 5.5. Genotype distribution of 58 HCV RNA positive CD2 cells 
5.4.6. Genotypes of HCV isolated from CD45 cells 
 
In the present study group, 57 patients were positive (67.1%) for HCV NS5b 
PCR in CD45 cells and therefore could be genotyped (samples 1, 2, 3 and 4 
could not be genotyped at CD45 because they were unavailable). From 
these RNA positive patients, genotype 1a was detected in CD45 cells of 11 
patients (19.3%). Genotype 1b was detected in CD45 cells of 33 patients 
(57.9%), genotype 2b (1.8) was detected only in one patient whereas 
genotype 3a in 13 patients (21.1%). Genotype distribution amongst CD45 
samples are shown in a pie chart enclosed in Figure 5.6. 
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Figure 5.6. Genotype distribution of 57 HCV RNA positive CD45 cells 
 
 
5.4.7. Distribution of HCV genotypes between compartments 
 
The genotypes within plasma and each cell type was always identical (data 
not shown), with the exception of patients 53 where genotype 4o was 
identified in CD2 cells and patients 63 where genotype 4d in was identified in 
CD14 cells, in both cases all other compartments in these patients were 
genotype 3a. 
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5.5. Statistical correlations related to HCV genotypes 
 
5.5.1. Correlation between HCV genotype in saliva and plasma 
 
There was complete concordance between the genotype of HCV in plasma 
and whole saliva (data not shown). 
 
5.5.2. Genotypes within different routes of acquisition 
 
Fisher’s exact test revealed no statistically significant difference in the 
frequency of the different genotypes in plasma and the route of acquisition 
(p=0.391). 
 
5.5.3. Distribution of patient age versus HCV genotype 
 
One way analysis of variance (ANOVA) revealed that there was a significant 
difference in the distribution of the three main genotypes (1a, 1b and 3a) 
Table 5.3. An additional comparison (post hoc) using the Bonferroni method 
revealed that there was a significant difference in the age distribution of 
genotypes 1a and 3a. Genotype 1a was more likely than 3a to be present in 
younger adults, while 3a was more likely than 1a to be present in older 
adults. One patient was removed from the analyses as they were the only 
individual with a genotype other than 1a, 1b or 3a (having genotype 2a). 
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Table 5.2. Plasma HCV genotypes according to route of acquisition 
Route Genotype  
  Negatives 1a 1b 3a Total 
Not available Count 8 3 19 7 37 
% within 
routeofacquistion 
21.6% 8.1% 51.4% 18.9% 100.0% 
% within Plasma_Gen 53.3% 18.8% 48.7% 46.7% 43.5% 
Sexual Count 0 1 1 0 2 
% within 
routeofacquistion 
.0% 50.0% 50.0% .0% 100.0% 
% within Plasma_Gen .0% 6.3% 2.6% .0% 2.4% 
Transfusion Count 5 7 15 5 32 
% within 
routeofacquistion 
15.6% 21.9% 46.9% 15.6% 100.0% 
% within Plasma_Gen 33.3% 43.8% 38.5% 33.3% 37.6% 
IV drug use Count 1 0 1 0 2 
% within 
routeofacquistion 
50.0% .0% 50.0% .0% 100.0% 
% within Plasma_Gen 6.7% .0% 2.6% .0% 2.4% 
Dyalisis Count 1 4 3 3 11 
% within 
routeofacquistion 
9.1% 36.4% 27.3% 27.3% 100.0% 
% within Plasma_Gen 6.7% 25.0% 7.7% 20.0% 12.9% 
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Other  Count 0 1 0 0 1 
% within 
routeofacquistion 
.0% 100.0% .0% .0% 100.0% 
% within Plasma_Gen .0% 6.3% .0% .0% 1.2% 
Total  Count 15 16 39 15 85 
% within 
routeofacquistion 
17.6% 18.8% 45.9% 17.6% 100.0% 
% within Plasma_Gen 100.0% 100.0% 100.0% 100.0% 100.0% 
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 Table 5.3. Distribution of patient age versus HCV genotype 
  
Genotype Mean N Std. Deviation Minimum Maximum Median 
1a 40.56 16 12.801 26 73 40.00 
1b 50.92 39 15.660 20 74 53.00 
3a 54.73 15 10.990 37 79 53.00 
Total 49.37 70 14.859 20 79 50.00 
 
Table 5.4. One way analysis of variance of distribution of HCV 
genotypes across patient age 
 
 Sum of 
Squares df Mean Square F Sig. 
Between Groups 1766.703 2 883.351 4.395 .016 
Within Groups 13467.640 67 201.010   
Total 15234.343 69    
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Table 5.5. Post-hoc comparison of genotypes 1a, 1b and 3a using the 
Bonferroni method 
 
Genotype 
(I) 
Genotype 
(J)  
 95% Confidence Interval 
Mean 
Difference  
(I-J) Std. Error Sig. 
Lower 
Bound Upper Bound 
1a 1b -10.361* 4.209 .049 -20.70 -.02 
3a -14.171* 5.095 .021 -26.68 -1.66 
1b 1a 10.361* 4.209 .049 .02 20.70 
3a -3.810 4.308 1.000 -14.39 6.77 
3a 1a 14.171* 5.095 .021 1.66 26.68 
1b 3.810 4.308 1.000 -6.77 14.39 
*. The mean difference is significant at the 0.05 level (p value). 
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5.6. Discussion 
 
The present study has examined the greatest number of patients from the 
north of Brazil than any other previous report. In addition it is the only 
investigation of genotype distribution across plasma, peripheral blood 
mononuclear cells (PBMC) and whole saliva. Many of the studies discussed 
in Table 5.1 employed gel-based assays which is applicable for clinical 
management of patients it does not provide the high level of resolution of 
sequencing/cloning which is considered the gold standard technique to 
assess viral diversity (Fan et al., 2009), and was the chosen technique at this 
study for this analysis. In view of the latter the present results must be 
considered to be highly robust and thus present a true picture of HCV 
genodiversity in the present group of patients. 
 
The results of the present study reveal that the genotype distribution is as 
might be expected for Brazil, namely that there is a dominance of genotype 1 
in plasma and PBMC. Only one previous study of Brazil residents has 
performed genotyping in oral fluids and plasma, but not for any PBMC (Lins 
et al., 2005) while three studies, one from Brazil (Cavalheiro et al., 2007) and 
two from Chile (Vera-Otarola et al., 2009, Barria et al., 2008) have conducted 
a genotyping investigation on plasma and PBMCs, although not oral fluids, of 
residents of South America. 
 
The consistency of the present results with those of other relevant studies 
indicates that the geographic locale is a principal factor that influences the 
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genotype of HCV infection. The geographic distribution of HCV genotypes in 
turn reflects the impact of changes in health care provision (e.g. increased 
use of blood and blood products, increased frequency of potential iatrogenic 
transmission and increased injecting drug use across the globe (Magiorkinis 
et al., 2009). The role of genetic factors in the geographic distribution of HCV 
genotypes remains unclear (Jonsson et al., 2008, Laouenan et al., 2009, 
Zuniga et al., 2009) but in the future may provide additional insight into this 
problem. 
 
In the present study there were no significant differences in the distribution of 
genotypes across the different groups according to the potential route of 
acquisition. This is in accordance with the results of some (Maieron et al., 
2010) but not all similar studies. In particular Subtypes 1a, 3a and 4 have 
been reported to be associated with injecting drug use (IDU) in some 
countries (Esteban et al., 2008) and 1b and 2 with blood transfusions – 
although this can depend upon the country in which the study patients are 
resident – as in China genotypes 3 and 6 may be associated with acquisition 
via IDU (Zhou et al., 2009). The present group of Brazilian patients did 
contain a substantial number of individuals who may have acquired HCV via 
blood transfusions or IDU, hence in a country known to have a dominance of 
genotype 1 it is perhaps unsurprising to find that genotype 1 is common in 
the present cohort. 
 
Interestingly, no patient in the present study had identifiable genotype 4 HCV 
in plasma or saliva, although, one previously untreated patient (53) which 
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was genotype 4o in CD2 cells, and genotype 3a in all other compartments, 
excluding saliva (which was negative). Another patient (63), who was under 
treatment at the time of examination, had no detectable HCV RNA in plasma, 
saliva or any PBMCs except for CD14 cells, which was genotyped as 4d via 
NS5b PCR. However, real time PCR could detect HCV RNA in all PBMCs of 
this patient, the viral load was low in all of the cell types and genotyping could 
not be performed. As the sequences derived from these compartments were 
unlike any typed in the laboratory previously, cross contamination from the 
laboratory setting can be excluded. 
 
In the present study genotypes 1a and 1b were the dominant genotype in 
patients who had received haemodialysis. There was no notable genotypic 
difference detected between this group of patients from the hospital and the 
one from the private dialysis clinic (data not shown). In Brazil genotype 1 is 
the most prevalent isolate in haemodialysis recipients (Amorim et al., 2010). 
A recently published study of samples obtained in 2002 from 51 
haemodialysis recipients from the Federal state of Brazil found that 1a was 
the most frequent subtype and of note, as this differed from the frequency in 
the local blood donor community it suggests that nosocomial acquisition of 
HCV may be occurring during dialysis (Amorim et al., 2010). It is of course 
well known that haemodialysis is itself a potential risk factor for HCV 
acquisition, although regular testing of all patients for HCV RNA, isolation of 
positive patients, use of dedicated dialysis machines and strict adherence to 
infection control policies are suggested as helpful measures to contain the 
HCV spread via dialysis units (Hussein et al., 2010). 
 248 
 
None of the patients who had received haemodialysis had more than one 
HCV subtype. This contrasts with the observation of mixed HCV genotypes in 
hemodialysis patients from Venezuela (Pujol et al., 1998). However this latter 
study examined only 14 patients at different time points hence it is possible 
the patients were multiply exposed to HCV during this time and have 
acquired new HCV subtypes.  
 
The present study found an age-related trend in which subtype 1a was more 
likely to be in younger persons while subtype 3a more likely in older 
individuals. Perhaps the most obvious reason for this trend would be an 
association with route of acquisition, but as there was no significant 
difference in the ages of groups according to route of acquisition this is 
unproven. Previous studies however have found that older individuals may 
acquire infection via iatrogenic routes (e.g haemodialysis or blood products) 
while younger persons become infected as a consequence of IDU (Esteban 
et al., 2008, Maieron et al., 2010) and as a consequence the infecting 
genotype is a reflection of the route of transmission rather than age alone (Di 
Tommaso et al., 2003).  
 
The present study found that there was good concordance of HCV subtypes 
between the different examined compartments. This concordance of 
subtypes between plasma and PBMC indicates that there is no 
compartmentalisation within blood of distinct subtypes and suggests that 
there may be some interplay (by unknown mechanisms) of HCV between 
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plasma and PBMC. The only exception was previously mentioned presence 
of genotype 4o in T lymphocytes (CD2) of patient 53, as opposed to 
genotype 3a present at his plasma and all other cellular compartments 
(saliva was negative for HCV), which could suggest compartmentalisation or 
maybe a case of mixed infections in a single patient. What draws even more 
attention towards genotype 4 detection in this study, which was also detected 
as previously mentioned in monocytes (CD14) of patient 63 (HCV negative in 
all other studied compartments), is the fact that genotype 4 is extremely rare 
in Brazil. There is a single case report for the whole state of Bahia, Northeast 
Brazil (Zarife et al., 2006) and isolated cases in the largest genotyping study 
in Brazil found in São Paulo (Campiotto et al., 2005), which highlight how 
unusual this genotype is in the country. The present study represents only 
the second study to report genotype 4 detection in Northeast Brazil. 
 
The concordance of HCV subtypes between saliva and plasma (all be it with 
small numbers of saliva samples) suggests that the mouth and/or salivary 
glands are not sites of likely independent HCV acquisition and/or replication. 
Indeed the results of the present chapter and those of chapter 3, in which the 
frequency of salivary carriage of HCV is low, increasingly point towards the 
mouth as being an unlikely site of HCV replication.  
 
Of relevance to the present chapter genotypic analysis has been employed to 
examine possible intrafamilial transmission of HCV. Such transmission has 
been suggested in some (Plancoulaine et al., 2008) but not all (Ndong-Atome 
et al., 2009) studies. However a recent study found some concordance of 
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HCV subtypes within Brazilian families and suggested that transmission 
could have occurred via non-sexual routes – including the sharing of 
toothbrushes (Cavalheiro et al., 2009). Nevertheless, the cumulative results 
of chapters 3 to 5 of the present work would suggest that it is unlikely that 
such transmission is common as HCV is rarely present in saliva. The virus is 
generally present in low levels and there is no evidence of 
compartmentalisation demonstrating oral replication of the virus. It is 
important to consider, though, that salivary components may be causing the 
polymerase not to work by inhibiting its activity. 
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Chapter 6 
 
 
Nucleotide changes and aminoacids variability between different 
compartments 
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6.1. Introduction 
 
6.1.1. Quasispecies variability and sequencing analysis 
 
Hepatitis C Virus (HCV) displays a high degree of genetic diversity. This 
arises from transcription errors (i.e nucleotide substitutions) due to a lack of 
proof reading by the HCV RNA polymerase and the absence of 5’ to 3’ 
exonuclease activity. The mean in-vivo frequency of nucleotide mutations 
varies between 1.4 X 103 to 1.9 X 103 substitutions per nucleotide per year 
(Le Guillou-Guillemette et al., 2007) however in-vitro a mutation rate of 3.5 to 
4.8 X 103 has been observed (Kato et al., 2009). Some of the mutations are 
silent (i.e. synonymous) having no effect upon the amino acid sequence of 
the related protein but may affect the secondary structure of the viral RNA. 
Non-synonymous mutations do lead to changes in amino acids of the viral 
protein and can lead to the emergence of viral variants. Some of the non-
synonymous mutants may of course be lethal to the virus, but the concern is 
whether such mutants have an impact upon the infectivity, pathogenicity of, 
and therapeutic response by HCV. 
 
The non-coding 5’ region is the most conserved region of the HCV genome. 
The most variable region of the HCV genome encodes the envelope proteins 
E1 and E2, such that the sequences of the hypervariable regions (HVR1 and 
HVR2) of E2 in strains from different individuals may vary by more than 50%, 
with the mutation rates of non-structural regions essential for RNA replication 
being lower than that of structural regions (Kato et al., 2009). 
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A viral quasispecies is a group of viruses related by a similar mutation or 
group of mutations that compete within a mutagenic environment (e.g. a 
human host). Quasispecies can be considered to be “clouds” of related 
elements that behave almost (“quasi”) like a single virus (“species”). The 
precise influence of quasispecies upon HCV disease is not entirely evident. It 
would seem that the complexity of quasispecies influence the response to 
interferon alone or interferon plus ribavirin (Jain et al., 2009). Anti-HCV 
therapy may itself drive the emergence of quasispecies (Jardim et al., 2009). 
The presence and diversity of quasispecies prior to therapy may, in some but 
not all instances, predict response to therapy (Moreau et al., 2008). Indeed 
this is no better than HCV viral load in predicting response to therapy 
(Salmeron et al., 2006). Similarly there are conflicting reports of the 
association of the diversity of quasispecies with disease progression 
(Kumagai et al., 2007) and histopathological hepatic change (Vallet et al., 
2007) although it may be that mutations influence progress to hepatocellular 
carcinoma (HCC) (De Mitri et al., 2007) and that there is some 
compartmentalisation of quasispecies within tumoural hepatocytes when 
compared to hepatocytes from non-neoplastic tissue (Sobesky et al., 2007). 
Quasispecies may allow HCV to escape from host cytotoxic T lymphocyte 
(CTL) and humoral immune responses (Domingo et al., 2007, Guglietta et al., 
2009) for example mutations within NS3/4A protease allow escape from CD8 
T cells (Salloum et al., 2010). 
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Quasispecies analysis can aid epidemiological studies as well as 
investigation of possible nosocomial transmission of HCV (Almroth et al., 
2010, Gutelius et al., 2010) and monitor potential resistance to therapy 
(Kuntzen et al., 2008).  
 
6.2. Quasispecies analysis within different compartments 
 
An understanding of the quasispecies within saliva compared to plasma and 
PBMC may provide insight into the source of HCV within the mouth and 
potentially indicate if there is any preferential compartmentalisation of HCV 
quasispecies in the mouth or salivary glands. Hence the aim of this chapter 
was to determine whether there are differences in the distribution of 
quasipecies in plasma, saliva and peripheral blood mononuclear cells.  
 
Compartmentalisation of HCV quasispecies in peripheral blood mononuclear 
cells (PBMC), serum, plasma and liver has been demonstrated (Vera-Otarola 
et al., 2009). The sequences of HVR1 of HCV isolates from plasma can differ 
from those of isolates from CD19+ cells and monocytes, although the 
variants within the cells have a low rate of non-synonymous mutations 
(Ducoulombier et al., 2004). Quasispecies within a specific cellular 
compartment may be statistically more genetically alike than quasispecies 
from different cellular compartments (Roque Afonso et al., 1999). The 
responses of quasispecies within plasma and PBMC to interferon therapy 
may differ (Fornai et al., 2001) and the complexity of quasispecies in liver 
may differ from those in plasma (Cabot et al., 2000). However the majority of 
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the data concerning compartmentalisation of HCV quasispecies is based 
upon studies of small groups of patients. This study includes a higher number 
of patients and also attempts to analyse viral evolution between different 
compartments, comparing amplicons in different sites instead of the general 
quasispecies analysis within a single compartment, usually plasma. The HCV 
infection is composed of a pool of genetically distinct but closely related 
variants which are called quasispecies (Martell et al., 1992). They arise from 
a combination of high error rate of viral RNA polymerase, the rapid replication 
rate of HCV and the large viral population size (Pawlotsky, 2006a) as 
previously seen in chapter 1 (refer to Section 1.6). By applying sequencing 
methods such as direct sequencing following block based PCR (Section 
2.3.9), we could detect nucleotide substitutions and classify them as 
synonymous (when the nucleotide change does not affect the aminoacid that 
it will code in its specific codon) or non-synonymous changes (when the 
nucleotide substitution will result in a codon that is translated into a different 
aminoacid). This kind of analysis is possible thanks to specific software such 
as SeqMan and MegAlign from the LASERGENE package (Section 2.3.12).  
 
Baseline quasispecies complexity is reported to be higher in patients that fail 
to achieve SVR as opposed to those who achieve SVR and baseline 
quasispecies complexity was also reported to predict treatment efficacy and 
was negatively associated with viral clearance rate (Shire et al., 2006).  
 
In summary, quasispecies dynamics has an impact on the biology of HCV, 
where escape variants contribute to viral persistence, disease progression 
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and treatment ineffectiveness (Domingo et al., 2007). These quasispecies 
can only be detected if the single copies of the viruses are isolated and 
sequenced accordingly. 
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6.3. Aim 
 
To establish if there are different quasispecies of HCV within plasma, saliva 
and peripheral blood mononuclear cells by means of analysing the 
compartments nucleotide changes and aminoacid variabilities. 
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6.4. Patients and samples 
 
6.4.1. Study population 
 
Samples were collected from two different locations. A general public hospital 
and a private dialysis clinic (refer to Section 2.1). All participants were of 
Brazilian nationality. Clinical data on all patients were obtained from standard 
medical records and documented onto standardized forms, which were linked 
to patient samples by numerical code. These forms were used during 
anamnesis undertaken before clinical examination. Oral findings and route of 
HCV acquisition can be found in Table 2.1. 
  
6.4.2. Sample collection 
 
Matched oral and blood samples were obtained from all patients as 
described in Sections 2.2.1 and 2.2.2.  
 
6.4.3. Sample processing  
 
After separation of plasma from the blood, the CD19+, CD14+, CD2+ and 
CD45+ cell subsets were immunomagnetically fractionated as described in 
Sections 2.2.3. WMS was not subjected to centrifugation and it was stored at 
-80°C until required. RNA was extracted from blood cell subsets and oral 
samples as described in Section 2.3.2. The presence of DNA in randomly 
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selected extracts was verified by using the Microzone DNA OK kit as 
described in Section 2.3.3. 
 
6.4.4. Molecular detection of HCV 
 
6.4.4.1. RNA extraction 
 
RNA extraction was performed both manually (Section 2.3.2.1) for all 
samples, but CD45 from patients 1 to 4 due to lack of blood for cell 
separation and automatically for whole saliva and plasma samples (Section 
2.3.2.2). 
 
6.4.4.2. Polymerase Chain Reaction (PCR) and direct sequencing 
 
Reverse transcription was carried out to generate cDNA for all samples 
(Section 2.3.4) followed by PCR of the NS5b region for all samples (Section 
2.3.6) and direct sequencing was performed for all compartments sampled 
from each patient, i.e. plasma, whole saliva, CD19, CD14, CD2 and CD45 
(Section 2.3.12). 
 
6.5. Phylogenetic analysis 
 
Phylogenetic trees were created for genotypes 1a, 1b and 3a (Figures 6.1, 
6.2 and 6.3 respectively). PBMC, saliva and plasma samples were either 
identical or closely related in each patient The adaptability of HCV via 
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quasispecies dynamics (refer to Chapter 1 for more details on quasispecies) 
could be clearly observed in our study as most of the patients had closely 
related sequences that usually would differ by variable number of 
nucleotides, resulting in silent or non-synonymous amino acid changes (more 
details later in this Chapter). It is possible to see that the majority of patients 
had closely related but not identical sequences, although some patients had 
identical sequences and one rare exception of a patient under dialysis (N12) 
where the sequence from the plasma was separate from the CD14 
sequence. 
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Figure 6.1. Phylogenetic tree of genotype 1a sequences  
 
Identical sequences observed in multiple compartments are represented by a single 
sequence and the compartments in which that have been observed are detailed in brackets 
S = saliva, P = plasma 
Nucleotide Substitutions (x100)
0
6.7
246
Patient 16N (P,CD19,CD2)
Patient 16N (CD14)
Patient 16N (CD45)
Patient 32 (P,CD19,CD45,CD2)
Patient 32 (CD14)
Patient 33 (P,CD14)
Patient 33 (CD2)
Patient 3 (P,CD2, CD19, CD14)
Patient 17N (P,CD19,CD14,CD2)
Patient 36 (P,CD2,CD14,CD19,CD45)
Patient 5N (P)
Patient 5N (CD14)
Patient 5N (CD2,CD19,CD45)
Patient 9N (P,CD45,CD14,CD2,CD19)
Patient 23 (CD2)
Patient 49 (P,CD19,CD45)
Patient 49 (CD2)
Patient 4 (P,CD19)
Patient 28 (P,CD45,CD2,CD14,CD19)
Patient 14N (P,CD19,CD2)
Patient 1N (S)
Patient 1N (P,CD45,CD19,CD14,CD2)
Patient 11N (P,CD14,CD19,CD2,CD45,S)
Patient 57 (CD19 clone 5)
Patient 57 (CD14,CD45)
Patient 57 (P)
Patient 57 (CD2)
Patient 57 (CD19 clone 2)
Patient 57 (S)
Patient 46 (P,CD45,CD19)
Patient 46 (CD14)
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Figure 6.2. Phylogenetic tree of genotype 1b sequences  
 
Identical sequences observed in multiple compartments are represented by a single sequence and the 
compartments in which that have been observed are detailed in brackets. S = saliva, P = plasma 
Nucleotide Substitutions (x100) 0 
10.2 
2 4 6 8 10 
Patient 19 (P) 
Patient 19 (CD45) 
Patient 19 (CD19) 
Patient 19 (CD14) 
Patient 19 (CD2) 
Patient 68 (CD14) 
Patient 68 (CD2,CD19,CD45) 
Patient 68 (P) 
Patient 41 (P) 
Patient 41 (CD14) 
Patient 41 (CD19) 
Patient 17 (P) 
Patient 17 (CD19) 
Patient 17 (CD14) 
Patient 17 (CD45) 
Patient 17 (CD2) 
Patient 50 (P,CD45)) 
Patient 50 (CD19) 
Patient 50 (CD14) 
Patient 44 (CD14) 
Patient 44 (P,CD2,CD19,CD45) 
Patient 34 (CD14,CD19) 
Patient 34 (CD45) 
Patient 34 (P) 
Patient 34 (CD2) 
Patient 7N (P,CD14,CD19,CD45) 
Patient 59 (P,CD19,CD45) 
Patient 59 (CD14) 
Patient 59 (CD2) 
Patient 40 (P) 
Patient 40 (CD2,CD19,CD14,CD45) 
Patient 40 (S) 
Patient N15 (CD19) 
Patient N15 (CD45) 
Patient N15 (P) 
Patient 2 (P,CD2,CD19) 
Patient 15 (P) 
Patient 15 (CD19,CD14,CD2,CD45) 
Patient 15 (S) 
Patient 54 (P,CD19,CD14) 
Patient 51 (P,CD2) 
Patient 51 (CD14) 
Patient 51 (CD45) 
Patient 51 (CD19) 
Patient N12 (P) 
Patient 16 (P) 
Patient 16 (CD14,CD19,CD2,CD45) 
Patient 66 (CD45) 
Patient 66 (CD2) 
Patient 66 (CD14) 
Patient 66 (P) 
Patient 66 (CD19) 
Patient 56 (P) 
Patient 56 (CD19) 
Patient 56 (CD45) 
Patient 56 (CD14) 
Patient 6 (P,CD19,CD14,CD45,CD2) 
Patient 56 (CD2) 
Patient 11 (P) 
Patient 11 (CD45) 
Patient 11 (CD19) 
Patient 11 (CD2) 
Patient 11 (CD14) 
Patient N13 (P) 
Patient N13 (CD19,CD45) 
Patient 31 (P,CD2,CD19,CD14,CD45) 
Patient N3 (CD14) 
Patient N3 (CD45) 
Patient N3 (P,CD19) 
Patient N3 (CD2) 
Patient 26 (P,CD45,CD14,CD2) 
Patient 26 (CD19) 
Patient 5 (P,CD19,CD14,CD45) 
Patient 22 (P) 
Patient 22 (CD45) 
Patient 22 (CD2) 
Patient 22 (CD19) 
Patient 22 (CD14) 
Patient 9 (S) 
Patient 9 (P,CD19,CD14,CD2,CD45) 
Patient 25 (P) 
Patient 25 (CD19) 
Patient 25 (CD45) 
Patient 25 (CD2) 
Patient 25 (CD14) 
Patient N12 (CD14) 
Patient 20 (P,S,CD19,CD14,CD2,CD45) 
Patient 21 (P,CD14,CD45) 
Patient 21 (CD19) 
Patient 21 (CD2) 
Patient 29 (CD2) 
Patient 29 (CD19) 
Patient 29 (CD45) 
Patient 29 (CD14) 
Patient 29 (P) 
Patient 52 (P) 
Patient 52 (CD2,CD19,CD14,CD45) 
Patient N4 (P,CD2,CD24,CD19,CD45) 
Patient 67 (P) 
Patient 67 (CD19) 
Patient 67 (CD2) 
Patient 67 (CD45) 
Patient 45 (P) 
Patient 45 (CD19) 
Patient 8 (P,CD14) 
Patient 8 (CD19) 
Patient 8 (CD45) 
Patient 47 (P,CD19,CD14,CD2,CD45) 
Patient 14 (P) 
Patient 14 (CD2) 
Patient 14 (CD19) 
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Figure 6.3. Phylogenetic tree of genotype 3a samples  
 
Identical sequences observed in multiple compartments are represented by a single 
sequence and the compartments in which that have been observed are detailed in brackets 
S = saliva, P = plasma 
 
Nucleotide Substitutions (x100)
0
6.8
246
Patient 38 (P,CD19,CD2)
Patient 38 (CD14)
Patient 38 (CD45 clone 2)
Patient 38 (CD45 clone 4)
Patient 10 (CD2,CD45,CD14,CD19)
Patient 10 (P)
Patient 10 (S)
Patient 55 (P,CD 19 clone 3)
Patient 55 (CD19 clone 1)
Patient 13 (P,CD19,CD14,CD2,CD45)
Patient 48 (CD14)
Patient 48 (CD2)
Patient 48 (CD19)
Patient 48 (P)
Patient 48 (CD45)
Patient 39 (P,CD19,CD14,CD2)
Patient 39 (CD45)
Patient 7 (P,S,CD19,CD14,CD2,CD45)  
Patient 10N (P,CD2)
Patient 10N (CD19)
Patient 10N (CD45)
Patient 27 (P,CD19,CD14,CD2)
Patient 10N (S)
Patient 30 (P)
Patient 30 (CD2)
Patient 30 (CD45)
Patient 30 (CD19)
Patient 65 (P)
Patient 18N (P)
Patient 18N (CD19,CD14,CD45,CD2)
Patient 61 (P,S,CD2,CD19,CD14,CD45)
Patient 8N (P,CD14,CD2,CD19,CD45)
Patient 53 (P,CD14)
Patient 53 (CD45)
Patient 53 (CD19)
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6.6. Nucleotide changes and amino acids variability between 
compartments 
 
For this study the direct sequence derived from the compartment and the 
associated predicted amino acid sequence were compared to that derived 
from the plasma. Compartments where the genotypes differed from the 
plasma were excluded from this analysis. This was a rare occurrence and 
was only observed in two patients; patient 53 in compartment CD2 which was 
genotyped as 4o and patient 63 in compartment CD14 which was genotyped 
as 4d.  
 
To establish if there was any difference in the sequences from different 
compartments Fisher’s exact test (refer to section 2.3.16) was employed to 
compare the expected amino acid sequences within the dominant 
quasispecies of individual HCV genotypes between the different 
compartments. This would thus detect the presence of non-synonymous 
mutations within the NS5b region of the HCV genome. In all analyses 
comparison was made to the plasma derived sequence.  
 
6.6.1. Comparison of plasma and saliva sequences 
 
In a comparison between matched saliva and plasma samples there were no 
amino acid changes in genotype 1a quasispecies while 50% of the genotype 
1b and 25% of genotype 3a quasispecies differed in saliva when compared 
to plasma respectively (Table 6.1). There were no statistically significant 
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differences in the frequency of amino acid sequence changes between these 
two compartments (Fisher’s exact test; P=0.709). No conclusions can be 
drawn from this analysis as there were very few patients who had detectable 
HCV in saliva.  
 
Table 6.1. Amino acid changes within each genotype in matched saliva 
and plasma samples 
 
Genotype No changes 1 or more 
changes 
1a 3 0 
1b 2 2 
3a 3 1 
 
6.6.2. Comparison of plasma and CD19 sequences 
 
In a comparison between matched CD19 cells and plasma only one (6.6%) of 
15 patients with genotype 1a had amino acid changes. In contrast nine of 38 
(23.1%) patients of genotype 1b had one or more amino acid difference 
between the two compartments. One of 14 patients with genotype 3a had a 
different amino acid sequence between the two compartments (Table 6.2). 
Fisher’s exact test did not reveal any statistically significant difference in the 
frequency of amino acid changes between these two compartments (P = 
0.255), although there appears to be a trend for changes to be more frequent 
with genotype 1b than 1a or 3a quasispecies.   
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Table 6.2. Amino acid changes within each genotype in isolates of 
matched CD19 cells and plasma samples 
 
Genotype No changes 1 or more 
changes 
1a 14 1 
1b 29 9 
3a 13 1 
 
6.6.3. Comparison of plasma and CD14 sequences 
 
In a comparison between matched CD14 and plasma samples none of 13 
patients with genotype 1a had amino acid changes between compartments. 
In contrast 12 of 33 (36.3%) of genotype 1b quasipecies had a change in one 
or more amino acid between the two compartments. There were no instances 
of amino acid change in 3a quasispecies (Table 6.3). Fisher’s exact revealed 
that the difference in the frequency of amino acid changes between plasma 
and CD14 cells in the matched patients was significant (P=0.003), this 
reflects the high number of changes in genotype 1b quasipecies. Although 
the numbers of samples analysed were low the differences in amino acid 
changes in genotype 1b were significant because there were no changes 
observed within genotypes 1a and 3a (table 6.3). 
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Table 6.3. Amino acid changes within each genotype in isolates from 
matched CD19 cells and plasma samples 
 
Genotype No changes 1 or more 
changes 
1a 13 0 
1b 21 12 
3a 11 0 
 
6.6.4. Comparison of plasma and CD2 sequences 
 
In a comparison between matched CD2 cells and plasma samples one of 14 
(7.1%) patients with genotype 1a had one or more amino acid change in the 
quasispecies (Table 6.4). In contrast, nine of 29 (31%) of genotype 1b 
quasispecies had a change in one or more amino acid between the two 
compartments. One of 12 matched genotype 3a samples had one or more 
amino acid change in quasispecies (Table 6.4). Fisher’s exact revealed that 
the difference in the frequency of amino acid changes between plasma and 
CD2 cells in the matched patients was not significant (P=0.153). There was 
however a trend for there to be differences in the amino acid sequence of the 
genotype 1b quasipecies.  
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Table 6.4. Amino acid changes within each genotype in isolates from 
matched CD2 cells and plasma samples 
 
Genotype No changes 1 or more 
changes 
1a 13 1 
1b 20 9 
3a 11 1 
 
6.6.5. Comparison of plasma and CD45 sequences 
 
In a comparison between matched CD45 cells and plasma samples none of 
14 genotype 1a patients had any amino acid changes (Table 6.5). In contrast 
12 of 33 (36.3%) of genotype 1b quasipecies had a change in one or more 
amino acid between the two compartments. Two of 12 (16.6%) matched 
genotype 3a samples had one or more amino acid change in quasispecies. 
Fisher’s exact test revealed that the difference in the frequency of amino acid 
changes between plasma and CD2 cells in the matched patients was 
significant (P=0.032), this reflects the differences within genotype 1b.  
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Table 6.5. Amino acid changes within each genotype in isolates from 
matched CD45 cells and plasma samples 
 
Genotype No changes 1 or more 
changes 
1a 11 0 
1b 21 12 
3a 10 2 
 
6.6.6. Positioning of amino acid changes 
 
An analysis of all quasispecies from all compartments indicates that 
synonymous and non-synonymous mutations are spread across the entire 
NS5B region (Figure 6.4). Non-synonymous changes were generally more 
frequent at the 5’ end, although there was were some “hotspots” towards the 
3’ end. There was no single codon that was more prone to mutation, although 
no mutations of either type occurred within codon 18. The amino acid 
changes and the compartments in which these occurred are summarised in 
Table 6.6. 
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Figure 6.4. Nucleotide mutations described per codon and association 
with synonymous or non-synonymous changes 
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Table 6.6. Table of amino acid changes between plasma and the different compartments 
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6.7. Discussion 
 
This chapter sought to establish if there are different quasispecies of HCV 
within plasma, saliva and peripheral blood mononuclear cells. Such 
knowledge would aid in establishing the source of HCV in oral fluids and 
indicate whether there is any notable compartmentalisation of a particular 
quasispecies in the mouth or salivary glands.   
 
The biological implications of a quasispecies distribution are well established, 
at least for some RNA viruses. Variants of measles virus influence its 
virulence, and distribution within the host (Steinhauer et al., 1987), while the 
rapid evolution of variants of Human Immunodeficiency Virus (HIV) leads to 
emergence of drug resistance (Rambaut et al., 2004). Although this is mainly 
a feature of RNA viruses Hepatitis B virus (HBV), a DNA virus, can also exist 
as a quasispecies and can mutate under drug pressure, as it replicates 
through reverse transcription - which lacks proof reading - of an RNA 
intermediate (Chotiyaputta et al., 2009). With regard to HCV, quasispecies 
can rapidly emerge in the early phases of infection such that quasispecies can 
differ by up to 7.8% (in the HVR1 region) (Herring et al., 2005). Increased 
complexity of HVR1 sequences of quasispecies has been associated with 
progression from acute to chronic infection (Farci et al., 2000). 
Compartmentalisation of HCV quasispecies in peripheral blood mononuclear 
cells (PBMC), serum, plasma and liver has previously been demonstrated 
(Vera-Otarola et al., 2009). The sequences of HVR1 of HCV isolates from 
plasma can differ from those of isolates from CD19+ cells and monocytes, 
although the variants within the cells have a low rate of non-synonymous 
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mutation (Ducoulombier et al., 2004). Quasispecies within a specific cellular 
compartment may be statistically more genetically alike than quasispecies 
from different cellular compartments (Roque Afonso et al., 1999). The 
responses of quasispecies within plasma and PBMC to interferon therapy may 
differ (Fornai et al., 2001) and the complexity of quasispecies in liver may 
differ from those in plasma (Cabot et al., 2000). Iatrogenic immunosupression 
following liver transplantation and HIV-related immunodeficiency (Fishman et 
al., 2009) may reduce quasispecies diversity suggesting that immune 
pressure may influence quasispecies diversification. However there is no 
consistent pattern of association between the diversity and complexity of e.g. 
HVR1 quasispecies with disease progression, risk of cirrhosis and 
hepatocellular carcinoma. Treatment responses may be influenced by the 
complexity and diversity of quasispecies (Fishman et al., 2009). While there is 
increasing knowledge of HCV quasispecies there remain inconsistencies in 
the available data and at present their identification and characterisation are 
not part of the routine virological monitoring of this infection.  
 
The present results indicate that there is no significant difference in HCV 
quasispecies of saliva when compared with plasma. This result is perhaps 
unexpected as so few of the patients had HCV in both saliva and plasma.  
Two of the 4 patients who had matched genotype 1b samples did have 
quasispecies that differed by more than one amino acid, thus mirroring the 
trend observed between plasma and all of the different PBMCs. However this 
does not provide any insight into the impact of the oral environment upon HCV 
mutation but would simply suggest that genotype 1b is more prone to mutation 
than the other genotypes, regardless of the site of host residence.  
 274 
 
In the comparison of quasispecies between plasma and PBMC the most 
striking, and consistent observation was the predisposition for mutations, and 
hence differences, in genotype 1b quasispecies. This could suggest that 
within PBMC (particularly CD2, CD14 and CD 45) an environment is created 
in which there is some selective pressure that allows emergence of stable 
mutations. However this presupposes that there is active HCV replication 
within PBMC, which as discussed in chapter 5 remains debatable. 
Alternatively these different cell types may favour entry of certain quasispecies 
but as NS5B does not code for entry proteins this notion cannot presently be 
supported. Since higher 1b prevalence may only reflect infections that 
occurred several decades ago (Oubina et al., 2001), the clear trend towards 
nucleotide changes more likely occurring in genotype 1b samples could be 
related to longer infections which would result in more quasispecies . 
 
In the present study there was no consistent mutation hotspot within any of 
the demonstrable quasispecies, hence it is not possible to conclude that any 
particular mutation favours compartmentalisation within peripheral blood cells, 
plasma or saliva. This does not entirely exclude the possibility that HCV may 
compartmentalise in oral tissues as the present study only utilized the NS5B 
region. This region was chosen for the present study as it is a short sequence 
(273bp) that is applicable for molecular epidemiological studies but in 
hindsight may not be appropriate for tropism studies. Of note however NS5B 
is important in the RNA polymerase of HCV and mutations within this region 
may be of relevance to resistance to ribavirin and newer agents such as 
polymerase inhibitors (Chow et al., 2010). Hipervariable region 1 (HVR-1) 
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would be an interesting HCV region to be studied with the 
compartmentalization approach of the current work, instead of NS5b as it has 
the potential to present more mutations than the region studied, which 
presents a higher rate of genetic stability (Blackard et al., 2007, Briat et al., 
2005, Ducoulombier et al., 2004, Harris et al., 2001, Herring et al., 2005, Kato 
et al., 1995, Kumagai et al., 2007, Moreau et al., 2008, Nainan et al., 2006, 
Roque Afonso et al., 1999, Schramm et al., 2008, Toyoda et al., 1999, 
Zehender et al., 2005). 
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Chapter 7 
 
 
Concluding discussion 
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This thesis sought to determine the frequency and virological character of 
HCV within whole saliva in a group of patients from Northern Brazil. The 
present findings  indicate that salivary carriage of HCV in this population is low 
and that such carriage is not influenced by local oral mucosal disease or HCV 
treatment status (chapter 3) but reflects the presence of HCV within peripheral 
blood mononuclear cells and plasma (chapter 4). Furthermore HCV isolates 
from whole saliva are genotypically identical to those of peripheral blood 
mononuclear cells and plasma (chapter 5) and there is no striking 
quasispecies phenomenon associated with whole saliva and hence the oral 
cavity (chapter 6).  
 
The present findings thus suggest that saliva is an unlikely vehicle for the 
transmission of HCV (as reflected in the overall epidemiology of HCV disease) 
and that the mouth is not a frequent site of extra-hepatic replication of HCV. In 
particular the lack of any quasispecies unique to the mouth would indicate 
that, despite HCV negative strands being observed in oral epithelium, the oral 
mucosa and salivary glands are unlikely sites of local HCV replication and 
hence not tissues that will be easily spared from the effects of anti-HCV 
therapy. 
 
However some caution must be placed upon entirely ruling out the mouth, or 
oral fluids, as being a possible source of transmission of HCV. As evidenced 
in chapter 1 and the introductions of chapters 3 and 4 there have been 
instances of possible intrafamilial HCV transmission and the HCV negative 
strand may be present within oral epithelial cells, hence salivary transmission 
of HCV must be possible, all be it very rare. 
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A striking feature of the present group of patients is the lack of evidence of a 
significant difference in hepatic function between the patients treated and not 
treated with appropriate HCV therapy. The treated patients did not reach a 
sustained virological response as evidenced by the presence of HCV in 
plasma. Of course the hepatic function and HCV load of the treated patients 
prior to therapy is not known, nevertheless this lack of response (possibly 
reflecting (unproven) variable compliance to therapy) does not detract from 
the overall conclusions as the trends observed in the treated patients were 
also seen in the untreated individuals. 
 
The lack of evidence of quasispecies unique to the mouth might reflect a lack 
of samples (as a consequence of the low frequency of HCV in oral fluids) and 
perhaps the use of a larger panel of HCV-infected whole saliva samples might 
prove definitively that the oral epithelium and/or salivary glands do not 
promote quasispecies emergence. Nevertheless based upon the present 
evidence quasispecies of oral origin are unlikely to be of relevance to the 
clinical presentation, hepatic function or viral carriage of HCV. 
 
It is presently concluded that, at least in a cohort of patients resident in 
Northern Brazil, oral carriage of HCV is uncommon and that the virological 
character of the virus in whole saliva is determined by that within plasma and 
peripheral blood mononuclear cells.  While salivary antibodies to HCV may be 
a useful means of identifying infected individuals, detailed virological 
assessment for HCV within oral fluids will not reliably indicate the 
haematological and hepatic HCV status of patients with likely HCV disease. 
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There is no evidence for HCV compartmentalization as sequences from 
different compartments were closely related, although mutations were 
identified more frequently within genotype 1b in all compartments. This finding 
suggest a new trend towards hepatitis C evolution, as genotypes 1a and 1b do 
not usually differenciate in terms of treatment outcome, being both traditionally 
related to poor antiviral response. 
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Appendices 
 
Appendix 1. Gender, age, biopsy results, biochemical markers of liver 
fibrosis (AST, ALT, ALP, GCT) and comments about the medical history 
of patients including co-morbidities, when present 
 
 
 
 
 
Gender Age Biopsy result Comments about medical history of the patients / co-morbidities AST ALT ALP GGT
1 M 50 26 15 96 25
2 M 34 A1F0 23 26 76 32
3 M 47 Chronic gastritis 180 283 92 227
4 F 37 A2F1 Under treatment when she was examined 31 25 53 22
5 M 73 HCV RNA and genotyping requested N/A N/A N/A N/A
6 M 33 HCV RNA and genotyping requested 271 213 174 214
7 F 65 A3F4 Anti-HIV was positive, scheduled to repeat exam 44 46 62 111
8 F 56 331 215 233 125
9 F 22 Waiting renal transplantation 67 73 165 48
10 F 53 34 38 79 51
11 F 39 31 32 107 69
12 F 43 11 10 79 23
13 M 45 62 108 91 68
14 F 69 Stopped Ribavirin because of Obsessive Compulsive Disorder 23 18 74 19
15 M 55 23 49 136 58
16 M 67 35 30 82 28
17 M 50 Biopsy to be scheduled 40 53 80 46
18 M 49 Under treatment when he was examined 33 22 60 51
19 M 73 132 106 111 337
20 M 65 16 20 100 41
21 F 58 44 42 87 70
22 F 71 43 27 149 288
23 M 53 20 23 100 68
24 M 30 Under treatment when she was examined (32th week) 31 47 68 139
25 F 62 47 24 123 101
26 M 52 57 90 103 78
27 F 37 28 30 87 15
28 M 36 HIV coinfected, IDU  (stopped 6 months before examination) 29 31 122 119
29 F 64 166 154 116 155
30 M 57 84 86 131 94
31 F 25 25 21 92 26
32 M 27 31 22 136 53
33 M 50 227 103 376 58
34 F 27 75 107 122 94
35 M 53 Under treatment when she was examined (6th week) 42 37 93 46
36 F 51 Biopsy performed at the day of the examination 76 90 203 341
37 F 48 62 50 269 194
38 F 60 33 33 367 300
39 F 62 Biopsy performed at the day of the examination 45 56 117 28
40 M 55 Biopsy performed at the day of the examination 52 82 99 183
41 M 20 33 45 64 265
42 M 47 23 19 100 19
43 M 44 Biopsy to be scheduled 21 19 126 35
44 F 30 24 28 238 362
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Biopsy results (METAVIR scoring system): The fibrosis is graded on a 5-point 
scale from 0 to 4. The activity, which is the amount of inflammation 
(specifically, the intensity of necro-inflammatory lesions), is graded on a 4-
point scale from A0 to A3. It is a simplified and widely used scoring system for 
chronic liver disease grading (Bedossa et al., 1996). 
Activity score / Fibrosis score (F4 grades cirrhosis):  
A0 = no activity / F0 = no fibrosis  
A1 = mild activity / F1 = portal fibrosis without septa  
A2 = moderate activity / F2 = portal fibrosis with few septa  
A3 = severe activity / F3 = numerous septa without cirrhosis  
Gender Age Biopsy result Comments about medical history of the patients / co-morbidities AST ALT ALP GGT
45 F 65 A2F3 41 45 213 65
46 M 53 A1F2 Treatment set to start in November 2006 64 100 60 301
47 F 49 A3F3 - 32 64 167 61
48 M 67 93 93 151 333
49 M 43 103 142 96 64
50 F 28 26 30 83 86
51 F 64 91 97 130 80
52 F 38 35 50 91 31
53 M 45 40 41 84 38
54 M 54 106 164 91 139
55 F 61 Treatment set to start in November 2006 77 136 100 117
56 F 53 170 169 182 147
57 M 45 HCV RNA and genotyping requested 68 116 131 520
58 M 47 Under treatment when he was examined 24 20 100 33
59 M 44 Fever and headaches because of IFN, no benefits 29 36 95 58
60 F 48 51 35 130 146
61 M 48 54 88 201 68
62 F 39 15 10 65 18
63 F 56 Under treatment when she was examined 24 15 86 40
64 F 51 93 135 69 25
65 F 46 18 25 62 26
66 M 57 Biopsy to be scheduled soon 141 274 170 669
67 M 43 21 40 65 94
68 M 51 Biopsy performed at the day of the examination 26 25 55 26
N1 M 44 Stopped treatment 2 months ago, without improvements 28 91 98 621
N2 M 40 10 <30 882 11
N3 M 52 20 15 153 39
N4 M 45 10 19 34 40
N5 F 34 21 21 919 125
N6 M 73 40 35 58 28
N7 M 74 11 28 38 93
N8 M 47 11 9 82 34
N9 M 26 54 113 141 67
N10 M 49 24 33 20 60
N11 F 27 20 10 115 185
N12 M 36 15 16 111 33
N13 M 63 25 <6 88 26
N14 M 27 19 13 1527 55
N15 M 70 24 33 143 165
N16 M 73 27 18 142 98
N17 M 29 3 14 103 24
N18 M 79 9 8 129 23
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Appendix 2. Individual patient data concerning age, estimated cell count (PDH), SVR, genotyping details, viral 
load and viral load per 1000 for specific compartments studied (plasma, saliva, CD19, CD14, CD2 and CD45) 
 306 
Colour coding in Appendix 2: cells highlighted in yellow represent negative 
results in a given assay, while positive results were obtained in the other 
assay. On the other hand, cells highlighted in blue represent the positive 
results in a given assay, while negative results were obtained in the other 
assay. Discrepancies have been approached in the discussion of Chapter 3. 
 
Appendix 3. Two examples of RFLP gels photographed under UV light 
 
 
 
